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ABSTRACT
LEUKEMIA INHIBITORY FACTOR (LIF):
MURINE PRE-IMPLANTATION EMBRYO DEVELOPMENT, 
IMPLANTATION RATES AND 
SKELETAL DEVELOPMENT.
Michael Hayes Mitchell
Old Dominion University, 1998 
Director: Dr. R. James Swanson
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine which demonstrates 
perplexing physiological effects. It has been demonstrated that LIF is essential 
for implantation in mice. Little is known relating to the manner by which LIF 
effects pre-implantation and post-implantation development. The objectives of 
this project were to determine the effects LIF on pre-implantation development, 
to determine the effects that it may have on implantation rates, successful 
pregnancy rates, and resorption rates, and to determine the effects that LIF has 
on the skeletal development of mice. For the embryo transfer experiments, 
embryos were exposed to test compounds in the transfer medium only at the 
time of transcervical embryo transfer.
The results obtained from this project illustrate that murine LIF stimulates the 
development of pre-implantation mouse embryos to the blastocyst stage. 
Additionally, human LIF and an anti-murine LIF antibody had and inhibitory 
effect. Dose dependent effects were demonstrated and murine LIF significantly 
enhanced development in a dose related manner with the highest developmental 
indices recorded for the highest concentration studied and significance observed
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for all concentrations. For the transcervical embryo transfer experiments, 
transfer medium supplemented with 5000 U/ml mrLIF almost doubled 
implantation, pregnancy, and resorption rates whereas the mcab approximately 
halved these rates when compared to controls. Finally, it was observed that 
transfer medium supplemented with 5000 U/ml mrLIF or 5000 U/ml of the anti- 
mrLIF mcab had profound effects on the skeletal development of mouse fetuses. 
Murine rLIF significantly reduced the overall length of the cartilagenous bone 
precursor as well as the length of the ossification centers in the humerus and 
scapula. The mcab reversed this behavior and actually stimulated both 
parameter significantly.
The clinical ramifications for LIF use in in vitro fertilization clinics as a 
medium supplement are obvious and have been suggested by clinicians. The 
results frcm this project show that LIF enhances the implantation of, not only 
healthy embryos, but those that would not normally survive to term. Additionally, 
a single expose at the time of embryo transfer significantly retards skeletal 
development in mice. These results warrant further studies before LIF is used in 
a clinical setting.
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INTRODUCTION
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine which demonstrates 
perplexing and varying physiological effects. It is known by no less than ten 
synonyms. This diverse nomenclature is a reflection of an equally diverse and 
sometimes paradoxical array of biological activities as illustrated by several 
reviews (Cornish, Callon, King, Edgar, and Reid, 1993; Heath, 1992; Hilton and 
Gough, 1991; Kurzrock, Estrov, Wetzler, Gutterman, and Talpaz, 1991; 
Yamamori, 1991). LIF belongs to a relatively new super-family of cytokines, 
characterized by their receptors and known as the hematopoietin receptor super­
family of cytokines. Various cytokines belong to this super-family including the 
interleukins (IL’s) 2, 3, 4, 6, 7, and 11, granulocyte-macrophage colony 
stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), 
ciliary neurotrophic factor (CNTF), prolactin, growth hormone, erythropoietin, 
oncostatin M (OSM), and cardiotrophin-1 (CT-1) (Cosman et al., 1990; Cullinan 
et al., 1996). This introduction begins with a description of the LIF gene and its 
protein. After the discussion of the LIF gene and protein, the various 
physiological properties attributed to LIF including its effects on various 
reproductive parameters will be reviewed.
Gene and Protein Structure
Partial sequence analysis of murine LIF (Hilton, Nicola, Gough, and Metcalf, 
1988) produced from Krebs ascites tumor cells was established by 
The journal model for this dissertation is Behavioral Neuroscience.
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Simpson and associates. These experiments led to the partial cloning of 
the LIF Gene (Gearing et al., 1987; Simpson et al., 1988). The initial sequencing 
resulted in the identification of 125 of the 179 amino acids comprising the 
protein. These authors determined that the protein had a molecular mass of 
approximately 60 kDa and a non-glycosylated form (treated with 
endoglycosidase F to remove carbohydrate moieties) with a mass of 22 - 24 kDa 
(Simpson et al., 1988). In 1987 Gearing and associates employed various cell 
differentiation assays to conclude that two forms of LIF are expressed in the 
mouse, LIF-A and LIF-B (Gearing et al., 1987). These authors characterized 
these two peptides as differing in the amount of glycosylation. LIF-A was 
determined to be the same as differentiation factor and macrophage-granulocyte 
inducer 2B or MGI-2B (Hilton et al., 1988). Additionally, the murine LIF-A gene 
was found to produce two different forms of the protein based on solubility. A 
diffusible or "D" form and a matrix-associated or "M" form were identified. It was 
determined that the differences in the two resulted from variant expression from 
the exon I/ll boundary and differing promoter regions. Rathjen and others 
suggested the "D" form had its effect on cells at great distances from its source 
and provided a wide variety of biological effects. They further postulated that the 
“M” form was associated with a more specific location and provided a focused 
effect or may be stored for later use (Rathjen, Toth, Willis, Heath, and Smith,
1990; Rathjen et al., 1990; Rathjen, Nichols, et al., 1990).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3
Gearing et al., used a yeast expression vector plasmid (YEpsecI) to 
introduce the gene into the genome of the yeast Saccharomyces cerevisiae and 
partially cloned the cDNA for murine LIF (mLIF) (Gearing et al., 1987). From 
these experiments, the structures of the LIF gene and the peptide were further 
described and comparison with other cytokines conducted. It was also 
demonstrated that LIF was produced by two murine T-lymphocyte-cell lines (LB3 
and E9.D4), as well as murine Krebs II ascites tumor cells. The latter also 
produced other cytokines such as (G-CSF), (GM-CSF), and tumor necrosis 
factor a (TNFa). Various assays have been employed to examine the biological 
properties of cytokines. Comparisons were established based on the ability of 
these proteins to induce differentiation in murine myeloid leukemia cell lines such 
as M1 and WEHI-3B D+. Some of these cytokines were able to induce a terminal 
macrophage-like phenotype in these cells, which terminated their 
neoplastic/proliferative nature. G-CSF, for example, was able to induce 
differentiation in both the M1 and WEHI-3B D+ cells, whereas GM-CSF 
produced a weak differentiation of the WEHI-3B D+ cells only. LIF induced a 
macrophage phenotype in the M1 line without effecting the WEHI-3B D+ cells or 
stimulating proliferation in normal granulocyte/macrophage progenitor cells.
These authors determined that the cloned mLIF gene produced a transcript of 
approximately 0.8 to 1.0 kilobases (kb). The mature mLIF peptide was found to 
consist of 179 amino acids. The un-glycosylated peptide exhibited a molecular 
mass of approximately 20 kDa, with seven potential N-linked and four potential
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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O-linked glycosylation sites. The glycosylated form of this peptide was shown be 
approximately 58 kDa if produced by the Krebs ascites tumor cells as compared 
to 67-100 kDa if derived from yeast (Gearing et al., 1987). A complete clone of 
the murine protein was produced the following year. This work resulted in the 
identification of a leader sequence consisting of 24 amino acids and the mature 
murine protein consisting of 179 amino acids with a non-glycosylated mass of 
19,758 Da (Gearing, King, and Gough, 1988).
The above authors cloned the human LIF (hLIF) gene in 1988, again using 
the yeast vector, S. cerevisiae. They observed 78% homology between the 
human and murine amino acid sequences. The recombinant human product had 
similar effects as the murine peptide in inducing differentiation in the M1 cell line 
and was able to compete with native mLIF for binding with receptors on murine 
cells. The human gene was found to consist of two exons separated by a single 
intron of 693 base pairs (Table 1, Gough et al., 1988).
Table 1
Percent Homology Between Murine and Human rLIF (Gough et al., 1988).
Gene Protein
Exon 1 88 91
Exon 2 77 74
Mature Protein 78
Using Southern analysis, Sutherland and co-workers determined that the 
gene for human LIF resided on the long arm of chromosome number 22
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(Sutherland et al.,1989). Kola and associates identified chromosome 11 as the 
location for the murine gene (Kola, Davey, and Gough, 1990).
In 1988 a protein named human interleukin for DA cells (HILDA) was 
purified and described by Godard and co-workers. This cytokine maintained the 
growth of an interleukin 3 (IL-3)-sensitive murine cell line known as DA2 and was 
shown to activate eosinophils. It was determined that this protein had a mass of
38 kDa and was active in concentrations between 10® - 10^ U/mg (Godard et al.,
1988).
HILDA was later determined to be identical to D-factor (Lowe et al.,1989). 
This work described a murine D-factor produced from Ehrlich ascites tumor cells 
and found it to be almost identical to LIF produced from Krebs II ascites tumor 
cells. D-factor contained one additional serine residue in the amino terminal end 
of the protein when compared to LIF. The authors predicted that the mature 
murine and human proteins contained 180 amino acids each and that both 
demonstrated a non-glycosylated mass of 19.7 kDa. In addition, a partial clone 
for the human D-factor gene was produced using COS-1 (transformed simian 
cells transfected with the human D-factor gene) and Escherichia coli as the 
expression vector. They determined the gene to consist of the two intron-three 
exon arrangement discussed in more detail below. Comparison of the human 
LIF and murine D-factor genes demonstrated a single difference between the 
two. Thymine was shown to be located at position 2203 for the human gene and 
cytosine at this same location for the murine gene. Protein products from COS-1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cells and E. coli were both active in inducing differentiation in various cell 
cultures. Two other phenotypes used to indicate differentiation in M1 cells were 
the expression of the Fc receptor and the synthesis of PGE2, both of which were 
demonstrated in the above experiment (Lowe et al., 1989). The nucleotide base 
sequence determined for murine D-factor was found to be the same as that for 
HILDA as determined by Moreau (Moreau et al., 1988).
Schmelzer et al.,describe the human, recombinant D-factor/LIF protein as 
being an approximately 45 kDa glycoprotein containing 30% neutral sugars and 
12% sialic acid (Schmelzer, Burton, and Tamony, 1990). They determined the 
activity for the recombinant human protein and reported the ED50 to be 0.25 
ng/ml (12.7 pM) based on one half of its maximum ability to induce 
differentiation in M1 cells.
These authors also determined that the non-glycosylated form had a mass 
of approximately 21.5 kDa and demonstrated biological activity as per M1 
differentiation with ED50 = 0.40 ng/ml (Schmelzer et al., 1990). This activity 
compares with 17 pM for native D-factor produced by L929 cells (Tomida, 
Yomamoto-Yamaguchi, and Hozumi, 1984a), 20 pM for D-factor produced by 
Ehrlich ascites tumor cells, and 6 pM for LIF-A (Tomida, Yomamoto-Yamaguchi, 
and Hozumi et al., 1984b).
Stahl and co-workers determined that the nucleotide base sequences for 
the murine and human LIF genes consisted of 6.0 and 6.3 kb respectively (Stahl 
et al.,1990). These genes consisted of three exons and two introns, four TATA-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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like segments, and two transcriptional start sites. One of the start sites, 
designated as the major start site, was located 60-64 base pairs upstream (5’) of 
the transcriptional start codon (positions 898 - 902), just downstream (3') from a 
TATA box located at positions 867 or 869. The second start site, designated as 
the minor start site, was found to be located 160 bp upstream of the start codon 
(positions 800 - 801), also next to a TATA-like box. The first exon coded for the 
first six amino acids of the leader sequence, exon two coded the rest of the 
leader sequence plus 53 amino acids of the mature protein, and exon three 
coded for the rest of the mature protein (137 amino acids). The mRNA 
synthesized from these genes was determined to be approximately 4.1 kb in 
size. Potential protein binding regions were identified in the promoter (5’) 
flanking region. A transcription activator protein-2 (AP-2)-like binding region was 
identified in the murine and human gene in addition to an SP-1-like binding 
region in the murine gene within the cloned sections near the LIF gene. AP1 
and SP2 were identified as transcription factors coded for by a group of nuclear- 
acting proto-oncogenes. This proto-oncogene family included c-fos, c-myc, c- 
myb, c-erbA, p53, and c-jun. (Bishop, J. M., 1987). Oncogenes were defined as 
those which caused or perpetuated the proliferative characteristics of cancer and 
have been shown to influence development on several levels (Klug and 
Cummings, 1994; Bishop, J. M., 1987). The polypeptide products from two 
groups of genes, fos and jun, were found to interact to stimulate the AP-1 
responsive gene (Chiu et al.,1988; Beckmann, Matsumoto, and Wilce, 1997).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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AP-1, related to AP-2 and SP-1, was found to consist of the protein products of 
the jun  and fos genes, as Jun homodimers or Fos/Jun heterodimeric complexes. 
These dimers were shown to function by binding to palindromic response 
elements on the DNA, thereby activating the genes. These transcription factor 
sequences are not well conserved in the human gene (Stahl et al.,1990). Schule 
et al., investigated potential metabolic effects of AP-1 by demonstrating that the 
glucocorticoid receptor and AP-1 repressed the other’s transcriptional activation 
(Schule et al., 1990). Recently, the c-fos binding component for exon one of the 
pro-opiomelanocortin (POM-C) gene was shown to be identical to the AP-1 
binding site. The c-fos proto-oncogene was shown to be stimulated by 
corticotropin releasing hormone (CRH) which synergized with LIF to stimulate an 
eight-fold increase in the POM-C gene induction (Bousquet, Ray, and Melmed, 
1997).
In 1992, Willson and others cloned the ovine and porcine LIF genes and 
compared the nucleotide base sequences of these to each other and to the 
human and murine genes described by Stahl and associates (Willson, Metcalf, 
and Gough, 1992). It was determined that the coding segments (exons) for the 
genes were highly conserved, whereas the non-coding segments (introns) were 
poorly conserved. One notable exception is a highly conserved segment of 
approximately 150 bases within intron one. The four TATA boxes and two 
transcriptional start sites identified above were also revealed in the porcine and 
ovine genes. Additionally, the murine gene contained a poorly conserved
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
sequence in intron one that coincided with an alternative gene transcript that 
coded for the matrix or "M" form of the protein as opposed to the diffusible or "D" 
form. Table 2 provides the sequence homologies for the four species observed 
(Stahl et al., 1990; Willson et al., 1992). The overall homology observed among 
all four species was approximately 71%. These authors determined that the 
ovine and porcine LIF genes consisted of the same structural and encoding 
arrangement as found in the murine and human genes, i.e. three exons 
separated by two introns. (Willson et al., 1992).
Table 2
Percent Homologies Among Rat, Human, Ovine, and Porcine LIF (Willson, 
Metcalf, and Gough, 1992).
Species Murine Rat Human Ovine Porcine
Murine 92 79 74 78
Rat 81 75 78
Human 88 87
Ovine 84
The gene and protein for oncostatin M (OSM), a glycoprotein belonging to 
the same super-family of cytokines as LIF, has also been described (Rose and 
Bruce, 1991). These authors found striking similarities in the genetic 
arrangement for LIF, OSM, and interleukin-6 (IL-6), another member of this 
cytokine super-family. As with LIF, the genetic structure of OSM demonstrated 
exon one encoding for the beginning of the leader sequence, exon two encoding
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the rest of the leader sequence plus the first segment of the mature protein, and 
exon three coding for the rest of the mature protein. Like the LIF gene, the OSM 
gene was also located on chromosome 22. These authors determined OSM to 
be a glycoprotein with a mass of approximately 28 kDa. In addition to sharing 
similar genetic structures, these cytokines share similarities in a receptor subunit 
known as gp130 (Gearing et al., 1992; Taga et al., 1989) and all are able to 
induce the differentiation of a macrophage phenotype in the murine myeloid 
leukemia cells known as M1 (Rose and Bruce, 1991). These authors also 
provided an amino acid sequence comparison for OSM, LIF, IL-6, and G-CSF. 
Significant differences were observed when the genetic structures for these four 
proteins were compared to the structural arrangement for granulocyte/ 
macrophage-colony stimulating factor (G/M-CSF), M-CSF, interleukins 1-5, 
tumor necrosis factor (TNF), Steel factor, and interferon (IFN), significant 
differences were noted (Rose and Bruce, 1991).
Another member of this cytokine family is cardiotrophin-1 (CT-1) which was 
observed to induce myocardiocyte hypertrophy. Pennica et al..described that 
during heart failure, fetal heart-development genes are reactivated which 
produce substances such as CT-1 that induce cardiac myocyte hypertrophy.
This compensatory reaction results in enlarged myocardiocytes, accumulation of 
sarcomeric proteins without mitotic division, and general myocardial dilation 
(Pennica et al., 1995b). Pennica and associates also observed that CT-1 
demonstrated many of the biological activities of LIF and bound to a soluble form
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of the LIF receptor (Pennica et al., 1995a). These authors suggest that the 
soluble form of the LIF receptor may be a normal pathway for some of the 
biological activities of CT-1.
The development of a human LIF-specific, double monoclonal antibody- 
based enzyme-linked immunosorbent assay (ELISA) was successfully 
completed by Kim et al.,and the methods published in 1992. This technique 
provided a simple and highly sensitive assay for LIF detection (Kim, Alphonso, 
Schmelzer, and Lowe, 1992).
Since its discovery several sources have been reported for LIF. LIF was 
found to be produced by a number of cells and tissues in situ and several in vitro 
cell lines which were found to synthesize high levels of the protein. Appendix i is 
provided as a partial listing of sources and some of the references for each.
Several of these sources are discussed throughout this introduction. Akita and 
associates reported LIF gene expression in human adult pituitary tissue and fetal 
pituitary corticotropes, somatotropes, and other cell types. It was demonstrated 
that, in murine cell cultures, LIF stimulated the pro-opio-melanocortin (POM-C) 
gene and adrenocorticotropin hormone (ACTH) synthesis (Akita et al., 1995). In 
1996 Wang, Ren and Melmed observed the constitutive expression of the LIF 
gene and the gene for the LIF receptor (LIFR) in mouse hypothalamic and 
pituitary tissue. These authors demonstrated an increase in LIF production by 
these tissues when lipopolysaccharide endotoxin (LPS) was administered to 
mice (Wang, Ren, and Melmed, 1996).
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The above discussion demonstrates the diverse nature of LIF related to the 
structural analysis, description, and sources for the gene and its protein. The 
following discussion will cover a varied array of physiological properties 
attributed to this protein which will add to an already diverse and sometimes 
disparate nomenclature.
Bone
Several groups demonstrated that LIF increased bone turnover, favoring 
resorption over deposition (Abe, 1988; Allan 1990; Lowe, Cornish, Martin, and 
Reid, 1991; Malaval, Gupta, and Aubin, 1995; Metcalf and Gearing, 1989a; Reid 
et al., 1990). It was shown that LIF shared certain physiological properties with 
osteoclast activating factor (OAF) (Abe et al., 1986). In 1995 Malaval, Gupta, 
and Aubin concluded that LIF had both anabolic as well as catabolic effects on 
rat calvaria cell cultures. For these experiments it was reported that LIF inhibited 
bone nodule formation by rat calvaria cell cultures (Malaval et al., 1995). LIF 
was observed to stimulate an increase in DNA synthesis as well as bone 
resorption in bone organ cultures (Lowe et al., 1991). In 1989, Metcalf et 
al..described various pathological conditions induced in mice by engrafting them 
with cells capable of synthesizing high levels of LIF. Among these conditions 
were cachexia (wasting syndrome in more detail under the Lipid Metabolism 
section of this introduction) as well as excessive new bone formation, and 
calcification in heart, skeletal muscle, and other tissues (Metcalf and Gearing, 
1989a) and neutrophil leucocytosis, enlarged spleen, and an increase in
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numbers of hemopoietic cells in liver and spleen (Metcalf and Gearing, 1989b).
Van Beek and associates reported that LIF inhibited growth and mineralization of 
mouse early fetal metacarpal cultures. They described how LIF inhibited 
resorption in 17-day old mouse metacarpal cultures with the osteoclast 
precursors remaining in the periosteum rather than the matrix. For day 18 and 
19 they also recorded significant inhibition of resorption (Van Beek et al., 1993).
LIF receptors were identified on osteoblasts, and, as observed for 
parathyroid hormone (PTH) receptors, they were not found to be expressed by 
osteoclasts. In light of LIF’s predominantly osteoclastic activity it was suggested 
that LIF stimulates the osteoblasts which, in turn, activate osteoclasts by some 
cell-to-cell mechanism which remains to be identified (Allan, 1990). Recently, 
Greenfield and others demonstrated that PTH stimulated osteoblasts to release 
IL-6 as well as LIF. Both of these cytokines were observed to stimulate 
osteoclastic activity resulting in bone resorption (Greenfield, Horowitz, and 
Lavish, 1996). Ishimi and associates determined that IL6 was released by 
osteoblasts and induced osteoclastic bone resorption (Ishimi et al., 1990).
Cornish et al.,determined that the bone resorption due to the effects of LIF was 
prostaglandin-dependent (Cornish et al., 1993; Abe et al., 1986; Allan, 1990). 
Additionally, elevated levels of LIF were measured in the synovial fluid of 
patients with rheumatoid arthritis, but not those with osteoarthritis, suggesting a 
role in the former pathological condition (Ichikawa, 1970; Ishimi et al., 1992). In 
the absence of a resorption cycle, LIF was shown to inhibit bone nodule
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formation in fetal rat calvaria cultures whereas dexamethasone stimulated such 
development. This inhibitory effect by LIF was demonstrated with and without 
dexamethasone added to the medium (Malaval et al., 1995). Dexamethasone 
was shown to inhibit the release of arachidonic acid, a precursor to 
prostaglandins (Gilman, Rail, Nies, and Taylor, 1990). Reid et al., detailed an 
experiment in which indomethacin (a drug known to block the synthesis of 
prostaglandins by inhibiting cyclooxygenase) (Gilman et al., 1990) inhibited LIF- 
induced activities such as an increase in calcium release from mouse calvaria 
cultures and an increase in the number of osteoclasts. This work supported the 
role of prostaglandins in LIF-mediated mechanisms (Reid et al., 1990). The 
exact relationships among LIF, prostaglandins, rheumatoid arthritis, and bone 
turnover remain to be elucidated. LIF and its transcript were identified in 
osteoblast-like cell cultures suggesting a possible autocrine or paracrine role 
(Abe et al., 1988; Ishimi et al., 1992). For mice in which the gene for the low- 
afinity LIF receptor was disrupted, acute osteopenia (reduction in bone 
formation) was observed. Fetal bone volume was more than three fold lower 
than controls with a six fold increase in osteoclasts, implicating LIF s having a 
role in skeletal development (Ware et al., 1995).
Hemopoietic Tissues
In 1979, Hozumi reported a factor or factors produced by the rat sarcoma 
cell line clone YS-722 which stimulated differentiation in the mouse myeloid 
leukemia cell line M1 (discussed in more detail below). Differentiation was
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represented by a terminal macrophage phenotype that demonstrated 
phagocytosis, motility, and lysosomal enzyme activities (Hozumi et al., 1979; 
Ichikawa, 1969; Ichikawa, 1970). Hozumi etal., later described other cytokines 
with similar effects on the M1 line (Hozumi, 1983). It was later reported by 
Tomida and others that a differentiation stimulating factor or factors (D-Factor) 
produced by the murine L929 cell line also induced differentiation of a 
macrophage phenotype in M1 cells (Tomida et al., 1984a). This D-Factor activity 
was also found to be produced by mouse Ehrlich ascites tumor cells (Yamamoto- 
Yamaguchi, Tomida, and Hozumi, 1986; Yamamoto-Yamaguchi et al., 1989) and 
by an osteoblastic cell line known as the MC3T3-E1 cell line (Shiina-lshimi, Abe, 
Tanaka, and Suda, 1986). Lowe et al., cloned the human gene for D-Factor (vide 
ante) and demonstrated similarities between LIF and D-Factor (Lowe et al.,
1989). In separate experiments, Takeda et al., found that a differentiation 
inducing factor (DIF), produced from monocytes and the phytohemagglutinin 
(PHA)-stimulated T cell line, HUT-102, induced differentiation in the M1 cells. 
However, this lymphokine exhibited a molecular mass of approximately 17 kDa 
and Takeda and co-workers suggested that it may be TNF (Takeda et al., 1986). 
During that same year, Abe and co-workers defined a differentiation inducing 
factor (DIF) from L929 and Ehrlich ascites tumor cells that induced differentiation 
in M1 cells and resembled OAF in its ability to stimulate bone resorption (Abe et 
al., 1986).
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Several groups demonstrated LIF’s influences on a variety of hemopoietic 
cell lines. It was not found to produce a proliferative effect on normal 
hemopoietic progenitor cells (Hilton, Nicola, Waring, and Metcalf, 1991; Metcalf, 
Hilton, and Nicola, 1988; Willson et al., 1992). A standard assay for measuring 
LIF’s activity sprang from its ability to induce a mature macrophage-like 
phenotype in the M1 cells (Abe et al., 1989; Gearing et al.,1987; Gough et al., 
1988; Hilton et al., 1988; Hilton and Gough, 1991; Hilton, Nicola, and Metcalf, 
1988; Lowe et al., 1989; Metcalf et al., 1988; Rose and Bruce, 1991; Tomida et 
al., 1984a; Tomida et al., 1984b). LIF receptors were identified on M1 cells by 
Hilton and co-workers (Hilton, Nicola, and Metcalf, 1988). By inducing this 
mature phenotype, LIF efficiently terminated the neoplasm's "immortal" or 
proliferative nature, thus the name leukemia inhibitory factor. Hozumi and others 
published a review article suggesting such induction of differentiation as a 
possible method of therapy for certain neoplasms (Hozumi, 1983; Maekawa, and 
Metcalf, 1989; Maekawa, Metcalf, and Gearing, 1990). LIF's effects on M1 cells 
are shared by IL-6 and G-CSF (Metcalf and Gearing, 1989a).
LIF was found to be identical to HILDA which maintained proliferation in the 
murine, interleukin-3-dependent, myeloid, leukemia cell line DA2, later renamed 
DA-1a (Gascan et al., 1989; Gascan et al., 1990; Godard et al., 1988; Moreau et 
al., 1987; Moreau et al., 1988). Leary et al., determined that LIF was as efficient 
in this respect as IL-6 or G-CSF (Leary, Wong, Clark, Smith, and Ogawa, 1990).
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This action was contrary to LIF’s ability to stimulate differentiation and 
thereby inhibit the continued proliferation in the myeloid leukemia M1 cells. 
Reported in 1988 was HILDA'S ability to activate eosinophils. The same article 
described HILDA as a 38 kDa glycoprotein produced by T-lymphocytic clones 
after antigen stimulation (Godard etal., 1988). Anegon and co-workers 
determined that HILDA/LIF was synthesized by activated monocytes, monocyte- 
derived macrophages, and myelomonocytic cell lines especially when these cells 
were stimulated with phorbol ester and 1,25-dihydroxycholicalciferol (vitamin D3 
or VD3) as well as (PHA) (Anegon et al., 1990). Other laboratories determined 
that LIF/HILDA stimulated the growth and proliferation of human erythroid and 
eosinophil precursors in the presence of serum (Verfaillie and McGlave, 1991).
It was later discovered that LIF/HILDA production was stimulated by interleukin-1 
(IL-1) and inhibited by dexamethasone in endothelial cells derived from human 
umbilical vein and human bone marrow (Grosset et al., 1995). Additionally, it 
was determined that LIF was secreted by bovine pituitary follicular cells and this 
inhibited the growth of adult bovine aortic endothelial cells. Paradoxically, LIF 
was observed to stimulate cell division in adrenal cortex capillary endothelial 
cells (Ferrara, Winer, and Henzel, 1992).
Metcalf and co-workers found that LIF alone had no effect on murine 
megakaryocyte colonies in vitro unless these colonies were first treated with IL-3 
(Metcalf, Hilton, and Nicola, 1991). When injected into mice, LIF caused weight 
loss, an increase in serum calcium concentration, and an increase in the number
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of megakaryocytes (precursors and mature) in both the spleen and bone marrow 
(Metcalf, Nicola, and Gearing, 1990). By observing LIF-deficient mice, Escary et 
al., concluded that LIF was required for the "support" of hemopoietic stem cells, 
especially from the spleen and bone marrow. They observed fewer spleen and 
bone marrow stem cells in LIF deficient mice suggesting that LIF maintained a 
population of pluripotent cells for these cell lines (Escary, Perreau, Dumenil,
Ezine, and Brulet, 1993). Leary and others observed that LIF increased the 
number of interleukin-3 (IL-3) stimulated cells in vitro, however, it demonstrated 
no influence without the IL-3 pre-treatment (Leary et al., 1990).
Observing the two neoplastic cell lines, Foss human melanoma and human 
neuroblastoma, Heymann et al., found that LIF and OSM stimulated an increase 
in the integrin known as avpi as well as an increase in tumor cell-fibronectin 
association. Integrins have been found to provide a role in cell-to-cell or cell-to- 
matrix association and may be involved in the migratory/metastatic behavior of 
certain neoplasms. The increase in integrin avpi was observed to be correlated 
with an increased association of, Foss human melanoma and the human 
neuroblastoma cell line, SK-N-SH, with their fibronectin matrix potentially 
reducing their metastatic capacity by "tightening" their matrix association. Similar 
results were also observed when treating the medium with TNFa. These authors 
suggested possible roles for these cytokines in the regulation of tumor cell 
metastasis (Heymann et al., 1995). In unrelated experiments, it was determined 
that the extracellular domain of the gp130 transmembrane signal transduction
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
19
component of the LIF receptor consisted of fibronectin type III units suggesting 
further association of LIF withthe extracellular matrix components (Hibi et al.,
1990).
Lipid Metabolism
Metcalf and associates demonstrated that, in mice engrafted with LIF- 
producing cells or mice injected with LIF, LIF inhibited lipoprotein lipase in 
adipocytes (Metcalf and Gearing, 1989b, Metcalf, 1989; Metcalf et al., 1990). 
These animals developed a pathologic condition known as cachexia in which a 
dramatic loss in body weight was observed due to an increase in subcutaneous 
lipid catabolism and a decrease in fatty acid intake by adipocytes. Several 
human pathologies such as cancer have been associated with various degrees 
of "wasting" seen in patients. Mori et al., 1989, demonstrated elevated LIF 
concentrations in a human melanoma cell line known as SEKI. These cells were 
derived from a patient suffering a form of melanoma concomitant with marked 
cachexia. When these cells were injected into tumor-bearing nude mice, marked 
cachexia developed. These effects were attributed to melanocyte-derived 
lipoprotein lipase inhibitor (MLPLI) determined to be the same as LIF (Mori, 
Yamaguchi, and Abe, 1989). Similar pathological conditions were reported when 
cultures of the adipocyte cell line 3T3-L1 were exposed to TNF (Price,
Olivecrona, and Pekala, 1986) or IL1 (Beutler and Cerami, 1985) and both teams 
found that these cytokines also inhibited lipoprotein lipase synthesis.
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In some patients with chronic myelogenous leukemia as well as certain 
primary malignant and stromal cell cultures, measurable levels of LIF were 
reported. In these cultures, LIF expression was shown to be augmented by 
cytokines such as IL-12, IL-1(3, TNFa , and transforming growth factor (3 (TGFp) 
(Wetzler et al., 1990).
Hepatic Function
Baumann and others demonstrated that LIF induced the production of acute 
phase proteins by cultured monocytes, tissue macrophages, keratinocytes, and 
hepatocytes. These proteins were shown to be produced by the liver in 
response to stress such as tissue damage or exposure to various toxins 
(Baumann, Onorato, Gauldie, and Jahreis, 1987; Baumann and Schendel, 1991; 
Baumann and Wong, 1989; Hilton, 1992). Examples of acute phase proteins are 
a-i -anti-trypsin, a-, -anti-chymotrypsin, a2 -macroglobulin, fibrinogen, 
hemopexin, cystein protease inhibitors, and others (Baumann et al., 1987; Hilton, 
1992). Baumann and associates concluded that LIF is identical to hepatocyte 
stimulating factor III (HSFIII) (Baumann and Wong, 1989; Baumann, Jahreis, 
Sauder, and Koj, 1984) which was previously observed to stimulate acute phase 
protein synthesis (Baumann, Won, and Jahreis, 1989; Baumann, Hil, Sauder, 
and Jahreis, 1986). LIF receptors were identified on fetal and adult parenchymal 
hepatocytes (Hilton, Nicola, and Metcalf, 1991).
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Neural Effects
In 1979, ciliary neurotrophic factor (CNTF) a cytokine with similar properties 
to cholinergic neuronal differentiation factor (CNDF), was identified as a factor 
from whole chick embryo extracts that supported the survival of chick ciliary 
ganglionic neurons. CNDF was also known as CDF or cholinergic differentiation 
factor (Martinou, Martinou, and Kato, 1992). It was determined that intraocular 
tissues contained relatively high levels of CNTF (Adler, Landa, Manthorpe, and 
Varon, 1979). CNTF was later purified, cloned, and found to be distinct from 
nerve growth factor (NGF) and LIF (Stockli et al., 1989; Lin et al., 1979). Rat and 
rabbit CNTF demonstrated 80% amino acid sequence homology and the genes 
were shown to have similar structures (Masiakowski et al., 1991). Fukada et al., 
reported a 45 kDa (22 kDa de-glycosylated form) protein factor produced by 
newborn rat heart cell cultures that induced adrenergic neurons to acquire a 
cholinergic phenotype, as evidenced by their synthesis of acetylcholine (Fukada, 
1985). Conover illustrated that, like CNDF, CNTF receptors were also expressed 
on embryonal stem (ES) cells and these proteins were able to maintain 
pluripotency in ES cells (Conover et al., 1993). Stahl et al., demonstrated that 
LIF and CNTF both used gp130 and perhaps the (3 subunit for theLIF receptor 
(LIFR-P). These authors reported similar signal transduction pathways (Stahl et 
al., 1993). It was also determined that LIF induced a cholinergic (acetylcholine 
producing) phenotype in sympathetic (adrenergic) neural progenitor cells as 
effectively as CNDF and CNTF (Fukada, 1985) and in 1989 Yamamori and co-
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workers, determined that LIF and CNDF were identical (Yamamori et al., 1989). 
CNDF/LIF was observed to induce the expression of acetylcholine and suppress 
both catecholamine synthesis and noradrenergic function in these cells (Adler et 
al., 1979; Yamamori et al., 1989; Fukada, 1985; Weber, 1981). In related 
experiments, Ludlam and Kessler reported that LIF and CNTF regulated the 
expression of muscarinic receptors on neonatal rat superior cervical ganglion 
(SCG) neurons (Ludlam and Kessler, 1993). Michikawa, Kikuchi, and Kim 
examined the effects of LIF on murine spinal cord neuron cell cultures and 
reported an increase in choline acetyltransferase activity in these cells under the 
influence of LIF (Michikawa, Kikuchi, and Kim, 1992).
Murphy reported the ability of LIF treated medium to function in concert with 
NGF in neural cell development. In these experiments, it was established that 
LIF was necessary for the initial differentiation step in which cells acquired 
neurofilaments and that further differentiation and survival of these cells relied on 
NGF (Murphy, Reid, Brown, and Bartlett, 1993). This work illustrated a temporal 
association between LIF and NGF in regard to neural cell development. Murphy 
and associates also showed that LIF supported the differentiation of sensory 
neurons in mouse embryo neural crest and dorsal root ganglion cell cultures 
(Murphy, Reid, Hilton, and Bartlett, 1991). Freidin observed that LIF increased 
the production of the neuropeptide, substance P (SP) in neuronal and non­
neuronal cultures. SP has been implicated in a number of neural/immunological 
functions (Freidin and Kessler, 1991). Ludlam and others demonstrated LIF-
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mediated IL-1-stimulated SP receptor transcript synthesis in rat neuronal 
explants and demonstrated possible relationships among LIF, IL-1 , and SP 
production in immune reaction after axotomy (Ludlam, Chandross, and Kessler, 
1995). In related studies, Nakagaito, et al., illustrated that LIF, not epidermal 
growth factor (EGF), stimulated glial fibrillar acidic protein (GFAP) expression in 
murine astrocyte progenitor cells obtained from embryonic cerebral 
hemispheres. GFAP is a specific marker for astrocyte differentiation (Nakagaito, 
Yoshida, Satoh, and Takeuchi, 1995).
Recently, Li and others discovered that LIF receptor-deficient/mutant mice 
demonstrated a 35% loss of facial motor neurons, 40% loss of spinal motor 
neurons, and 50% loss of neurons from the nucleus ambiguous, suggesting 
possible roles for this cytokine in the normal development of motor, as well as 
sensory neurons (Li, Sendtner, and Smith, 1995). In related experiments,
CDF/LIF was shown to increase survival of day 14 fetal rat motor neurons 
(Martinou, Martinou, and Kato, 1992).
Renal
Bard and Ross examined the effects of LIF on renal development. They 
determined that supra-physiological levels of LIF selectively inhibited 
nephrogenesis without having an effect on the development of the collecting 
ducts. These experiments illustrated that LIF was able to inhibit the development 
of the mesenchyme which generates the nephrons while having no effect on the
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epithelium that undergoes successive bifurcation to form the collecting ducts 
(Bard and Ross, 1991).
The multiplicity of physiological effects (the pleiotropic nature of LIF) 
disscussed thus far was well demonstrated by a series of experiments by Ware 
and associates which targeted genetic disruption at the low-affinity LIF receptor.
In mutant mice, placental development was disrupted thereby obstructing 
nutritional flow to fetuses, however, fetuses developed to term. An acute 
reduction in the fetal vascular component of the placenta was observed. In 
addition, acute osteopenia (reduction in bone formation) was observed. Fetal 
bone volume was more than three fold lower than controls with a six fold 
increase in osteoclasts. Central nervous system effects were reflected in 
reduced astrocytes in both the brain and spinal cord of mutant mice. Hepatic 
lesions were indicated by abnormally large glycogen stores suggesting possible 
metabolic disorders. The multiplicity o f defects proved to be incompatible with 
life and the term pups died on the first day post parturition (Ware et al., 1995). 
Metabolism
In a series of experiments conducted by Hilton and others, native and 
recombinant LIF were injected into mice to determine their clearance rates. Both 
were found to have an initial clearance half-life of six to eight minutes with a 
longer second clearance phase. The predominant organ for metabolic 
breakdown was determined to be the kidneys, however, LIF accumulation was
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observed in several other organs/tissues (Hilton, Nicola, Waring, and Metcalf,
1991).
Receptors
Concomitant with the diverse biological properties attributed to LIF is an 
equally diverse distribution of its receptors (appendix ii). Smith and others 
observed ES cells that possessed 4500 high-affinity (dissociation constant or 
= 90 pM) LIF receptors per cell (Smith et al., 1988). Yamamoto-Yamaguchi, 
Tomida, and Hozumi (1986) reported high-affinity binding of D-factor to the M1 
cells discussed earlier. This factor was derived from mouse Ehrlich ascites 
tumor and L929 cells (Yamamoto-Yamaguchi et al., 1986). Hilton and 
associates studied the binding of 125l-labeled LIF in several normal and cultured 
cell lines. These authors demonstrated that LIF binding occurred on normal 
murine macrophages, monocytes and their precursors from the peritoneal cavity, 
bone marrow, and spleen. Also examined were several cell lines, however, only 
the M1 murine monocytic leukemic line revealed binding at high levels. Three to 
five hundred high-affinity (Kd = 100 - 200 pM) receptors per cell were observed.
In addition, half of the maximum induction of M1 cells occurred with only five 
percent of the receptors occupied by ligand. Hilton et al., reported that no 
binding was observed on neutrophilic or eosinophilic cell lines, mast cells, or 
erythrocytes (Hilton et al., 1988). These findings were later reconfirmed (Hilton 
et al., 1991). Cells of macrophage/monocyte lineage illustrated binding to 125l- 
labeled LIF with approximately 150 receptors per cell. In the same article the
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authors describe receptor binding in several cell lines and an especially high 
level of binding was seen on hepatocytes from fetal and adult hepatic 
parenchyma with as many as 2000 receptors per cell (Hilton et al., 1991).
Layton and others identified a murine serum protein that binds LIF. This 
protein had a molecular mass of 90 kDa and displayed a dissociation constant 
found in the low-affinity range (K<j = 600 pM). These investigators also 
determined that the protein was a truncated form of the a chain of the cellular 
LIF receptor. Concentrations as high as 1 pg/ml were measured for this LIF 
binding protein (LBP) and these levels rose during pregnancy. LBP (later 
determined to be the soluble form of the LIFR-P) inhibited the activities of LIF in 
culture and may have a similar role in vivo (Layton et al., 1992). Analysis of a 
recombinant soluble mouse D-factor/LIF receptor (expressed in COS-7 cells) 
indicated the receptor to be a 150 kDa protein with a dissociation constant of 12 
nM when mouse LIF was bound to the mouse soluble LIF receptor and 0.67 nM 
when human LIF binds to the mouse soluble receptor. These authors observed 
that the murine LIF had a mass of 50 kDa (Tomida, 1995). Two forms of the 
murine LIF receptor, a membrane-bound form and a soluble form, were 
described by Owczarek et al., as being the product of differential splicing of the 
same gene locus. The authors found differential expression of the two forms of 
the LIF receptors. High levels of receptor transcripts were identified in the liver, 
placenta, and uterus during pregnancy and pseudopregnancy (Owczarek,
Layton, Robb, Nicola, and Begley, 1996).
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Gearing et al., succeeded in producing a clone for the murine and human 
LIF receptor and provided data pertaining to its structure (Gearing et al., 1991; 
Gearing, 1993). Nicola and Metcalf published a mini-review describing binding 
promiscuity amongst various cytokine receptors with various ligands. This may 
in part explain the pleiotropic nature for some of these cytokines (Nicola and 
Metcalf, 1991). It has been demonstrated that, although hLIF binds to both the 
hLIF receptor (hLIFR) and mLIF receptor (mLIFR), mLIF is only able to bind 
hLIFR (Layton, Lock, Metcalf, and Nicola 1994; Owczarek et al., 1993). 
gp 130
The receptor for IL-6 was described by Taga et al., in 1987. The cytokine 
was shown to bind to an 80 kDa polypeptide which associated with murine 
gp130 (Taga et al., 1989). Gearing et al..found that OSM bound to the high- 
affinity LIFR but not the low-affinity LIFR. They determined that gp130 was the 
candidate subunit that induced high-affinity binding properties in the otherwise 
low-affinity receptor and this same gp130 was responsible for binding of OSM to 
the high-affinity LIFR. (Gearing et al., 1992). CNTF, which shared several 
biological properties with LIF, also expressed the gp130 signal transducing 
receptor subunit (Ip et al., 1992). Additionally, Davis and associates described 
the CNTF receptor complex as a tripartite system consisting of the CNTF 
receptor a subunit, the LIF receptor p subunit, and the gp 130 protein (Davis et 
al., 1993).
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Hibi st al., studied the gp130 component and found it to be a 918 amino 
acid peptide that consisted of a transmembrane domain and an extracellular 
domain (approximately 200 amino acids) that was composed of six units of 
fibronectin type III (Hibi et al., 1990). The gp130 subunit had a large 
intracytoplasmic domain, yet displayed no catalytic activity. However, its 
activation, due to ligand binding to its receptor, resulted in rapid phosphorylation 
and activation of a kinase pathway which resulted in gene transcription (Lord et 
al., 1991; Murakami et al., 1993)
Ernst, Gearing, and Dunn demonstrated another protein associated with the 
LIF receptor complex. They reported that Hck, a Src-related tyrosine kinase, 
mediated LIFR signal transduction and physically associated with gp130. With 
increased Hck production by mutagenic cell, the LIF required to maintain ES 
cells in their pluripotent state was reduced by approximately 15-fold (Ernst,
Gearing, and Dunn, 1944). The exact relationship between Hck and LIF 
physiology remains to be determined.
The crystalline structure for LIF was described as four alpha helices with 
long crossover loops between the first two and the last two helices (Robinson et 
al., 1994). Hudson, Vernallis, and Heath characterized the receptor binding sites 
of hLIF. They reported that the hLIFR binding sites on hLIF were the amino 
terminus of the D-helix, carboxyl terminus of the B-helix, and the C-D loop. The 
A and C helices were reported to be the binding sites for gp130 (Hudson,
Vernallis, and Heath, 1996).
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Signal Transduction Mechanism
LIF and CNTF induced a tyrosine phosphorylation cascade that involved 
three proteins known as CLIP1, CLIP2, and CLIP3. Tyrosine phosphorylation of 
the three proteins was specific for LIF and CNTF and was not observed in 
several other cytokines tested such as fibroblast growth factor (FGF), nerve 
growth factor (NGF), platelet derived growth factor (PDGF), EGF, and others. 
These authors found that LIF as well as CNTF induced the CLIP phosphorylation 
pathway which was followed by activation of the tis11 immediate-early response 
gene. The response reached maximum transcription in 45 minutes and returned 
to basal levels within 120 minutes. Whereas, the tis11 gene was activated in the 
MAH (rat pathoadrenal progenitors immortalized with the v-myc oncogene) and 
EW-1 (Ewing sarcoma) cell lines, the c-fos immediate early response gene was 
activated by these two cytokines in the EW-1 cell line only. Beta fibroblast 
growth factor (FGF), on the other hand, induced gene activation in MAH cells 
after stimulation with FGF without activating the tis11 gene. LIF also induced the 
phosphorylation of proteins of the same size as CLIP1, CLIP2, and CLIP3 in M1 
cells. However, IL-6 induced the phosphorylation of the CLIP2 and CLIP3 and 
thereby revealed a possible bifurcation in the pathways stimulated by these two 
cytokines. CNTF did not induce tyrosine phosphorylation in the M1 cell line and 
CNTF receptors were not demonstrated on these cells. These authors 
discovered that CLIP1 and CLIP2 possessed extracellular domains that probably
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participated in the receptor complex and that the CLIP2 was identical to gp130 
(Ip et al., 1992).
Michishita and associates (1991) found that ligand binding to the receptor 
resulted in the phosphorylation of a 27 kDa heat shock protein (hsp27) with an 
iso-electric point of 5.6. This activity was measurable within five minutes and 
reached a maximum within ten minutes.
Although the signaling transduction pathway for LIF has not been fully 
described, data for the OSM and other related cytokine pathways have 
accumulated. OSM was determined to be another pleiotropic cytokine related to 
LIF, IL-6, IL-11, and CNTF. In 1991, Rose et al., exhibited data that showed that 
OSM bound to a LIF/OSM receptor (Rose and Bruce, 1991). Ligand binding of 
these cytokines with their receptors involved homo-dimerization of gp130 or 
hetero-dimerization of gp130 with the LIF receptor (Chauhan et al., 1995).
Cytokine binding to these receptors activated a series of tyrosine kinases. OSM 
activation of gp130 was shown to induce tyrosine phosphorylation of JAK2, 
however, JAK1 or Tyk2 (members of the tyrosine kinases of the Janus family of 
protein kinases), were unaffected. In other systems, gp130 was shown to 
associate with JAK1 as well as JAK2. JAK2 was also activated by prolactin 
binding to its receptor (Ferrag, Chiarenza, Goffin, and Kelly, 1996). Chauhan 
and associates demonstrated an interaction between phosphorylated JAK2 and 
the SH2 domain of growth factor receptor binding protein (Grb2). OSM 
stimulated mitogen activated protein kinases (or MAP kinases) in a pathway that
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depended on the Grb2 proteins. Sos (son of sevenless, a protein first described 
in Drosophila and later mammals) was found located within the JAK2-Grb2 
complex. Sos appeared to bind to the SH3 domain of the Grb2 protein. Given 
that Sos was involved in the activation of Ras genes, this relationship may have 
indicated a position for Ras genes in the OSM induced pathway cascade. 
Similarities between this OSM pathway and that for LIF signal transduction 
remains to be uncovered (Chauhan et al., 1995). Other proteins found to be 
related to the Ras/MAP kinase activation pathway were mitogen-activated 
protein kinase kinase (MAPK kinase), and S6 protein kinase (Boulton, Stahl, and 
Yancopoulos, 1994; Schiemann etal., 1994; Schwarzschild etal.,1994; Yin and 
Yang, 1994).
EGF, another related cytokine, was found to elicit homo-dimerization and 
phosphorylation of its membrane receptor (encoded by the erb B gene) resulting 
in a cascade of reactions. Again, SOS complexed with Grb2, was found to be 
included in the pathway. In addition, this pathway included members of the ras 
family, Raf 1 (a serine-threonine kinase), MAP kinases, as well as MAPK. The 
path leading to the nucleus effected transcription factors such as myc,jun, Erk-1, 
Erk2 (Marx, 1993a; Marx, 1993b; Stokoe, MacDonald, Cadwallader, Symons, 
and Hancock, 1994; Wu et al., 1993). Darnell and associates described a signal 
transduction pathway in which interferon activated the phosphorylation of signal 
transducers and activators of transcription (STAT) proteins which entered the 
nucleus to induce transcription (Darnell, Kerr, and Stark, 1994). Symes et al.,
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studied a signal transduction pathway for the LIF-stimulated transcription of the 
vasointestinal peptide (VIP) gene (Symes, Corpus, and Fink, 1995). They 
demonstrated that LIF and interferon-y (IFN-y) stimulated the phosphorylation of 
members of the Jak-Tyk family of tyrosine kinases, however, their receptors did 
not demonstrate endogenous kinase activity. Also within the cascade pathways 
for LIF and INF-y were found Jak-STAT (signal transducer and activator of 
transcription) proteins. Once activated by phosphorylation, these STAT proteins 
(STAT1 from IFN and STAT3 from LIF stimulation) migrated to the nucleus to 
activate transcription. Yet LIF and IFN exhibit different biological properties. LIF 
induced an increase in VIP from sympathetic neurons and neuroblastoma cell 
lines (NBFL) in vitro and was reported to be the major physiological activator of 
VIP after post-ganglionic axotomy of the superior cervical ganglion (Rao, 1993).
LIF binding to its receptor induced the STAT proteins to bind to the cytokine 
response element (CyRE) on the gene. This CyRE was found to be 
approximately 180 bp long and located about 1330 bp upstream from the start 
site in a portion of the promoter. It was shown to be activated by LIF, CNTF,
OSM, and IL-6. Mutation studies of the STAT site indicates that, although the 
STAT site was important to the activation of the CyRE, alone it was insufficient to 
induce maximum transcription. Transcription did occur after targeted mutagenic- 
deletion of the STAT site. The authors suggest that a region of the CyRE, other 
than the STAT-binding portion, must have also contributed to this transcription. 
Possible candidates included the C/EBP-related binding sites which were shown
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to bind to a protein complex. Its role in the signal transducing pathways for LIF 
and IFN remains to be described. LIF also activated other signal transduction 
pathways. LIF as well as CNTF stimulated the phosphorylation of phospholipase 
C , phosphoinositol-3-kinase, phosphotyrosine phosphatase, and pp120src 
substrate (Symes et al., 1995) as well as the Ras pathway discussed earlier. 
Reproduction
The earliest reports that linked LIF to reproductive physiology involved 
media conditioning techniques. It was known that co-culture of cells along with 
specialized "feeder" cells could effect the differentiation/development of the 
former. In 1975, Martin and Evans developed a technique of employing a 
murine fibroblast cell line, known as STO fibroblasts, as an efficient feeder cell 
system (Martin and Evans, 1975). That same technique was later used to 
examine the totipotent/pluripotent nature of ES and embryonal carcinoma (EC) 
cells. EC cells were pleuripotent cells derived from teratocarcinoma cell lines as 
described by Bradley and associates (Bradley, Evans, Kaufman, and Robertson, 
1984; Wobus, Hozhausen, Jakel, and Schoneich, 1984). Evans and Kaufmann, 
for example, extended the use of STO fibroblasts as feeder cells for the 
development of a system which provided a source of totipotent cells derived from 
early embryos. These ES cells were harvested from embryos that were in the 
blastocyst through early post-implantation stages of development (Evans and 
Kaufman, 1981; Hooper, Hardy, Handyside, Hunter, and Monk, 1987). Once the 
embryo developed beyond these stages, differentiation of the cells began and
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totipotency was eventually lost. The authors discovered that ovariectomy and 
hormone treatment of pregnant mice at appropriate times induced the embryos 
into a condition described as "delayed implantation" in which development/ 
differentiation slowed and nidation (implantation of the embryo) was postponed. 
These embryos were then cultured and separated into trophoblast and inner cell 
mass (ICM) groupings according to the technique of Solten and Knowles (Solter 
and Knowles, 1975). Those cells from the ICM were then cultured until an "egg 
cylinder" developed. At this point the cells were co-cultured with mitomycin C- 
treated inactivated STO fibroblasts. This system maintained the ES cells in their 
totipotent state which prevented differentiation (Evans and Kaufman, 1981;
Nichols, Evans, and Smith, 1990).
In 1981, Martin developed a second technique for observing pluripotent 
cells. In this system EC’s were used. ICM cells from normal embryos were 
cultured with PSA-1 EC cells and STO fibroblasts. The ICM cells acquired 
characteristics that were indistinguishable from teratocarcinoma tumor cells, 
which maintained their pluripotent/totipotent nature (Martin, 1981).
Koopman and Cotton described a polypeptide of approximately 57 kDa that 
was derived from the STO mouse fibroblast-treated medium. They termed this 
activity as differentiation retarding factor (DRF). These authors employed the 
use of pluripotent EC cells (NG2 and F9 lines) and determined that DRF inhibited 
differentiation in these cells (Koopman and Cotton, 1984). In similar studies, 
Gearing and associates were able to produce LIF-releasing E. coli which
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prevented differentiation in ES cells. DRF was determined to be identical to LIF 
(Gearing etal., 1989).
Another feeder cell system was developed using buffalo rat liver (BRL) 
cells. This system also prevented differentiation in ES and EC cell lines. In this 
case, the putative agent was named differentiation inhibiting activity (DIA). The 
authors determined this to be a 20 - 35 kDa peptide (Smith and Hooper, 1987). 
Smith et al., later compared DIA with HILDA and LIF and observed structural and 
functional similarities. In these experiments, DIA was shown to be a glycoprotein 
with a molecular mass of 43 kDa (20 kDa deglycosylated). It was further 
demonstrated that DIA prevented ES differentiation at concentrations of 10 ng/ml 
and removal of DIA induced the ES to differentiate (Smith et al., 1988; Smith, 
Nichols, Robertson, and Rathjen, 1992).
Another comparison among DIA, feeder cells, and LIF was conducted by 
Williams and others. These authors determined that differentiation of several ES 
and EC cell lines was prevented by DIA or feeder cells. One such feeder cell 
system used the human bladder carcinoma ceil line known as 5637, which was 
shown to produce LIF. During these experiments, the authors reported that DIA 
and LIF were peptides of approximately 50 kDa and that both were heavily 
glycosylated. They also observed that both DIA as well as LIF were produced by 
the 5637 cell line, both peptides were able to maintain totipotency/pluripotency in 
ES and EC cells, and both promoted proliferation in the murine DA1.1a cell line.
The authors also reported that 50% of the maximum effect of LIF on ES cells
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was obtained at an activity of 50- 100 U/ml. Dissociation constants were
determined to be approximately 9 x 10'9 or 9 pM for the three ES/EC cell lines, 
EKCS-1, PCCA1, and F9 (Williams etal., 1988).
In 1990, Pease et al..presented data detailing the maintenance of 
totipotency in several strains of the MBL ES cell lines with no loss of 
developmental potential. In these experiments it was shown that LIF effectively 
replaced feeder cells in this regard (Pease, Braghetta, Gearing, Grail, and 
Williams, 1990). Pease and associates published another article in which they 
reported that LIF was substituted for feeder cells in the maintenance of the ES 
cell line D3 using 1000 U/ml LIF (Pease and Williams, 1990). Similar results 
were demonstrated using other cytokines in the same family such as CNTF 
(Conover et al., 1993) and LIF, IL-6, OSM, and CNTF (Piquet-Pellorce, Grey, 
Moreau, and Heath, 1994) to maintain ES totipotency.
An anatomical description of the granulated cells in the mouse endometrial 
(metrial) gland was provided by Stewart and Peel in 1981. In this study, the 
authors described the manner in which these cells were concentrated in the 
decidua basalis and metrial glands around implantation sites. The authors 
suggested a possible role for implantation/pregnancy regulation by products from 
these cells (Stewart and Peel, 1981).
One requirement for implantation was determined to be the "hatching" of 
the embryo from its surrounding zona pellucida on day 4 - 5 of gestation. The 
outer layer of cells, the trophoblasts or trophectoderm, were shown to give rise to
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components of the placenta and extraembryonic membranes. The inner cell 
mass (ICM) contributed to the embryo proper and umbilical cord (Nobil, Neill, 
Greenwald, Marked, and Pfaff, 1994). LIF was found to be associated with the 
trophoblast cells by Conquet and Brulet in 1990. Transcripts (mRNA) for LIF 
were assayed in mouse embryonic and extraembryonic tissues. They described 
LIF transcripts located in extraembryonic ectoderm on day 7.5 (post coitus or 
p.c.), however none was found in the decidua (maternal tissue). After analyzing 
the placenta, they determined that transcripts were synthesized on days 9.5,
10.5, and 12.5 p.c., yet no LIF mRNA was detected from the embryo proper. 
Therefore, transcripts appeared to be synthesized by the fetal contribution of the 
placenta (from the trophoblasts) and not the maternal contribution to the 
placenta or embryo proper. Transcripts produced by the blastocysts were 
detected just before nidation on day 3.5 p.c. (Conquet and Brulet, 1990). The 
relationship between the trophectoderm and the ICM have not been completely 
described. These experiments suggested that the murine trophectoderm cells 
maintained a regulatory role in controlling ICM development vis-a-vis LIF 
production. LIF receptors were located on ICM-like ES cells which suggested to 
the authors that trophectoderm-derived cells may have had an influence on ICM 
cells. It has been suggested that for these ES cells, the ICM may regulate the 
growth and development of the trophectoderm (Conquet and Brulet, 1990;
Layton etal., 1992; Robertson, Lavranos, and Seamark, 1990). Other cytokines 
that are produced by the pre-implantation blastocysts and the placenta include
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transforming growth factor (TGF-a, TGF-P), and PDGF (Conquet and Brulet,
1990; Graham, Lysiak, McCrae, and Lala, 1992; Rappolee, Brenner, Schultx,
Mark, and Werb, 1988), GM-CSF (Robertson and Seamark, 1992), as well as 
human placental uterotrophic hormone (UTPH) (Beas and Flores, 1969; Roblero, 
Beas, Arrau, and Rojas, 1983; Roblero, Beas, and Rojas, 1981; Roblero, Beas, 
Arrau, and Rojas, 1981).
In a series of experiments investigating which mouse tissues synthesize 
LIF, Bhatt et al., found that LIF transcript was most abundant in the uterine 
endometrial glands, particularly on day 4 of pregnancy. This transient synthesis 
of LIF temporally corresponded to implantation. Similar timing for LIF release 
was observed in pseudopregnant females and those undergoing delayed 
implantation (Daniel, 1970) suggesting maternal control of LIF synthesis (Bhatt, 
Brunet, and Stewart, 1991; Finn and McLaren, 1967). Similar experiments 
conducted by Shen and associates revealed that peak LIF mRNA levels were 
observed just after ovulation and relatively high levels were found in the mouse 
uterus throughout pregnancy and during pseudopregnancy. High levels were 
also recorded for the period when the blastocyst arrived in the uterine lumen. In 
addition, these authors reported that LIF partially blocked embryonic body 
development in vitro by inhibiting the formation of primitive ectoderm (not 
primitive endoderm). For these experiments, Shen et al.,employed ES (D3 and 
CCE cell lines) cells co-cultured with mitomycin C-treated embryonic STO 
fibroblasts (known to produce LIF). Several cell markers were used to
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differentiate the effects LIF had on ectodermal vs endodermal differentiation and 
development (Table 3). This data suggested that LIF inhibited the formation of 
primitive ectoderm in embryonic bodies that otherwise would have appeared in 
ES cells (Shen and Leder, 1992).
Table 3
Tissue Markers for the Study o f LIF.
Tissue examined Protein Marker Effect vs control
Endoderm
- visceral a-fetoprotein little effect
- visceral and parietal H19 little effect
- parietal collagen type IV little effect
laminin Pi little effect
mesoderm
- primitive RBC islands c-globulin inhibited
- cardiac & skeletal musclea cardiac actin inhibited
- primitive ectoderm & streak Fgf-5 inhibited
- undifferentiated ES & ICM cells REX-1 remains high
- ICM & primitive ectoderm Oct-3 remains high
(in various embryonic tissues in the mouse - Shen and Leder 1992).
In addition to production by placental components, LIF was shown to be 
synthesized by the embryo. Polymerase chain reaction (PCR) techniques were 
used by Murray et al., to determine the presence of IL-6 and LIF transcripts in 
mouse blastocysts on day 3.5 of gestation. They suggested a role for LIF in the 
growth and development of the trophoblasts as well a ES cells. (Murray, Lee, 
and Chiu, 1990). Conquet and Brulet also determined that LIF was synthesized 
by the mouse embryo on day 3.5 of pregnancy by using in situ hybridization and
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reverse transcription polymerase chain reaction (RT-PCR) techniques (Conquet 
and Brulet, 1990).
LIF secretion patterns in the rabbit closely paralleled those in mice. Low 
levels were detected in the endometrial epithelium, myometrium, and 
endometrial glands of non-estrous and estrous females. High levels were 
reported on day five of pregnancy and pseudopregnancy and levels declined 
during days six and seven. No LIF was detected in the serosa and stromal cells 
during the study. Very little LIF was detected by day 13 (Yang, Le, Chen, and 
Harper, 1994). During the following year, Yang and associates described the 
expression of the LIF receptor and gp130 in the rabbit. They found low levels of 
the receptor in estrous and non-estrous animals with peak levels observed on 
days five and six of pregnancy and pseudopregnancy. The authors found little 
difference in the levels found in the mesometrial and antimesometrial regions of 
the implantation sites. Maximum gp130 levels were observed on day 6 of 
pregnancy and pseudopregnancy. They did not observe the receptor or gp 130 
in the stromal cells (Yang, Le, Chen, Yasukawa, and Harper, 1995).
Continued experimentation by Yang et al., revealed a differential regulation 
of LIF expression/secretion as reflected by mRNA synthesis. These authors 
found that, in the rabbit, LIF was upregulated by progesterone alone or in 
combination with estradiol-17-p. Estradiol-17-p alone had no effect in the rabbit. 
However, in the mouse, estradiol-17-P alone or in combination with progesterone 
caused upregulation of LIF, but progesterone alone had no effect. The results
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from these experiments demonstrate variable regulation of LIF in different 
species. (Yang, Chen, Le, and Harper, 1996) Parallel results were observed 
when studying the effect of steroids on implantation. In the mouse and rat, 
estradiol-17-p is necessary for implantation if the uterus has been primed by 
progesterone (Yoshinaga and Adams, 1966). However, in the rabbit, hamster, 
and pig, estradiol-17-p was not and absolute requirement (Kwun and Emmens, 
1974; Orsini and Meyer, 1962; Heap, Flint, and Gadsby, 1981).
Anegon et al., observed peak levels of LIF transcripts in the porcine 
endometrium on day 11 of the estrous cycle, with maximum protein levels 
reported on day 12 and 13. Implantation of the blastocyst was recorded around 
day 14 of pregnancy (Anegon et al., 1994; Perry and Rowlands, 1962).
In the ovine uterus, LIF transcripts were found in peak levels from day 16 to 
day 20 of pregnancy in both epithelial and stromal cells. LIF protein was found 
at maximum levels in the luminal epithelium associated with glandular caruncles 
as well as in trophoblast cells from day 17 blastocysts. These levels were 
reduced under the influence of estradiol-17-p treatment and further reduction 
was observed by adding progesterone and estradiol-17-p to the medium 
(Vogiagis, Fry, Sandeman, and Salamonsen, 1997).
Human studies revealed that increased levels of LIF mRNA synthesis 
occured in the endometrial tissues and decidua. Low levels were recorded for 
the first trimester chorionic villi and term placenta. During these experiments,
LIF synthesized by the endometrial glands during the menstrual cycle were
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examined. A 9.5 fold increase in LIF was observed during the secretory phase 
as compared to the proliferative phase. In addition it was determined that the 
epithelial component of the endometrium synthesized a 3.3 fold greater level of 
LIF than the stromal components (Kojima et al., 1994).
In 1995, Kojima et al.,reported LIF receptor subunit mRNA synthesis in the 
human endometrium, placenta, and decidua. They determined two components 
of the receptor complex, the LIF receptor proper (LIF-R) and the previously 
mentioned glycoprotein, gp130. Their findings reported no detectable LIF-R 
mRNA in the non-pregnant endometrium, yet transcripts for gp130 were found in 
all tissues examined. Throughout pregnancy the authors detected no increase in 
LIF-R while reporting an increase in gp130 after the second trimester. In this 
same report the authors described the presence of LIF-R and gp130 on BeWo 
human choriocarcinoma cells in culture. Further, they determined LIF's ability to 
inhibit forskolin-induced human chorionic gonadotropin p (hCG-P) subunit 
synthesis by these cells (Kojima et al., 1995).
Charnock-Jones and associates determined that, in the human uterus, LIF 
transcript production was low or undetectable during the proliferative phase and 
observed a six fold increase during the mid to late stage of the secretory phase. 
The authors found that the endometrium synthesized LIF at the time of 
implantation and that the blastocyst expressed mRNA for LIF receptors 
(Charnock-Jones, Sharkey, Fenwick, and Smith, 1994).
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Delage and associates formulated an HILDA/LIF production index or HLPI. 
They calculated HLPI by Day 5:Day 1 LIF ratios using human endometrial 
explant cultures. Enzyme-linked immunosorbent assays were employed to 
reveal LIF production by the endometrium at every phase of the reproductive 
cycle in both normal women and those presenting a history of reproductive 
failures. Although LIF was indeed synthesized in both groups, its levels were 
significantly lower in the latter (Delage et al., 1995).
Additional human studies were conducted by Chen and associates. They 
observed LIF synthesis in the human endometrium by both glandular epithelial 
as well as stromal primary culture cells. Their experiments showed LIF 
production was low during the follicular and late luteal phase of both tissues 
examined. Maximum production levels of LIF were recorded during the mid- 
luteal phase at a time that correlated with implantation. Levels were consistently 
lower in the stromal tissues as compared to the epithelial tissues for all phases of 
the reproductive cycle studied (Chen et al., 1995). Cullinan and associates 
reported LIF expression (not OSM or CNTF) in the human endometrial glands 
during the secretory/postovulatory period, not the proliferative/preovulatory 
period. They found the LIFRp to be expressed during the proliferative and 
secretory phases in the luminal epithelium only. Both the luminal and glandular 
epithelium expressed gp130 throughout the cycle (Cullinan et al., 1996). Similar 
data were reported by Arid and associates who observed peak LIF transcripts in 
the human endometrium during the mid and late luteal phase. These authors
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also found transcripts in decidual tissues from the first trimester of pregnancy.
An increase in LIF expression was noted when endometrial stromal cultures 
were treated with IL-1, TNFa, PDGF, EGF, and TGFp. Interferon-y (IFNy) 
inhibited this induction (Arid, Engin, Attrar, and Olive, 1995). Vogiagis and 
associates reported LIF mRNA in the human endometrium during the middle and 
late secretory phases. They found moderate to high levels of LIF in the stroma 
throughout the cycle and low levels in the epithelium during the proliferative 
phase and maximum epithelial levels in the middle and late secretory phases 
(Vogiagis, Marsh, Fry, and Salamonsen, 1996).
Little variation was observed in the LIF transcript levels produced by the 
human fallopian tubes throughout the normal menstrual cycle. However, 
significant increases in tubal LIF transcripts were associated with ectopic 
pregnancy. Highest levels were observed in the mucosa of the ampulla as 
compared to the more proximal segments. IL1a, TNFa, TGFp all increase the 
expression of LIF in both epithelial and stromal cells. TGFp increased stromal 
production by fourfold. Epithelial cells produced approximately 13 times greater 
levels than stromal cells unless stromal cells were treated with TGFp, TNFa, or 
IL1a, or a combination of EGF and PDGF (Keltz et al., 1996).
Jokhi et al., demonstrated an increase in specialized LIF-producing 
leukocytes during implantation in humans. Leukocytes comprised 40% of the 
cells found in the early decidual stroma and of these, 70-80% were found to 
belong to the natural killer (NK) cell type. These cells were defined as being able
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to recognize and kill many types of tumor cells without damaging normal cells 
(Paul, 1993). An increase in CD56 -NK cells was observed during the secretory 
phase in women, a time congruent with the time of implantation. In addition,
CD56 cells were especially numerous in the decidua basalis. This was
recognized as the location for trophoblast migration into the endometrium during
♦
implantation. During this process, CD56 cells were observed in close proximity
to the trophoblast cells and a functional relationship was suggested. These
+
authors also suggested a role of CD56 NK cells as producers of cytokines that
effect trophoblast differentiation. They described the ability of decidual CD56 
NK cells to produce LIF, CSF-1, IFN-y , as well as TNF-a and TNF-Pt. Those
CD56 NK cells found in the peripheral circulation were observed to produce 
only the latter two cytokines (Jokhi, King, Sharkey, Smith, and Loke, 1994).
LIF was shown to have various biological effects on the same reproductive 
tissues in which it was made. For cultured mouse placental cells, LIF, OSM, IL- 
6, and IL-11 were all found to inhibit growth hormone-releasing hormone (GHRH) 
secretion. The signal transduction component for all four cytokines was gp130.
The significance of GHRF's impact on placental biology is unknown, however, it 
has been demonstrated that it regulates growth hormone expression by 
somatotropes in the fetal pituitary gland. These cells appear in the embryo at 18 
days post-coitus (Yamaguchi et al., 1995). Yamaguchi and associates also 
examined the effect of LIF on other mouse placental cytokines. These authors
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found that LIF, IL-11, and OSM inhibit murine placental lactogen II (mPL-ll) from 
placental cell cultures from days 7, 9, and 12 of pregnancy while stimulating 
mPL-l release on day 9. Additionally, LIF and OSM were found to reduce the 
amount of mPL-ll mRNA in these cells. All three of these cytokines were shown 
to increase the number of syncytiotrophoblasts (giant cells) containing mPL-l 
alone or both mPL-l and II, however, the number of cells containing mPL-ll alone 
decreased. Therefore, it appeared that these cytokines inhibited giant cell 
differentiation. IL-6, which also utilized the gp130 signal transduction protein, 
had no effect on mPL-l expression and only inhibited mPL-ll release before mid­
pregnancy unless soluble IL-6 receptor plus IL-6 were both added to the culture 
medium. The authors suggested that functional receptors for IL-6 were not 
expressed in the embryo until after mid-pregnancy . These experiments also 
demonstrated that the cytokines studied shared a common subunit in their signal 
transduction systems, yet employed additional, unique components allowing for 
a variety of different biological properties. Table 4 provides other cytokines and 
hormones and their effects on mPL levels (Yamaguchi, Taga, Kishimoto, and 
Miyake, 1995).
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Table 4
Other Cytokines and their Effects on Placental Lactogens (Yamaguchi, Taga, 
Kishimoto, and Miyake, 1995).
Progesterone decrease in mPL-l
EGF and TGF increase in mPL-l
EGF + TGF + IL-6 + TNF decrease in mPL-ll
Note. Abbreviations for Table 4: EGF (epidermal growth factor); TGF 
(transforming growth factor); IL-6 (interleukin 6); TNF (tumor necrosis factor) 
Note: gp130 is not a component of the TGF receptor)
LIF was shown to have specific effects on proteinases which have been 
implicated in contributing to the processes by which the embryonic trophoblasts 
invade the maternal endometrial tissues thereby facilitating nidation. Two 
classes in particular have been studied in relationship to LIF. These are the 
plasminogen activators (PAs) and the matrix metalloproteinases (MMPs). PAs 
are serine proteinases which transform plasminogen into its active form, plasmin, 
and have been implicated in the process of implantation (Dano et al., 1985; 
Axelrod, 1985). Although plasmin may directly degrade the extracellular matrix 
(ECM), its primary action was thought to be involved in the proteolytic cascade 
that was responsible for activating MMPs. Two major forms of PAs have been 
isolated in mouse and rat reproductive systems. The first, tissue PAs (tPAs), 
were observed as products of mouse and rat oocytes and no synthesis was 
noted past the 2-cell embryo stage. The second major class of PAs, the
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urokinase PAs (uPAs), were observed to be produced by the 2-cell rat embryo 
and the mouse blastocyst. Receptors for uPAs were identified on human 
trophoblasts, which reflected the proteolytic activity at the leading surface of the 
invading cells (Huarte and Vassalli, 1985; Zhang, Kidder, Zhang, Khamsi, and 
Armstrong, 1994; Roldan et al., 1990). In addition to these enzymes, their 
inhibitors have also been implicated in the regulation of implantation. For 
example, sows have been shown to demonstrate a particular non-invasive form 
of implantation and uterine fluid from pregnant females contained inhibitors of 
PAs which implicated PAs in the invasive type of implantation observed in other 
mammals (Mullins, Bazer, and Roberts, 1980). The MMPs have been shown to 
be the rate-limiting enzymes in ECM remodeling (Werb, 1989). Harvey et al., 
studied the levels of these enzymes during pregnancy in the mouse. They found 
transcripts for the receptors of tissue inhibitors of metalloproteinases (TIMP) and 
uPA in the pre and peri-implantation embryo. Both uPA and a related enzyme, 
matrix metalloproteinase gelatinase B (MMP-9) were reported in the peri- 
implanting mouse embryo. It was found that MMP-9 was produced by the 
trophoblast giant cells of the 7.5 day mouse embryo while TIMP-3 was 
synthesized by the decidua near the implantation site. LIF and EGF were both 
shown to stimulate uPA and MMP-9 after three days of culture and EGF had no 
effect by days 5-6 of culture. LIF was shown to reduce the levels of both 
enzymes. uPA activity was localized to the trophoblasts and the ectoplacental 
cone (Harvey et al., 1995).
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In addition to its effect on uterine and placental cells, LIF was shown to 
influence primordial germ cells (PGCs). De Felici and Dolci studied the effect of 
LIF (and other cytokines and growth factors) on mouse PGCs. These authors 
co-cultured PGCs with an LIF-producing Sertoli cell feeder system known as 
TM4 They found that LIF prolonged the proliferation of PGCs and retarded the 
degree of PGC degeneration (DeFelici and Dolci, 1991). Matsui et al.,also 
examined the effect LIF exerted on mouse PGCs and observed results similar to 
those of De Felici and Dolci. They determined that Steel factor and its receptor, 
the c-kit ligand (and its tyrosine kinase receptor) as well as LIF were temporally 
involved in the normal development of PGCs (Matsui et al., 1991; Williams, De 
Vries, Namen, Widmer, and Lyman, 1992). This growth factor has been 
identified in a membrane-bound and soluble form. The membrane-bound form of 
Steel factor is necessary for normal hematopoiesis (McNiece, Langley, and 
Zsebo, 1991). Also known as mast cell growth factor (MGF), stem cell factor 
(SCF), or kit ligand, Steel factor demonstrates a complex history similar to that of 
LIF. It is a pleiotropic growth factor that effects differentiation and development 
(Williams et al., 1992). Steel factor has been shown to be the ligand for the 
receptor c-Kit (a proto-oncoprotein) and binding causes tyrosine phosphorylation 
of many cellular proteins (Sattler et al., 1997). In related work, Cheng et al., 
observed LIF receptors on the surface of PGCs. Anti-LIFR antibodies abolished 
PGC survival stimulated by LIF. These authors found that OSM and CNTF also 
promoted PGC growth in vitro (Cheng et al., 1994). The members of the
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hemopoietic family of cytokines were shown to differentially effect PGC 
development and behavior. OSM and LIF promoted proliferation of migratory 
PGCs and the viability of colonizing PGCs. IL-11 stimulated migratory PGC 
growth, yet had no effect on the colonizing cells. IL-6 and ciliary neurotrophic 
factors had no effect on PGCs (Koshimizu et al., 1996). LIF and CNTF were 
also determined to prolong the survival of Sertoli cells and gonocytes, in culture, 
in a temporal and dose dependent manner. During these experiments, IL-6 had 
no effect on either cell type (De Miguel et al., 1996).
In 1990 Robertson, Lavranos, and Seamark demonstrated similarities 
between D-factor, DRF, and LIF and examined LIF for possible embryotrophic 
effects. They exposed 8-cell mouse embryos to 1000 U/ml LIF and observed no 
effect of LIF on pre-blastocyst embryos and an increased trophoblast outgrowth 
(expressed in arbitrary units) due to LIF treatment, especially after day 5 of 
culture (Robertson et al., 1990).
In order to more precisely ascertain the reproductive functions for LIF 
Stewart et al., conducted a series of elegant experiments in which a mouse 
strain was produced for which the LIF gene was mutated (Stewart, 1994; Stewart 
et al., 1992). Functional LIF was not produced by these mice. Several insights 
into LIF's function were brought to light by these experiments. First, was the 
discovery that LIF was critical to implantation in mice. Implantation did not occur 
in the mutant recipient females whether transferred embryos were homozygous 
for the mutation or wild-type embryos able to produce LIF. Furthermore, it was
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found that the mutant males and females were both fertile. They were able to 
produce viable gametes and normal fertilization took place. If the resultant 
embryos were transferred to wild-type females, implantation and development 
progressed normally. However, if the embryos were allowed to remain in the 
mutant female, implantation failed to occur and the embryos entered into a state 
indistinguishable from that seen during delayed implantation. Characteristic of 
such embryos is the cessation of proliferation subsequent to their hatching from 
the zona pellucida (Daniel, 1970). From these results it was deduced that LIF of 
endometrial gland origin was essential for implantation (Stewart et al., 1992, 
Stewart, 1994). This information supported the findings of Bhatt and associates 
in 1991. They demonstrated that LIF was produced at the time of implantation 
and its appearance coincided with elevated estrogen levels. A single injection of 
estrogen was sufficient to induce implantation in "delayed" mouse embryos 
(Bhatt etal., 1991).
In 1995, Lavranos, Rathjen, and Seamark demonstrated an increase from 
62.1% to 85.1% in the number of 8-cell mouse embryos developing to the 
hatching stage when exposed to 1000 U/ml human LIF in vitro. They also 
reported an increase in hatching embryos from 7.65% to 33.8%, an increase in 
trophoblast outgrowth from 0 to 13.5% at 120h post human chorionic 
gonadotropin (hCG) injection, and an increase in trophoblast outgrowth from 
47.0% to 85.1% at 144h post hCG injection. In addition, these authors observed
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an increase in embryo survival after transfer of LIF-treated embryos to 
pseudopregnant females (Lavranos, Rathjen, and Seamark , 1995).
Mitchell and co-workers observed a significant increase in the number of 2- 
cell mouse embryos that reached the blastocyst stage when cultured in medium 
supplemented with 1000 U/ml mrLIF. These authors also determined that mrLIF 
significantly reduced embryo fragmentation/degeneration (Mitchell, Swanson, 
Hodgen, and Oehninger, 1994).
Kauma and Matt observed an increase in 2-cell mouse embryo from the 
B ^ F ,  strain that developed to blastocyst when these embryos were co-cultured 
in medium containing the LIF-producing Vero cells or embryonic fibroblasts 
which were shown to produce LIF (Kauma and Matt, 1995).
Fry et al.,completed experiments observing LIF's effect on ovine embryos.
For these experiments the authors exposed ovine morulae or early blastocysts to 
1000 U/ml LIF and examined the effects on cultured embryos as well as embryo 
transferred to recipient females (Fry, Batt, Fairclough, and Parr, 1992). They 
reported an increase in the number of embryos that hatched form the zona 
pellucida from 16% for cultures without LIF to 64% for LIF treated embryos. Also 
observed was a decrease in the number of degenerating embryos from 27% for 
controls to 9% for this treatment group. Pregnancy rates were analyzed and 
results demonstrated the highest rate of 89% for those ewes that received two 
embryos soon after embryo collection (no LIF treatment, no prolonged culturing). 
The lowest rate (16%) was observed for ewes receiving only one embryo after
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48 h in a control culture (no LIF treatment). Pregnancy rates of 52% was 
observed for ewes that received only one embryo soon after embryo collection 
(no LIF treatment, no prolonged culturing). Fifty percent (50%) pregnancy rates 
were observed for ewes receiving only one embryo after 48 h in an LIF treated 
medium. When only one embryo was transferred to recipient ewes, the results 
clearly demonstrated the deleterious effects of culturing embryos for 48 h in this 
system which was compensated for by LIF treatment. (Fry, 1992; Fry et al.,
1992).
Funston and associates found varying results for bovine embryos treated 
with LIF under different culture medium conditions. In one, serum free medium, 
they reported no improvement in the percentage of embryos to reach the 
blastocyst stage, however, they recorded an increase in the number of cells per 
blastocyst. In medium supplemented with LIF, no increase in development to 
blastocyst was recorded (Funston, Nauta, and Seidel, 1997).
LIF was found to have varied effects on human embryos and the data 
available is conflicting. Using 5, 7.5, 10, and 20 ng/ml recombinant hLIF 
Jurisicova found no significant difference in human 2-cell to 6-cell embryos that 
developed to blastocysts as compared to controls (Jurisicova, Ben-Chetrit, 
Varmuza, and Casper, 1995). Dunglison et al., however, found a significant 
increase in the number of embryos that developed to the blastocyst stage when 
cultured in a special medium containing 1000 U/ml recombinant hLIF. Not only 
did the Jurisicova group find an increase in the number of blastocysts, they
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reported an increase in the quality of those blastocysts using a grading scale 
based on morphology (Dunglison, Barlow, and Sargent, 1996).
Studying chimeric mouse embryos engineered to over express LIF,
Conquet, Peyrieras, Tiret, and Brulet reported that over expression of the 
diffusible (D) form of LIF had little effect on embryo morphology while over 
expression of the matrix associated (M) form has significant effects. In the latter 
group the authors observed an atypical production of tissues. In addition, 
gastrulation was inhibited as exemplified by the fact that embryonic ectoderm 
failed to differentiate into mesoderm. These conditions were not compatible with 
life and became lethal by day 9.5 postcoitus (Conquet, Peyrieras, Tiret, and 
Brulet, 1992).
Nachtigall et al., described another possible role for LIF in the process of 
implantation. They reported that LIF decreased the production of human 
chorionic gonadotropin (hCG) and its 3 subunit mRNA by human trophoblasts.
They also observed an significant increase in trophouteronectin (TUN) a type of 
oncofetal fibronectin which anchors the trophoblasts to the endometrium. No 
effect was observed on the steroidogenic activity (progesterone production) of 
the trophoblasts. This work suggested a mechanism by which LIF switched the 
phenotype of the trophoblasts from the hormone producing syncytiotrophoblasts 
to the anchoring trophoblast type in much the same way as TGFp thus bringing 
about embryo attachment during the process of implantation (Nachtigall et al.,
1996; Strickland and Richards, 1992). Conversely, Sawai et al.,reported that LIF
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increased levels of hCG produced, in humans, by the trophoblasts & decidua as 
compared to chorionic tissues (Sawai et al., 1995).
Little is known about the effect of LIF on the development of the embryo 
exposed to LIF as early as the two-cell stage. Information concerning the effect 
of this peptide on the process by which the embryo "hatches" from the zona 
pellucida is also lacking. This hatching is a necessary prerequisite to 
implantation. Also lacking is information comparing LIF’s effects on different 
strains of the same murine species. Additionally, possible dose dependent 
effects on the early embryo are not available. Finally, no data are available 
comparing the results of exposing murine embryos to LIF and/or its monoclonal 
antibodies on embryo transfer, resorption rates, pregnancy rates, and gross 
morphological anomalies.
The objectives of this project were to clarify various effects that leukemia 
inhibitory factor had on the mouse embryo and fetus, both pre- and post­
implantation. Insight into factors capable of supporting embryo development in 
vitro and in vivo will lead to understanding better the complex relationships in 
embryo development and has direct application in the growing field of 
reproductive medicine. Experiments were divided into three major categories or 
experimental groups reflecting the specific aims of the project.
Category A experiments examined possible effects of (1) murine 
recombinant LIF (mrLIF) (2) human recombinant LIF (hrLIF) (3) an anti-human 
recombinant LIF monoclonal antibody (anti-hrLIF mcab) (4) combinations of the
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mrLIF or hrLIF with the mcab - on pre-implantation embryo development from 
the 2-cell to the blastocyst/hatching stage. Conducted were seven sub-divisions 
of this category (experiments 1 through 7) in addition to controls. Two-cell 
mouse embryos were cultured in medium conditioned with murine recombinant 
LIF (mrLIF), human rLIF (hrLIF), and/ora mouse anti-hLIF monoclonal antibody.
A brief description of the seven experiments for category A follows:
Experiment 1. Temporal effect of exposing embryos from females of the 
CDt and BsCBAFt /J strains to mrLIF . (1) Protocol 1: Embryos exposed 
immediately upon collection at the 2-cell stage or day 1 of embryonic 
development. (2) Protocol 2: 2-cell embryos allowed to culture in control 
medium for 24 h then exposed to LIF on day 2 of embryonic development. (3) 
Protocol 3: 2-cell embryos allowed to culture in control medium for 36 h then 
exposed to LIF on day 3 of embryonic development. The null hypothesis for the 
Experiment 1 was - LIF and/or its antibodies will have no significant temporal 
effect on the number of 2-cell embryos developing to the hatched blastocyst 
stage.
Experiment 2. The effects of murine recombinant LIF (mrLIF) on 2-cell 
embryos from BeCBAFi /J females mated with CD1 males. The null hypothesis 
for Experiment 2 was: mrLIF will have no significant effect on the number of 2- 
cell embryos that develop to the hatched blastocyst stage.
Experiment 3. The effects of human recombinant LIF (hrLIF) on embryos 
from B6CBAF.| /J females mated with CD-, males. The null hypothesis for
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Experiment 3 was - hrLIF will have no significant effect on the number of 2-cell 
embryos that develop to the hatched blastocyst stage.
Experiment 4. The effects of a murine anti-human LIF monoclonal antibody 
on embryos from BeCBAF, /J females mated with CD! males. For Experiment 4, 
the null hypothesis was - the murine anti-human LIF monoclonal antibody will 
have no significant effect on the number of 2-cell embryos that develop to the 
hatched blastocyst stage.
Experiment 5. The effects of mrLIF plus a murine anti-human LIF 
monoclonal antibody on embryos from females of BeCBAF! /J mice, mated with 
CD-, males. The null hypothesis for Experiment 5 was - mrLIF plus a murine anti­
human LIF monoclonal antibody will have no significant effect on the number of 
2-cell embryos that develop to the hatched blastocyst stage.
Experiment 5. The effects of hrLIF plus a murine-anti human LIF 
monoclonal antibody on embryos from BsCBAF, /J females mated with CDi 
males. The null hypothesis for Experiment 6 was - hrLIF plus a murine anti­
human LIF monoclonal antibody will have no significant effect on the number of 
2-cell embryos that develop to the hatched blastocyst stage.
Experiment 7. The effects of various concentrations of mrLIF on embryos 
from females of the CD, strain mated with CD, males. For Experiment 7, the null 
hypothesis was - Varying the concentrations of mrLIF will have no significant 
effect on the number of 2-cell embryos that develop to the hatched blastocyst 
stage for CD-, mice.
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Category B experiments were designed to determine the effects of a single 
exposure to mrLIF, or an anti-mrLIF monoclonal antibody (mcab), at the time of 
transcervical embryo transfer, on implantation rates, pregnancy rates (as 
determined by the number of viable pups on day 17), and resorption rates. For 
all embryo transfers, day zero (0) was considered to be the day that the donor 
females were examined for the presence of vaginal plugs as an indication of 
mating. The null hypothesis for this category was - a single exposure of mrLIF or 
an anti-mrLIF mcab at the time of transcervical embryo transfer will have no 
significant effect on implantation rates, pregnancy rates, and resorption rates in 
embryos transferred.
Category C experiments were designed to determine the effects of a single 
exposure to mrLIF, or an anti-mrLIF monoclonal antibody (mcab), at the time of 
transcervical embryo transfer, skeletal development in this species.
Transcervical embryo transfers were conducted as in category 2 experiments .
For category three experiments, the null hypothesis was - a single exposure of 
mrLIF or an anti-mrLIF mcab at the time of transcervical embryo transfer will 
have no significant effect on the skeletal development in embryos transferred.
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MATERIALS AND METHODS
Experiments were placed into one of three major categories: Category A in 
which two-cell embryo were exposed to various combinations of mLIF, hLIF, and 
an anti-human LIF monoclonal antibody; Category B in which transcervical 
embryo transfer supplementing the transfer medium with mLIF or an anti-murine 
LIF monoclonal antibody were conducted to determine implantation, pregnancy, 
and resorption rates; Category C employed fetal clearing and differential staining 
of developing cartilage and bone for assessment of skeletal development.
Embryos from the mouse, Mus musculus were observed during this project. 
Six to eight week old CDi (Charles River Laboratories, Wilmington, 
Massachusetts) and BeCBF, (The Jackson Laboratory, Bar Harbor, Maine) were 
given water and food (Agway PROLAB) ad libitum. Females from both strains 
will be mated with CD1 males (at least 8 weeks of age).
A modified Kreb’s medium (mKreb’s) supplemented with 4 mg bovine 
serum albumin (4% BSA)/ml (Sigma, St. Louis) was used for collection and 
culture of embryos as described by Ackerman (Ackerman, Swanson, Adams, 
and Wortham, 1983). Medium was prepared filter-sterilized through 0.22 
cellulose acetate membrane filters (Corning), dispensed into 25 cm2 tissue 
culture flasks (Corning), and refrigerated at 0 - 4° C until utilized. Medium was 
incubated at 37° C in 5% C02 in 100% humidified air for at least 2 h prior to use.
Superovulation was induced by injecting female mice with 5 IU pregnant 
mare's serum gonadotropin (PMSG - Sigma, St. Louis) IP followed in 48 h by
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injecting 5 IU human chorionic gonadotropin (hCG - Sigma, St. Louis) IP. At the 
time of hCG injection each female was placed with an individually caged, proven 
fertile male CD,. The following morning, approximately 16 h after the hCG 
injection, the female mice were inspected for vaginal plugs. This was 
considered to be day 0 of pregnancy throughout these experiments. On the 
morning after inspection for vaginal coagulation plugs (day 1 of pregnancy), the 
pregnant donor females were killed by cervical dislocation and the abdominal 
skin will be removed. Under sterile conditions the abdomen was opened and the 
oviducts removed and placed in culture medium. Using a Zeiss Urban 
Quadrascope/dissecting microscope the embryos were removed from the 
oviducts by inserting into the fimbriated end of the oviduct a 30-gauge needle 
connected to a 1cc tuberculin syringe filled with mKreb’s medium applying gentle 
pressure to expel the embryos.. The 2-cell embryos were flushed from the 
oviducts into sterile 35 X 10 mm polystyrene culture dishes (Falcon) containing 2 
ml of culture medium. Morphologically normal 2-cell embryos were collected and 
appropriated to the various test/control groups using micropipettes hand-drawn 
from Pasteur pipettes. Embryos were cultured in 100 pi droplets under mineral 
oil at 37° C in 5% C02 in 100% humidified air.
Category A Experiments
Collected 2-cell embryos were exposed to test compounds in vitro under 
three temporal protocols. For Protocol 1, fifteen 2-cell embryos were introduced 
to a 100 pi droplet containing 1000 U/ml of the test compound immediately after
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the embryos were collected from the oviducts. Fifteen 2-cell embryos were also 
introduced to a 100 pi droplet of mKreb’s medium as the control. All droplets 
were covered with mineral oil prior to embryo collection and allowed to equilibrate 
in the incubator. Embryo development was observed and recorded during the 
next 6 days. For Protocol 2, fifteen 2-cell embryos were introduced to a 100 pi 
droplet of mKreb’s culture medium and allowed to culture as controls for 24 h at 
which time they were transferred into a 100 pi droplet of test medium containing 
1000 U/ml of the test compound. Fifteen 2-cel! embryos were similarly cultured 
in mKrebs medium as controls. Embryo development was observed and 
recorded during the next 5 days. For protocol 3 fifteen 2-cell embryos were 
introduced to a 100 pi droplet of mKreb’s culture medium and allowed to develop 
as controls for 48 h at which time they were transferred to a 100 pi droplet of test 
medium containing 1000 U/ml of the test compound. Again, fifteen 2-cell 
embryos were similarly cultured in mKrebs medium as controls. Embryo 
development was observed and recorded during the next 4 days.
Category A experiments were further divided into Experiments 2-7 
according to the test compound used. With the exception of Experiment 8 
(varying concentrations of mrLIF), each was conducted using the temporal 
protocols described above. These experiments were performed using embryos 
from female B6CBFi mated with CDi males.
• Experiment 2 - Test compound: 1000 U/ml murine rLIF using embryos 
from B6CBFi females mated with CDi males.
• Experiment 3 - Test compound: 1000 U/ml human rLIF using embryos 
from BeCBFi females mated with CDi males.
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• Experiment 4 - Test compound: 1000 U/ml murine anti-human LIF 
monoclonal using embryos from B6CBFi females mated with CDt 
males.
• Experiment 5 - Test compound: 1000 U/ml murine rLIF plus 1000 U/ml 
murine anti-human LIF monoclonal antibody, using embryos from 
B6CBFi females mated with CDt males.
• Experiment 6 - Test compound: 1000 U/ml human rLIF plus 1000 U/ml 
murine anti-human LIF monoclonal antibody, using embryos from 
B6CBFi females mated with CDt males.
• Experiment 7 - to determine whether a dose dependent effect of LIF on 
blastocyst development and fragmentation existed. For these 
experiments embryos from CDi females will be mated with CDt males. 
Embryos were exposed to 1000, 2000, 5000, and 10000 U/ml murine 
recombinant LIF under the protocol 1.
For Category A experiments, murine and human recombinant Leukemia 
Inhibitory Factor (derived from Chinese hamster ovarian cells) as well as a 
murine anti-human LIF monoclonal antibody were provided by Genentech, San 
Francisco, Ca.
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Category B Experiments - Transcervical embryo transfer - implantation, 
pregnancy, and resorption rates
For Categorie B and C experiments, murine recombinant LIF and a goat 
anti- murine recombinant LIF monoclonal antibody (IgG) was purchased from 
R&D Systems Inc. Test groups included: (1) 5000 U/ml mrLIF (2) 1000 U/ml anti- 
mLIF mcab (3) 2500 U/ml anti-mLIF mcab and (4) 5000 U/ml anti-mLIF mcab. 
Two groups of female mice were prepared, one group as embryo donors 
(BgCBF,), the other as the recipient females (CD0. Females from both groups 
received IP injections of 5 IU (0.1 ml) of pregnant mare serum gonadotropin 
(PMSG - Sigma, St. Louis) followed in 48 hours by IP injection of 5 IU (0.1 ml) of 
human chorionic gonadotropin (hCG - Sigma, St. Louis). The injection schedule 
for recipients was one day later than that for donors to allow cultured embryo 
development to syncrhonize with pseudopregnant uterine development. Donor 
females were placed with proven fertile CD! males. The next morning 
(approximately 16 hours) donor females were examined for the presence of 
vaginal coagulation plugs as an indication of mating. The recipient females were 
placed with vasectomized males in the afternoon of this day immediately 
following the hCG injection (day 0 of pregnancy) and examined for vaginal plugs 
the following morning. Embryos from donors were cultured in mKreb’s medium
for 72 h at 37°C in 5% C02 in 100% humidified air. On day 4 of embryonic 
development, pseudopregnant or recipient females were tranquilized using 0.1 
mg/Kg body mass acepromazine maleate (10mg/m, Promace, Henry Schein
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Inc., Fort Dodge). The embryo transfer tubing used was Clay Adams PE 10 
tubing (I.D. 0.28 mm; O.D. 0.61 mm, Baxter Scientific) connected to a 30 ga 
needle fitted to a 500 fjl, threaded, Halmilton syringe( Hamilton #1750TP). The 
PE10 tubing and syringe were filled with mKreb’s culture medium.
Approximately one cm of air was pulled into the distal tip of the tubing followed 
by 3 cm (1.85 (il) medium containing fifteen blastocysts from the donor group. 
Embryos were collected in as little medium as possible (1/4 turn of threaded 
Hamilton syringe) to reduce the risk of having them wash out of the uterus upon 
removal of the transfer tubing. An additional 0.5 cm of air was drawn into the 
transfer tube. The cervical os was visualized with the aid of a glass speculum 
constructed from a Pasteur pipette. Using a Wild Heerbrugg dissecting 
microscope, the distal end of the embryo transfer tube was inserted 
approximately 1.5 - 2 cm into the cervical os and the embryos flushed out of the 
tube until the proximal air spacer was observed passing the cervical os. The 
transfer tubing was gently removed and females individually caged and allowed 
to recover from anesthesia. On day 17 of pregnancy, pregnant females and their 
fetuses were killed by lethal overdose using IP injection of sodium pentobarbital 
(64.8 mg/ml, Anpro Pharmaceuticals - Henry Schein Inc.). The abdominal skin of 
pregnant females was removed and the abdomen opened in order to externalize 
the uterus. The uterus was then inspected for number of fetuses and/or 
resorption sites which were then removed. Fetuses were then removed from 
amniotic membranes and separated from the placentas. The following data were
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recorded: number of fetuses; which uterine hom they were collected from; fetal 
tail length, fetal crown-rump length; fetal mass; placental mass and linear 
dimensions; number of resorption sites and their dimensions; resorbing embryos 
were weighed if fetal attributes could be recognized. Implantation rates, 
pregnancy rates, and resorption rates were determined. The following definitions 
pertain to data: (1) Implantation rates - includes all implantation sites (those of 
both viable pups and resorbed fetuses) (2) Pregnancy rates - viable pups which 
appeared morphologically normal at day 17 (3) Resorption rates - amorphous 
resorption sites or fetuses demonstrating severe developmental retardation. 
Category C Experiments - Whole fetus clearing/staining for determination 
o f Skeletal Development
Fetuses were removed and measured as described for category 3 experiments 
on day 17 of pregnancy then cleared and differentially stained for cartilage and 
bone as described by Hanken and Wassersug (Hanken and Wassersug, 1981) 
in order to evaluate skeletal development. Once removed from uteri and 
measurements taken, the fetuses were fixed in 10% neutral buffered formalin (4g 
NaH2P04 + 6.5 g Na2HP04 in 1 L 10% formalin) for at least 24 hrs. After fixation, 
evisceration was facilitated by using watchmaker forceps. At this time the 
fetuses were washed in several changes of distilled water to remove most of the 
formaldehyde. After washing, fetuses were placed in an alcian blue solution (10 
mg alcian blue - Sigma Chemical Co. + 70 ml 100% ethanol, + 30 ml glacial 
acetic acid) for 12-48 hours. Once the cartilage was stained, the dehydration
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step ensued by placing the fetuses in a minimum of two absolute alcohol baths 
for 24 hours each. Next the fetuses were exposed to a series baths consisting 
of decreasing concentrations of ethanol (i.e. 75% - 2 hrs; 50% - 2 hrs; 25%) each 
for two hrs followed by two consecutive distilled water baths for one hr each.
After re-hydration, fetuses were partially macerated for one or two hrs in a 
solution containing 1 g of trypsin., 30 ml saturated aqueous sodium borate 
(Na2B40710H2O Fischer Scientific, Co.), and 70 ml distilled water. Fetuses were 
left in this solution until the soft tissues become transparent and the embryo 
proper had a consistency of warm gelatin. Bone was stained by placing fetuses 
a solution of 0.5% KOH then adding drops of 0.1% alizarin red in water (Sigma 
Chemical Co.) until the solution turned deep, almost opaque purple. Fetuses 
remained in this solution for 24 hours. The final step was embryo clearing. 
Fetuses were placed in a 25% glycerin in 0.5% aqueous KOH solution for 48 
hours. To this solution, 1 ml hydrogen peroxide for every 10 ml glycerin was 
added. Fetuses were then placed in succeeding solutions of increasing glycerin 
concentrations, 50% glycerin with 0.5% KOH; 75% glycerin with 0.5% KOH, and 
100% glycerin each for 24 hours. Specimens were be stored in glycerin to which 
a few drops of 88% liquid phenol (Mallinckrodt) was added. Fetuses were then 
examined and photographed using a Wild Heerbrugg dissecting microscope. 
Number and condition of ribs, humerus length (HLN), length of diaphyseal 
ossification (bone) in the humerus (HOL), width of dorsal gap between the 
vertebral pedicles or the vertebral space (VSPC), estimated percentage of
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ossification in the exoccipital bone (EX), length of ipsilateral scapula (SLN) 
measured from vertebral border to glenoid cavity, and length of ossification 
center in scapular spine (SOS) were recorded. All lengths were measured in 
millimeters (mm).
Vasectomy
Eight to ten week old CD! males were tranquilized by an IP injection of 0.1 
mg/Kg body mass acepromazine maleate (10mg/ml, Promace, Fort Dodge - 
Henry Schein Inc.) and anesthetized using 30 mg/kg body mass sodium 
pentobarbital (64.8 mg/ml, Anpro Pharmaceuticals - Henry Schein Inc.), IP. This 
protocol has proven to be very efficacious in our laboratory. Dopram-V (20 
mg/ml, Doxapram hydrochloride - Aveco - Henry Schein Inc.) was available if 
needed as an antidote in the case of any life threatening reactions to the general 
anesthesia. The scrotum was shaved and swabbed with 100% ethanol. 
Approximately 0.25 - 0.50 ml 2% lidocaine hydrochloride (Abbott Laboratories - 
Henry Schein, Inc.) was subcutaneously injected as a local analgesic/anesthetic. 
A 0.5 cm, mid-line incision, through the skin of the scrotum is was made, taking 
care not to involve the underlying tunics. The skin was separated from these 
underlying layers before proceeding. A 0.5 cm incision was made through the 
tunic approximately 0.25 cm to either side of the midline septum or raphe. The 
tunic layer was stabilized with self-closing watchmaker forceps. By rotating the 
testis within the scrotum, the vas defferens could be visualized and externalized 
without removing the testis which greatly facilitated replacement of tissues. The
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vas defferens was ligated approximately 0.05 cm from the cauda epididymis. 
Another ligature was placed approximately 1.0 cm proximal to the first. The 
segment of vas deferens between the two ligatures was removed using micro­
scissors. Any externalized viscera was replaced into the abdominal cavity.
Wound closing was effected by 06 Prolene sutures, for the abdominal wall (tunic) 
incision with discontinuous sutures spacing them 2-4 mm apart. 06 Prolene 
sutures were also used to close the skin incision with the same technique. I do 
not recommend continuous suturing because if the animal removes any 
segment, the rest will untie rather easily. A surgical staple was also used to 
provide an excellent deterrence to the animal removing its own sutures. Animals 
were placed in recovery and observe daily. Approximately one month minimum 
recovery was observed prior to mating.
Statistics
For Category A experiments, Cochran-Mantel-Haenszel (CMH) statistics 
were employed to determine potential differences in the means of that data used 
to determining the developmental indices (ID's) used throughout experiments 1 - 
7. As explained below, these indices evaluate the reproductive vitality of the 
embryos.
For Category B & C experiments, Multiple analysis of variance (MANOVA) 
was utilized to determine significant differences observed among the various 
dependent variables with Tukeys studentized range (HSD) test used to
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determine in which independent variables the differences existed. All lengths 
were measured in millimeters (mm) and masses in grams.
Justification of animal use
The species used was Mus musculus. This was a basic research project to 
determine fundamental mechanisms of embryo development once fetuses were 
exposed to leukemia inhibitory factor or its monoclonal antibody. This species is 
a large enough animal to perform transcervical and transtubal embryo transfer 
with ease, collection of fetuses is relatively simple, and the species has been 
proven to be very proliferative. The latter insures maximum numbers for embryo 
retrieval with minimum adult animal expenditure. Additionally, this work was a 
continuation of 20 years of research on embryotoxicity in this laboratory. 
Therefore a substantial data base was available to compare with new results.
The principal investigator was familiar with abided by all parts of the Animal 
Welfare Act, and the provisions described by the USDA, OPRR, and the 
University's assurance. No veterinary care of these animals was required.
To ensure minimum discomfort, distress, pain, and injury , mice were 
anesthetized to stage III, plane III of the surgical level of anesthesia, and the 
standard techniques for vasectomy for appropriate males as mentioned earlier 
was employed. Anesthetic, tranquilizer, and analgesic used were: Pentobarbital 
Sodium (anesthetic), Acepromazine Maleate (tranquilizer), and Lidocaine 
Hydrochloride (analgesic). Acepromazine maleate (0.1 mg/Kg), a veterinary 
tranquilizer, was administered intra-peritoneally (IP) on all animals at least one
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hour before surgical anesthesia was induced by peritoneal (IP) injection of Na- 
pentobarbital (30 mg/Kg). Intradermal (ID) and/or subcutaneous (SC) Lidocaine 
HCI (2% solution) was used at all surface sites prior to incisions. Animals were 
not allowed to reach consciousness throughout the duration of the experiment 
until wound closure was completed. Surgical experience for the principal 
investigator consisted of five years of training (1990 -1995) under the 
supervision of Dr. Swanson. Techniques include: Inhalation & general 
anesthesia, local analgesia and general surgery. Experiences include work with 
1) mice, 2) rats, 3) rabbits, and 4) hamsters
When euthanasia was required the drug and/or procedure to be used was 
(1) cervical dislocation or (2) overdose (OD) with IV injection of Na-Pentobarbital. 
Both of these procedures are consistent with the recommendations of the 
American Veterinary Medical Association Panel on Euthanasia for the species 
concerned (AVMA, 1978), the Guide for the Care and Use of Laboratory Animals 
(USDHHS-NIH publication No. 86-23), and the Experimental and Surgical 
Technique in the Rat (Waynforth and Fleckness, 1992).
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Results 
Category A, Experiment 1 - Temporal Effects
For category 1 experiments a developmental index (Dl) was formulated in 
which embryos in each stage of development were assigned developmental 
scores. These scores were ranked from -1 to 7 and corresponded to the 
following developmental stages respectively: -1 for fragmenting or degenerating 
embryos (f/d); 0 for 2-cell embryos; 1 for 3-4-cell embryos; 2 for 5-8-cell 
embryos; 3 for morulae (M); 4 for early blastocysts (e); 5 for expanded 
blastocysts (E); 6 for hatching blastocysts (h); 7 for completely hatched 
blastocysts H, Table 5 ). This index was designed to allow a negative impact for 
f/d embryos and included several developmental stages to reflect the graded 
response to treatment. This developmental index represents the following 
formula: The developmental scores (DS’s) were multiplied by the number of 
embryos in that developmental stage for a particular day of development and 
these numbers were summed. This total was divided by the total number of 
embryos in that test group to get an average representing the development of 
the entire group of embryos (Table 5). The Dl is represented by the following 
formula:
Dl = £ (DS x number of embrvos in each staged 
total embryos in each treatment group
Developmental indices were statistically analyzed using Cochran-Mantel- 
Haenszel (CMH) statistics to compare means.
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Figures 1, 2, 3, and 4 provide data on experimental sub-category 1, the 
effect of exposing murine 2-cell embryos to the various test compounds at 
different times during early embryo development. For protocol 1, 2-cell embryos 
were exposed to test compounds on the day they were collected from the 
oviducts. For protocols 2 and 3, embryos were exposed to test compounds after 
culturing as controls for 24 and 48 hours respectively. Table 6 provides a 
simplified presentation of sub-category 1 experiments. For this table, “>“ and “<“ 
characters were employed to indicate when a statistically significant increase (>) 
or decrease (<) was recorded between any of the three temporal protocols for 
developmental days three through six for each of sub-categories one through 
five. When comparing the effect of exposing preimplantation embryos to the 
various test compounds under the three different protocols, results varied 
according to the test compound studied (Table 6, Figures 1 - 4). For sub­
category 2 embryos (exposed to mrLIF) and sub-category 5 embryos (exposed 
to mrLIF plus the mcab), the order of temporal effect from highest developmental 
index (Dl) to lowest follows the pattern: protocol 1, 2, and 3, with protocol 3 
having the lowest Dl. For sub-category 3 embryos (exposed to hrLIF) as well as 
sub-category 6 embryos (exposed to hrLIF plus the mcab), protocol hierarchy 
followed a pattern of protocol 2, 3, and 1 or 2 and 3 compared to 1. When 
combined, as in the latter pattern (2 and 3 compared to 1), no significant 
difference was detected between protocols 2 and 3. Embryos exposed to the 
mcab alone, sub-category 4, protocol 2 demonstrated a higher Dl than protocol 1
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for developmental days three and four, whereas protocols 2 and 3 had 
significantly higher Dl values for developmental days five and six (Table 6, 
Figures 1 - 4).
Similar analysis was conducted to determine the effect that mrLIF had on 
embryos derived from CD-, females mated with B6CBAF,/J males (sub-category 
7). For these experiments, no significant differences were observed among the 
three protocols for days 3, 4, and 5. However, on day 6, protocol 3 embryos 




' Developmental Developmental Number of embryos
Score (DS) Stage in Stage
-1 fragmenting or 
degenerating
n i
0 2-cell n 2
1 3-4-cell n 3
2 5-8-cell n4
3 morula n 5
4 early blastocyst n 6
5 expanded blastocyst n 7
6 hatching blastocyst n 8
7 hatched blastocyst n 9
Dl = S (PS x number of embryos in each stage i.e. n n a) 
total embryos in each treatment group
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Table 6
Category A, Experiment 1. Comparison of Developmental Indices for Protocols 
1, 2, and 3.
mrLIF hrLIF mcab mrLIF + ab hrLIF + ab
Day 3 NS 2 > 1 2 > 1 NS 2 > 1
Day 4 1 & 2  > 3 2 > 3 > 1 2 > 1 1 & 2 >3 2 & 3 > 1
Day 5 1 > 2  > 3 2> 3 > 1 2 & 3 > 1 1 & 2 > 3 2 & 3 > 1
Day 6 1 > 2  > 3 2 & 3 > 1 2 & 3 > 1 1 & 2 > 3 2 & 3 > 1
Note. Increases (>) or decreases (<) in developmental indices indicate 
statistically significant differences between the protocols.



































mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 1. Temporal comparison - Day 3 - Category A, Experiment 1. 
Protocols 1 and 2. p values located above histograms for each group.


































mrLIF hrLIF ab mrLIF + ab hrLIF + ab ™  Protocol 3 - test
Figure 2. Temporal comparison - Day 4 - Category A, Experiment 1.
Protocols 1, 2, and 3. p values located above histograms for each
group. Within each group, histograms with the same letter are not significantly different.
O)
0.0060.008
Protocol 1 - test 
























mrLIF hrLIF ab mrLIF+ ab hrLIF+ ab
Figure 3. Temporal comparison - Day 5 - Category A, Experiment 1.
Protocols 1, 2, and 3. p values located above histograms for each
group. Within each group, histograms with the same letter are not significantly different
Protocol 1 - test 
Protocol 2 - test 



















W/A Protocol 1 - test 
Protocol 2 - test
Protocol 3 - testmrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 4. Temporal comparison - Day 6 - Category A, Experiment 1.
Protocols 1, 2, and 3. p values located above histograms for each
group. Within each group, histograms with the same letter are not significantly different.
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Category A, Experiments 2-6 - mrLIF, hrLIF, and mcab
Table 7 provides the magnitude in differences for developmental indices for 
each test compound compared to its control as well as the direction for that 
change (i.e. increase or decrease in developmental indices). For these 
experiments embryos were collected from BeCBAF/J females mated with CD, 
males. Appendix iii provides developmental index categories (Dl), data totals, 
percents for each developmental stage, and developmental indices for individual 
developmental day for each protocol for Experiments 2-6. Appendix iv shows 
the raw data collected for these experiments. Figures 5 -1 5  provide bar/column 
graphs for individual developmental day (days 3 -6 )  for each protocol for 
experiments 2-6.
For protocols 1 and 2, 1000 U/ml mrLIF (Experiment 2) enhanced 2-cell 
embryo development for every developmental day observed when compared to 
controls (Figures. 5-12). For days 3 -6 ,  mrLIF significantly increased the 
developmental indices during protocols 1 and 2 except for day 5 of protocol 2. 
Although an increase was observed on this day, it was not statistically significant 
( p = 0.5444, Table 7). For protocol 3 (Figures 13-15), no increase was 
observed on day 4 for the mrLIF group and a slight decrease in development 
was recorded for day 5 (Figures. 13 and 14) with a greater decrease for day 6 
(Table 7), although neither of these were significant (p = 0.298 and 0.124 for 
days 5 and 6, protocol 3, Table 7). When combined with 1000 U/ml of an anti- 
hrLIF monoclonal antibody (mcab) (Experiment 5) the stimulatory effect of 1000
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U/ml mrLIF was still observed for all developmental days during protocols 1 and 
2 (Figures 5-15,  Table 7), however, none of these were statistically significant. 
As with the mrLIF alone, the combination of mrLIF and the mcab had an 
insignificant effect on embryos for protocol 3 (Figures 13 - 15, Table 7). 
Supplementing medium with mrLIF tends to over-ride the inhibitory effect seen 
from the mcab alone, but not with statistical significance.
Human rLIF, at a concentration of 1000 U/ml (Experiment 3), had an 
increasingly inhibitory effect on 2-cell embryo development with each ensuing 
day for protocol 1 when compared to controls with significance observed on day 
4 (p = 0.033, Table 7). For protocols 2 and 3, hrLIF had an stimulatory effect on 
embryonic develop as reflected by developmental indices when compared to 
controls with statistically significant results recorded for days 3, 4, and 6 during 
protocol 2 and day 4 for protocol 3. The inhibitory effect of hrLIF was also 
observed when 1000 U/ml hrLIF was combined with the 1000 U/ml of the mcab 
(Experiment 6) for each developmental day during protocols 1, 2, and 3. 
Statistically, this inhibition was significant for all developmental days for protocol 
1 and for days 4 and 5 (p = 0.019 and 0.001 respectively) for protocol 2 (Figures 
5 -15 ,  Table 7).
The anti-hrLIF mcab alone (1000 U/ml) had very little effect on embryonic 
development compared to controls for developmental day 3 of protocol 1 
(Experiment 4). However, a significant decrease in development was recorded 
for developmental day 4 and the magnitude of this tendency increased
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temporally through day 6 (p = 0.022, 0.004, and 0.006 respectively). For 
protocol 2, an increase in development was observed, for days 4 - 6  with only 
day 4 being significant. A slight decrease was recorded for all 3 developmental 
days of protocol 3 with none of these being significant (Table 7).
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Table 7
Category A, Experiments 2-6 - Comparison o f Test Compounds.
Protocol 1
Treatment -»• m h ab m + ab h + ab
(n=138) (n=105) (n=106) (n=30) (n=31)
Devel Day 3 + 0.2 -0.1 -0.01 + 0.4 -0.4
p=0.003 p=0.239 p=0.927 p=0.189 p=0.004
Devel Day 4 + 0.5 -0.5 -0.43 + 0.73 -1.5
p=0.003 p=0.033 p=0.022 p=0.246 p=0.001
Devel Day 5 + 1.4 -0.8 - 1.3 + 1.2 -1.8
p=0.003 p=0.131 p=0.004 p=0.125 p=0.002
Devel Day 6 + 1.5 -1.3 - 1.4 + 1.5 - 1.4
p=0.003 p=0.057 p=0.006 p=0.054 p=0.026
Protocol 2
Treatment -* m h ab m + ab h + ab
(n=100) (n=61) (n=62) (n=30) (n=31)
Devel Day 3 + 0.3 + 0.2 + 0.3 + 0.2 -0.1
p=0.001 p=0.041 p=0.035 p=0.944 p=0.944
Devel Day 4 + 0.5 + 0.5 + 0.3 + 1.1 -0.4
p=0.011 p=0.001 p=0.082 p=0.049 p=0.019
Devel Day 5 + 0.8 + 1.2 + 0.2 + 1.4 -0.9
p=0.444 p=0.060 p=0.470 p=0.095 p=0.001
Devel Day 6 + 0.8 + 1.4 + 0.4 + 1.7 + 0.1
p=0.003 p=0.046 p=0.196 p=0.051 p=0.683
Protocol 3
Treatment -> m h ab m + ab h + ab
(n=95) (n=57) (n=59) (n=30) (n=31)
Devel Day 4 = + 0.3 -0.3 -0.8 -0.4
p=0.965 p=0.037 p=0.807 p=0.140 p=0.056
Devel Day 5 -0.2 + 0.8 -0.2 - 1.2 -0.3
p=0.298 p=0.607 p=0.805 p=0.135 p=0.795
Devel Day 6 -0.5 + 1.1 -0.2 - 1.5 -0.3
p=0.124 p=0.137 p=0.937 p=0.166 p=0.143
Note. Embryos from BeCBAF^J females mated with CD-, males. Comparison of 
developmental indices exposing 2-cell embryos to 1000 U/ml: mrLIF (m), hrLIF 
(h), an anti-hrLIF monoclonal antibody (ab), and combinations of the ab with m 
and h. Upper numbers indicate the magnitude of increase (+) or decrease (-) in 
the developmental index as compared to controls for each treatment. Lower 
numbers are p values derived from Cochran-Mantel-Haenszel (CMH) statistics.






















°  4 0<d
5





mrLIF hrLIF ab mrLIF + ab hrLIF + ab
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Figure 5. Category A, Experiments 2 - 6, Protocol 1, Day 3.






























mrLIF + ab hrLIF + abmrLIF hrLIF ab
Figure 6. Category A, Experiments 2 - 6, Protocol 1, Day 4.

























mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 7. Category A, Experiments 2 - 6, Protocol 1, Day 5.
p values located above histograms for each group.
























mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 8. Category A, Experiments 2 - 6, Protocol 1, Day 6.
p values located above histograms for each group.






























Figure 9. Category A, Experiments - 2 - 6, Protocol 2, Day 3.
p values located above histograms for each group.
0.944
mrLIF hrLIF ab mrLIF + ab hrLIF + ab



















mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 10. Category A, Experiments 2 - 6, Protocol 2, Day 4.
p values located above histograms for each group.



















mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 11. Category A, Experiments 2 - 6 ,  Protocol 2, Day 5.
p values located above histograms for each group.


















mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 12. Category A, Experiments 2 - 6, Protocol 2, Day 6.
p values located above histograms for each group.

























mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 13. Category A, Experiments 2 - 6, Protocol 3, Day 4.
p values located above histograms for each group.
























mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 14. Category A, Experiments 2 - 6, Protocol 3, Day 5.































mrLIF hrLIF ab mrLIF + ab hrLIF + ab
Figure 15. Category A, Experiments 2 - 6, Protocol 3, Day 6.





Category A, Experiment 7 - Dose Dependency Experiments
Experiment 7 investigated dose dependent effects of various concentrations 
of U/ml mrLIF on 2-cell embryo development. Table 8 provides the magnitude in 
differences for developmental indices for each test compound compared to its 
control as well as the direction for that change (i.e. increase or decrease in 
developmental indices). Figure 16 gives the results of these experiments and 
Appendix v provides data totals, percents for each developmental stage, and 
developmental indices for the individual developmental day for each protocol for 
experiment 7 with Appendix vi providing raw data. For these experiments, 
protocol 1 only was observed using embryos collected from CDt females mated 
with CD-, males. When testing 1000, 2000, 5000, and 10,000 U/ml mrLIF, 
maximum embryo development was observed at the highest dose tested (10,000 
U/ml) for each day when compared to controls. Significant increases in 
development were documented for developmental days 3 and 4 for all four levels 
of mrLIF. For developmental day 5, significant increases were observed for 
1000 U/ml and 10000 U/ml mrLIF groups. For developmental day 6, only the 
10000 U/m mrLIF group demonstrated a significant increase in development 
(Table 8, Figure 16).
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Table 8









Devel Day 3 + 0.5 + 0.6 + 0.7 + 0.7
p=0.005 p=0.001 p=0.001 p=0.001
Devel Day 4 + 1.1 + 1.2 + 1.0 + 1.5
p=0.001 p=0.001 p=0.001 p=0.001
Devel Day 5 + 0.7 + 0.2 + 0.3 + 0.9
p=0.007 p=0.615 p=0.105 p=0.034
Devel Day 6 + 0.6 + 0.3 -0.2 + 1.3
p=0.110 p=0.277 p=0.798 p=0.002
Note. Developmental indices for embryos collected from CD! females mated 
with CDt males comparing various concentrations of mrLIF to controls in order to 
examine potential dose dependent responses. Upper numbers indicate the 
magnitude of increase (+) or decrease (-) in the developmental index. Lower 
numbers are p values derived from Cochran-Mantel-Haenszel (CMH) statistics.
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Figure 16. Category A, Experiment 7, Dose Dependent Study, Protocol











Category B Experiments - Implantation, Pregnancy, and Resorption Rates
Implantation and Pregnancy rates for embryos derived from B6CBAF1/J, 
exposed to 5000 U/ml mrLIF, were approximately twice the rates for controls 
(62.96% and 55.56% compared to 33.33%, p = 0.0002 and 30.00%, p = 0.0001) 
respectively (Table 9, Figure 17). However, embryos in this group were also 
observed to have about a two-fold increase in resorption rates (51.85%) when 
compared to controls (30.00%, p = 0.011). Embryos exposed to the two lower 
concentrations of an anti-LIF monoclonal antibody (anti-mLIF mcab) reflected 
results similar to the LIF-treated embryos with and increase in implantation, 
pregnancy, and resorption rates as compared to controls. Significantly different 
results were observed when embryos were exposed to 5000 U/ml anti-mLIF 
mcab. For this group, decreases in implantation rates (15.38%) were reflected in 
both pregnancy (7.69%) and resorption (11.54%) rates as compared to controls 
(33.33%, p = 0.002; 30.00%, p = 0.001; and 30.00%, p= 0.011 respectively). No 
significant difference was observed when comparing females with resorption 
sites only (failed pregnancies with no viable pups) among the five dependent 
variables (p = 0.622). Two-by-five contingency tables were employed to 
investigate possible differences in the various rates (implantation, pregnancy, 
and resorption).
Multiple analysis of variance was utilized for fetal body mass, crown-rump 
length, tail length, placental length and width, and placental mass (TablelO).
The Wilks’ lambda indicated significant differences for these dependent
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variables (p = 0.0001). The individual ANOVA results of this analysis 
demonstrated a significant difference in body mass (p = 0.0002) and placental 
length (p = 0.0078). Tukey’s studentized range (HSD) test located the 
differences in body mass to be greatest between the 5000 U/ml anti-mLIF mcab- 
treated group and the 5000 U/ml LIF-treated group compared to the 1000 U/ml 
and 2500 U/ml anti-LIF-treated groups respectively. For placental lengths, the 
greatest difference was observed between controls and 1000 U/ml anti-mLIF 
mcab-treated embryos. Raw data for category B experiments is provided in 
Appendix vii.
Table 9
Category B - Implantation, Pregnancy, and Resorptiojn Rates.



















Note. C= Control; 50 = 5000 U/ml mcab; 25 = 2500 U/ml mcab; 10 = 1000 U/ml 
mcab
n= # recipients/group
Implantation Rates: including resorption sites as well as fetuses determined to be 
morphologically normal (apparently viable) at day 17.
Pregnancy Rates: Those fetuses determined to be morphologically normal 
(apparently viable) at day 17 .
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
99
TablelO
Catetory B - Fetal Lengths and Masses.
Treatment Body M C/R TL PL PW PM
Controls (n=21) 0.572 17.667 7.000 9.762 9.524 0.174
5000 U/ml LIF (n=43) 0.528 17.559 6.884 9.488 9.326 0.156
1000 U/ml mab (n=15) 0.629 17.333 7.400 8.533 9.000 0.154
2500 U/ml mab (n=19) 0.730 18.210 7.680 8.789 9.789 0.174
5000 U/ml mab (n=7) 0.450 16.570 6.860 9.714 9.000 0.200
Note. Linear parameters and masses for various test groups and controls. 
Category 2 Experiments: n = number of fetuses in each group. Body M = body 
mass, C/R = crown-rump length, TL = tail length, PL = placental length, PW = 
placental width, PM = placental mass.





















^  5000 U/ml mrLIF
Controls 
1000 U/ml mcab 
2500 U/ml mcab
Implantation Rates Pregnancy Rates Resorption Rates
Figure 17. Category B Experiments, Implantation, Pregnancy, & Resorption
Rates, p values located above histograms for each group. * = non-significant.
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Category C Experiments - Murine Skeletal Development and LIF
Multiple analysis of variance demonstrated significant differences observed 
among the various dependent variables: humerus length (p = 0.0027), length of 
diaphyseal ossification in the humerus (p = 0.0001), width of space between the 
vertebral pedicles/laminae (p = 0.0073), approximate percentage of ossification 
in the exoccipital bone (p = 0.0003), length of ipsilateral scapula (p = 0.0099), 
and length of ossification center in scapula (p = 0.0001). Tukeys' studentized 
range (HSD) test was used to determine between which independent variables 
the differences existed (Table11, figure 18. raw data for category C experiments 
provided in Appendix viii). Figure 18 shows significant differences between the 
1000 U/ml and 2500 U/ml anti-mLIF mcab groups compared to the 5000 U/ml 
LIF and controls which were significantly higher compared to 5000 U/ml anti- 
mLIF mcab group. In the latter group, significantly lower values were recorded 
for all variables except the space between the vertebral pedicles. Although not 
significantly different from controls, LIF-treated embryos demonstrated lower 
values for ossification and overall bone length when compared to the 1000 U/ml 
and 2500 U/ml anti-mLIF mean groups with higher values compared to 5000 
U/ml anti-mrLIF mcab. Tukey’s studentized range (HSD) test demonstrated that 
these differences were observed for HLN, HOS, SLN, and SOS. For the 
estimated amount of ossification in the exoccipital bone (EX) a significant 
difference was observed between the 50 U/ml anti-mLIF mean group and all the 
other independent variables. Finally, the greatest amount of difference for the
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variable SOS was determined to exist between the 50 U/ml anti-mLIF mean 
group and the 25 U/ml anti-mLIF mean group.
LIF-treated fetuses were not significantly different when compared to 
controls for overall bone length and length of ossification centers. When 
controlling for fetal size by using an ossification index, significant differences 
were observed. This index was formulated by dividing the length of the 
ossification center in the bone (humerus and scapula) by the total length of the 
developing bone. Table 12 shows that when using this index, LIF-treated 
fetuses demonstrate significantly lower values for bone ossification/development 
when compared to controls (p = 0.0001). No significant differences were noted 
between the controls and the 1000 U/ml anti-mrLIF mcab-treated fetuses or the 
2500 U/ml anti-mrLIF mcab-treated fetuses. Additionally, the fetuses treated 
with the 5000 U/ml anti-mrLIF mcab showed significantly lower values for 
skeletal development compared to the LIF-treated fetuses.
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Table11
Category C - Skeletal Development.
Test Group HLN HOS VSPC EX SLN SOS
50 U/ml mcab (n=9) 2.848+ .587+ .946 46.70+ 2.251 + .564+
LIF (n=42) 2.992 .891 + .818 82.75- 2.400 .911
CONTROLS (n=21) 3.058 1.052 .822 88.57- 2.401 .977
10 U/ml mcab (n=16) 3.277- 1.293- 1.027 90.00- 2.660- 1.211
25 U/ml mcab (n=19) 3.412- 1.293- .960 94.44- 2.759- 1.280-
MANOVA p values 0.0027 0.0001 0.0073 0.0003 0.0099 0.0001
Note. C— Control; 50 = 5000 U/ml mcab; 25 = 2500 U/ml mcab; 10 = 1000 U/ml 
mcab n= # recipients/group “+" and indicate groups, within columns that are 
statistically different from each other. HLN = total length of humerus, HOS = 
length of ossification center of humerus, VSPC = dorsal gap between vertebral 
pedicles/lamina, EX = estimated percent ossification of exoccipital bone, SLN = 
total length of scapula, SOS = length of ossification center of scapula.
Table12
Category C - Ossification Index.
Test Group HO/HL SO/SL
CONTROLS (n=21) 0.333a 0.403a
LIF (n=42) 0.296b 0.384b
1000 U/ml mcab (n=16) 0.386a 0.446a
2500 U/ml mcab (n=19) 0.386a 0.453a
5000 U/ml mcab (n=9) 0.206c 0.249c
MANOVA p values 0.0001 0.0001
Note. C= Control; n= # recipients/group. HO/HL = length of ossification center 
in the humerus divided by the total length of the humerus. SO/SL = length of 
ossification center in the scapula divided by the total length of the scapula. 
Groups with different letters following the ossification indices are significantly 
different.
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Figure 18. Category C Experiments, Skeletal Development.
Histograms with the same letter are not significantly different. 104
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Discussion
Leukemia inhibitory factor (LIF) is a multifunctional (pleiotroic) cytokine that 
enhances in vitro murine pre-implantation embryo development with temporal 
and dose-dependent effects (Mitchell et al., 1994). It has been shown that LIF is 
essential for implantation in murine species (Stewart, et al., 1992).
This project shows that LIF has a significant effect on pre-implantation 
embryo development, both in a temporal and dose dependent manner. 
Additionally, LIF was shown to have a significant effect on implantation, 
pregnancy (i.e. successful pregnancy), and resorption rates as well as the 
skeletal development of the mouse fetus.
Category A, experiment 1 demonstrated the effect that LIF exerted on the 
pre-implantation development of 2-cell murine embryos to the hatched blastocyst 
stage. Different temporal protocols were shown to be optimal for embryos 
exposed to different test compounds. Protocol 1 was optimal for embryos 
exposed to 1000 U/ml mrLIF or a combination of the mrLIF plus the mcab. For 
mouse embryos exposed to mrLIF, the day 2 protocol demonstrated 
developmental indices significantly less than those for protocol 1 and significantly 
higher than those for protocol 3. This data indicates that these embryos will 
develop best when exposed to recombinant mLIF at the time of 2-cell embryo 
collection. Additionally, it appears that the longer these embryos culture without 
being exposed to rmLIF, the lower their developmental potentials will be.
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Protocol 2 was optimal for development of embryos exposed to hrLIF, the 
mcab alone, and a combination of the hrLIF plus the mcab (table 6). Therefore, 
murine embryos from female BeCBAF^J mice obtain the highest developmental 
index when exposed to mrLIF immediately after their collection from the fallopian 
tubes. However, if these same embryos are exposed to hrLIF, they tend to 
develop further if allowed to culture as controls for 24 hours prior to exposure to 
hrLIF (protocol 2). This is not surprising considering the fact that hrLIF is a non­
native xenobiotic cytokine for the murine species.
Investigated in category A, experiments 2-6, was the effect that 1000 U/ml 
mrLIF, hrLIF, the anti-hLIF monoclonal antibody alone as well as in combination 
with the two previous test compounds, had on the development of 2-cell embryos 
(table 7, figures 5 through 15). Supplementing culture medium with mrLIF (sub- 
category 2) exerted a stimulatory effect on development for embryos derived 
from BeCBAF/J female mice, whereas, supplementation with hrLIF exerted an 
inhibitory effect, significant on day four and six. The exception for the stimulatory 
effect from mrLIF was noted for protocol 3. Additionally, hrLIF exerted a 
stimulatory effect during protocol 2 with significance on days 3, 4, and 6 and 
protocol 3 with significance on day 3. There is evidence of the presence of low 
affinity and high affinity binding. It is possible that high affinity binding to 
receptors is acquired by the embryo by day 3 and this high affinity binding is 
sufficient to bind enough hrLIF to cell membrane receptors to allow some 
positive effect. No evidence to this effect has been demonstrated. It is possible
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that by the third day of development a window for the positive effect of mrLIF- 
supplemented medium has passed, however, this is purely speculation and 
requires further investigation. Even though 78% homology has been described 
between LIF derived from these two species (Gough et al., 1988), it is not 
surprising that xenobiotics, such as hrLIF in the mouse, do not exert as much of 
a stimulatory effect as endogenous cytokines, and as in this case, and they 
produce significant inhibitory effects. The anti-hrLIF monoclonal antibody 
demonstrated an inhibitory effect for protocol 1, a slightly stimulatory, however, 
predominantly non-significant effect or protocol 2, and a non-significant inhibition 
for protocol 3. These results suggest that native mLIF (produced by the test 
animals) may be associated with the anti-human rLIF mcab to induce a negative 
effect during the first day of development when compared to controls. In light of 
the fact that the mcab alone was inclined to exert an inhibitory effect on pre­
implantation development, a surprising result was the fact that a stimulatory 
effect was observed in sub-category 5 (mrLIF plus anti-hrLIF mcab). If binding of 
this anti-human rLIF mcab to native and recombinant mLIF is weak, and if the 
stimulatory effect of mrLIF is strong, it is possible that the significant stimulatory 
effect from the mrLIF is great enough to override the non-significant inhibitory 
effect seen by the mcab alone. The inhibitory effect of the combined hrLIF plus 
mcab for each protocol may reflect the antibodies ability to bind to its ligand, the 
hrLIF, with a high enough affinity to reduce the stimulatory effect of hrLIF during 
protocol 2 and 3.
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LIF transcripts hav been detected in 3.5 post-coital mouse embryo and 
transcripts for the receptor have been observed in the 4-day-old embryos 
(Conquet and Brulet, 1990; Murray et al.t 1990). Additionally, LIF was shown to 
be produced by the mouse uterine endometrial glands on day 4 of pregnancy 
(Bhatt et al., 1991). These authors and others have demonstrated that 
maximum LIF release from endometrial glands corresponds to implantation 
(Bhatt et al., 1991; Conquet and Brulet, 1990; Shen and Leder, 1992). The 
results from these and the present project suggest a physiological role for LIF in 
the process of implantation. The present study demonstrates definitive embryo 
trophic effects of mrLIF, hrLIF, the anti-human rLIF mcab and combinations of 
these on the development of 2-cell mouse embryos.
Category A, experiment 7, investigated possible dose dependent effects for 
2-cell embryos, derived from CD, females mated with CD, males exposed to 
mrLIF. Compared were concentrations of 1000 U/ml, 2000 U/ml, 5000 U/ml, and 
10000 U/ml with controls. For sub-category 7 experiments, only protocol 1 was 
utilized. For each of developmental days 3 - 6 ,  test groups demonstrated 
significantly higher developmental indices when compared to controls (table 8,
10, figure 16). Additionally, the highest concentration examined (10000 U/ml) 
resulted in the highest developmental indices for each day suggesting that 
supplementing medium with supra-physiological levels of mrLIF enhances 
embryo development to the blastocyst and hatching/hatched blastocyst stages.
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However, as will be discussed below, unfavorable side effects may develop from 
using such supra-physiological levels.
It has been shown that LIF plays a critical role in murine reproduction. LIF 
has been shown to be an absolute requirement for implantation in murine 
species (Stewart, et al., 1992). Although its precise function in humans is 
unknown, its therapeutic potential in IVF clinics merits investigation. In vitro 
experiments indicate that 1000 U/ml LIF are required to maintain undifferentiated 
embryonal stem (ES) cells (Williams et al., 1988). In our lab we have 
demonstrated that LIF has a pronounced effect on implantation and resorption in 
the mouse. These experiments demonstrate that transfer medium, 
supplemented with LIF increases the implantation rate of both healthy or viable 
embryos as well as those of “poorer quality” that may not otherwise survive to 
term as demonstrated by almost parallel increases in both successful pregnancy 
rates and resorption rates (fialed pregnancies). Further studies are needed to 
determine if LIF will increase the risk of resorption or spontaneous abortion 
(miscarriage) in primates such as humans.
The lower levels of anti-mLIF mcab actually increase rather than decrease 
implantation rates (table 9). These lower levels of mcab may not be sufficient to 
block all LIF-receptor binding. Additionally, lower levels of the mcab may be 
binding to other, inhibitory proteins, in a non-specific manner. More work needs 
to be conducted to determine the mechanism of this effect. Significant
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reductions in implantation rates are seen when transfer medium is supplemented 
with 5000 U/ml anti-mrLIF mcab.
LIF has been shown to increase the resorption of bone (Abe et al., 1988; 
Ishimi et al., 1992; Reid, et al., 1990). High levels have been associated with 
pathological conditions such as cachexia, tissue calcification, pancreatitis, 
gonadal and thymus anomalies (Metcalf and Gearing, 1989). Malaval and 
associates demonstrated the ability of LIF to inhibit bone nodule formation in 
fetal rat calvaria cell cultures (Malaval, Gupta, and Aubin, 1995). Additionally,
LIF was observed to inhibit growth and mineralization of early fetal mouse long 
bone cultures (Van Beek et al., 1993).
For the present study we investigated the effects of a single exposure of LIF 
on the skeletal development of mice in vivo. These data show that LIF does not 
significantly inhibit the development of the overall bone length (cartilagenous 
template). However, LIF has a significantly inhibitory effect on the ratio of 
ossification to overall bone length (Table 12). This indicates that supplementing 
embryo transfer medium with supra-physiological levels of LIF may significantly 
impair skeletal development. Further investigation is warranted to determine the 
effect that various concentrations of LIF-supplemented transfer medium may 
have on mouse as well as human embryos.
In conclusion, mrLIF has a significant positive embryotrphic effect. It 
increases the number of embryos developing to the hatched blastocyst stage.
LIF has been shown to have a pronounced effect on implantation. It increases
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the implantation of both healthy embryos as well as those that may not otherwise 
survive until term. Finally, LIF exerts an inhibitory effect on the process of 
ossification in developing bone. More studies are warranted before LIF or its 
monoclonal antibody should be used in the clinical setting.
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Normal cell types displaying LIF receptors with receptors per cell (RPC) and 
dissociation constants (DC) in parentheses (when available) compared to 
Embryonyl stem cell (ES) and embryonic carcinoma cell (EC) lines.
Cell Type RPC (DC) Cell TvDe RPC (DC)
Bone Marrow ES and EC Cell Lines
monocyte............. .... 155 M1(ES)................... ..300-500 (100-200
promonocyte........ .... 270 PM)
lymphocyte........... .... 70 M 1........................... ..170 (1 x 10- M)
Spleen EKcs-1 (ES)........... ..295 HA (90 pM)
blast...................... .... 430 PCC3A1 (EC)......... .190 HA (90 pM)
monocyte............. .... 240 F 9(E C ).................. .330 HA (90 pM)
lymphocyte........... .... 120 D3 (ES)
Peritoneal Cavity NG2
Macrophage......... .... 360 PC13
Lymphocyte......... .... 170 P19
fetal hepatocyte ... ....1500 CBL63 (ES)
fetal hepatic blast. .... 140 HD5 (ES)
adult hepatocyte.......2000 CC (ES)
serum LBP........... ..1 pg/ml CP1 (ES)
osteoblasts
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1988; Hilton, Nicola, and Metcalf, 1988; Hilton, Nicola, and Metcalf, 1991; Ip, et 
al., 1992; Layton, etal., 1992; Shen and Leder, 1992; Tomida, 1995;
Willaiams, et al., 1988; Yamaguchi, et al. 1995; Yamamoto-Yamaguchi,
Tomida, and Hazumi, 1986;)
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APPENDIX iii CONTINUED
Category A, Experiments 2 -6  
Developmental Indices, Percents, and Totals 
Protocol 1
lDSrDay3 I rmabl %i Seri cf %i Scr h+abi %T Serf c| %i Scr
141
0 2
1 3-4 i 3!
215-8 11 3.33| 2.0|
31m 161 53.33 48.0 ! 9.ol





Tot 301100.001 102 ! 32
Devel. Indices 3.401
p = 0.189:















3! 10.001 12.0! 3.0I 9.68! 12.0
5|E
6'h
16’ 53.33! 80.0: 7.0! 22.58 ! 35.0 
9' 30 001 54 0114 0? 45 16'! 84 0
7!H
-1 jd 1 3.33! -1QI 5.0’ 16.131 -5.0
Tot ! 30 i 100.00 i 148! 31 ’ 100.00 i 131.0
Devel. Indices 4.931 4.2
p = I 0.246!
! Devel :





4|e 21 6.67! 8i 2j 6 25: 8.0
51E 4| 13.33! 20! 31 9.38| 15.0
6|h
7!H
6 1 20.00 i 36! 81 25 00 48.0
161 53.331 112! 12! 37.50! 84 0
-1 Id 2! 6.671 2̂! 7! 21.88| -7 0
ITot
[pevel. Indices









4le i 2! 6.25 8.0 2 6.45 8.01 !
S j E 3! 10.001 1S| i 0.00 0.0 31 9.68 15.0 !
6|h 2 6.67 12| 3 9.38 18.0 11 3.23 6.0 4| 12.90 j 24.0
7in i 231 76.67 161| 19 59.38 133.0 191 61.29 133.0 25l 80.65 i 175.0
-1 I d  | 2| 6.67 -2 8 25.00 -8.0 6 19.35 -6.0 2 1 6.451 -2.0
|Tot I 301 100.00 186 32| 100.00 151.0 31 100.00 156.0 311 100.001 197.0
Devel. Indices - ► 6.2l i 4.7 5.0j ! ; 6.4
L_ J _ _ _ _ _ I _ _ _ _ : P = .  0.054] 1 . . . . .P  = 0.026L > 1
11 3.231 O.Oj
191 61.291 57.01 9
111 35.48! 44.0122
I




p =  0.004
h+abi %: Scr' c: %; Scr
1 i 3.23! 0.0 i
3! 9.68! 9.01 1' 3.231 3.0
81 19 351 24.0! 1' 3.23! 4.0
17! 54.84 ! 85.0I 9! 29.03! 45.0
6.45! 12.01 19! 61291 114.0
1 i 3.23! 7.0
6.45! -2.0!
31 i 100 00! 128.0! 31 i 100.001173 0
4.1! 5.6




Scr; ci %: Scr
6.45! 8.O1 11 3 23! 4 0
38.711 60.01 S i  16.13; 25.0
6.45! 12.0112! 38.71 72.0
29.03! 63.01131 41 941 91.0
19.35! -6.0!
100.001 137.0! 31 i 100.00! 192.0
4.4! 62
p=  0 002!
h+abi Sen c! %i Scr
3-4 = 3-4-cell embryo; 5-8 = 5-8-cell embryo; M = morulae; e = early blastocyst E = expanded 
blastocyst h = hatching blastocyst H = completely hatched blastocyst f/d = fragmenting or 
degenerating embryos, m = mrLIF; h = hrtlF; ab = anti h-LIF monoclonal antibody; DS = 
Develpmental Score; p values derived from Cochran-Mantel-Haenszel (CMH) statistics.
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APPENDIX iii CONTINUED
Category A, Experiments 2 -6  
Developmental Indices, Percents, and Totals 
Protocol 2
iD S rD a y3 fm f %i Scr! cl %f Scr h[ %[  Scrl ci ~ % [  Scr abi %: Seri c! % i Scr
0| 21 i ; 5j 3.57i 0.0 i ; 2 ! 2.00' 0.0 i 1 0.96! 0.0
; l {  3-4! 11 1.09| 1.0j 4| 2.86| 4.0 ’ i ' ; I 2! 1.92! 2.0
! 2! 5-8 j 1! 1.09 ( 2.01 5i 3.57| 10.0 2| 3.28| 4.0 ! 6, 6.001 12.0 3 2.88! 6.0
' 3i mi 491 53.26| 147.0! 9oi 64.29|270.0 381 62.30i 114.01 701 70.0oj210 0 40! 64 52! 120.0! 75: 72.12! 225.0
, 4| ei 41; 44.57! 164.0! 36i 25.711144.0 211 34.43 i 84.0 i 221 22.00! 88.0 21; 33.87! 84.0! 20! 19.23i 80.0
, 5 1  E| i I
6| n ;
7 Hi , i
: - i ! : I 1| 1.61; -1 Oi 31 2.881 -3.0
I ; Tot 
Devel. Inc
921 100.001 314'°> 140 100 00! 428.0 611 100.001 202.01 1001 100.001 310.0 621 100.00! 203.0! 104' 100.00l 310 0
ices 3.4! 3.1 3.3I 3.1 3.3! 3.0
: P =10.001! p = [0  041! p =' 0.035!
I ;
I I
Day4 mi %■ Scrl ci %! Scr hi %, Scrl ci %i Scr abi %: Seri c: %; Scr
0| 2! 2; 1.45! 0.0 1! 1.001 0.0
1 3-4 2: 1.45 20
2! 5-8 1! 1.09* 2.0i 2i 145 4.0 1 0.99; 2 0
: 3i ml 4 i 4.35i 12.01 2| 1.45| 6.0 > . 2l 2.001 6.0 31 4 921 9.01 1i 0.99! 3.0
4! e! 231 25.00! 92.01 58) 42.03! 232.0 12| 19 671 48.01 54 ! 54.00; 216.0 161 26.231 64.0 ! 491 48.511 196.0
' 5I e ! 47| 51.09! 235,o| 32{ 23.19i 160.0 31' 50.82! 155.01 14: 14.00! 70.0 24! 39.341120.01 221 21.78' 110.0
i 6l h{ 18j 17 39| 96.01 31 i 22.46i 186.0 15 i 24.59! 90 0 241 24 00' 144.0 17! 27 87' 102.0i 24 { 23.761144 0
7! Hi i ' ' 3! 4.92! 21.0| 3i 3.001 21.0 :
-1i dl 1! 1.091 -1.0} 91 6.521 -9.0 ■ 2 2.001 -2.0 1i 1.641 -1.01 41 3 96' -4.0
: Toti92i 100.001 436.0! 138! 100 001581 0 61! 100.001 314.01 100! 100.001455.0 611 100 001294.0! 101! 100.00! 451 0
Devel. Indices ^  4.71 4.2 5.1 4.6 4.8! 4.5
p =i 0.0111 ' p = i  0 001 p =i 0.082'
•





4! ei 4| 6.351 16.0i 1i 161! 4.0 3' 10.341 12.0 1 ! 3.03! 4.0 i 1 3 131 4.0
' 5i E !  22! 34.92! 110.01 15i 24.19| 75.0 10l 32.26 i 50.0| 3i 10.34! 15.0 7! 21 21 ' 35 0! 9! 28 13: 45 0
6l hi 22! 34.92! 132.0! 18! 29.031108.0 13i 41.94i 78 0j 12! 4138' 72.0 9! 2727' 54 0! 10' 31 25! 60.0
7| H |12i 19.05! 84.0, 16i 25.81! 112.0 8! 25.81; 56.0 i 6! 20.69! 42.0 151 45.45! 105.01 111 34 38 : 77.0
1-1!  di 3! 4.76i -3.0! 12! 19.351-12.0 5| 17 241 -5.0 i j  3.03! -1.01 1: 3.13: -1.0
; Tot 
[Devel. Indi
63! 100.001 339.0! 62j 100.001287 0131 i 100.00i 184.01 29! 100.00! 136.0! 33I 100.00! 197.0' 32! 100.00! 185.0
ces - ^  5.4i 4.6 5.9! 4 7 6 0 5 8
p =10.444! p = '0.0601 p =' 0.470!
I Day6i mi %, Scr! hi %, Scr! ! abi %, Scr1
0l
11 3-41 , '
2 5-8
3i mi i
4 j el 41 6.35! 16.01 1i 1.61 4.0 l 31 10.34' 12.0 •
' 5i E  9i 14.29| 45.0! 5| 8.06 25.0 4! 12.90 20.01 1; 3 9.09! 15.0! 7! 21 881 35.0
: ei h; si 7.94| 30.0| 6| 9.68 36.0 5! 16.13 30.0i Si 17 241 30.0 5! 1515| 30.0i 2: 6.25! 12.0
! 7| H 40! 63.491280.01 371 59.68 259.0 21! 67 74 147.0 15| 51.72|105.0 251 75.76! 175.0! 22! 68.75! 154.0
, -1| d 5j 7.941 -5.01 13 i 20.97 -13.0 1| 3.23 j -1.0 5! 17.241 -5.0 0.00 0.0! 1i 3.13 i -1.0
L . 1 Tot
: Devel. Indie
63| 100.001 366.01 621100.001311.0 311 100.001 196.0 29! 96.55! 142.0! 33! 100.00 220.0! 321 100.00i 200.0
:es 5.81 I 5.0 6.3 i 4.91 i 6.7' 6.3
! . 1 . .  1 1 P =: 0.003} [  L 1 _p=! 0 046[ i . 1 1 P =0.196 L .
|3-4 = 3-4-cell embryo; 5-8 = 5-8-cell embryo; M = morulae; e = early blastocyst; E = expanded blastocyst: h -  hatching 
1 blastocyst; H = completely hatched blastocyst; f/d = fragmenting or degenerating embryos, m = mrtlF; h = hrLIF; ab = anti h-LIF 
{monoclonal antibody; DS = Develpmental Score; p values denved from Cqchran-Mantel-Haenszel (CMH) statistics.
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APPENDIX iii CONTINUED
Category A, Experiments 2 -6  
Developmental Indices, Percents, and Totals 
Protocol 2
DS f Day31 mi-ab' %' Scr: ci %! Scr h*ab %I Scr! ci % Scr
Ol 21 2 6.251 0.0 0.00! 0.0!
1 ! 3-4 1 3 9 38! 3.0
2 5-8
3! mi 23 : 76.671 69.0 ! 9 28.131 27.0 12 38.711 36.01 9! 29.03 270
' 4! e 1 7' 23.331 28.0 17 53.131 68.0 19 61.291 76.01 22! 70.97 88.0
5 E! ; ; . : .
6 l hi
; 7| HI ! ;
-H dl i 1 3.131 -1.0 ! : ! i
Totl 30! 100.001 97.0 32! 100.001 97.0 31
OCMOOOO 31. 100.00 115.0
! Devel. Indices ► 3.2! 3.0 3.6! 3 7
p=l 0.944 p =i 0.9441
Day4! nv-ab % i Scr c % Scr h+ab Scr' c: % Scr
0: 2!
1 i 3-4|
2; 5-8! 1 3.23! 2.0
I 3i ml 1 3.23! 3.0 ; 1: 3.23 3.0
. 4! e 2 6.451 8.0 31 9.68i 12.0 2. 6.45 i 8.0! 1! 323 4.0
; 5i E 20 64.52! 100.0 7[ 22.58! 35.0 231 74.191 115.0! 9! 29.03 45.0
i s| h 8 25.81; 48.0! 141 45.161 84.0 5i 16.13| 30.01 19! 61 29 114.0
7! H 1 3 23! 70! 1 3 23! 70! 1i 3.231 7 0
-1! d 5! 16.13! -5.0 ,
Totl 311 100.001 163.0131! 100.001 131.0
Devel. Indices 5.31 4.2
p =! 0.0491




; 2 6.25 8.0
E i
n r
8 1 25.811 40.01 3 9.38
14| 45.16j 84.01 8 1 25.00
HI 91 29.03T 63.0 i 12| 37.50 84.0
-11
■ . L Tot! 31] 100.001 187 0132 







Day6! m-t-ab % Scr! h+ab1 %! Scr:
0 2:
1 3*4 i !
2 5-81 : , ; i
3 I m ! ; ! : 1
4 e! i 2 6.25| 8.0 1! 3.23 4.0!
5 E 7 22.581 35.01 ' 41 12.90 20.0!
6 h 4 12.90! 24.0i 3| 9.38! 18.0 4i 12.90 24.0 4! 12.90! 24.0
7 H 20 64.52! 140.0119| 59.381 133.0 22! 70.97 154.0 251 80.65! 175.0
-1 d I  si 25.00 1 -8.0 ! ' 2! 6.45 i -2.0r
I Devel. Indices
31! 100.00! 160 0131! 100.00
52!




1! 4.76! 4.0! 1! 3.231 4.0
141 66.67! 70.01 5| 16.131 25.0 
5j 23.81 ] 30.01 12i 38.71! 72.0~
11 4.761 7 01131 41.94 ; 91.0
I
21! 100.001 111 0131! 100.001 192.0
5.3! 6.2
p =i 0.001
[  Toti 31 j 100.00l 199.o[ 321100.001 151.01 31 j lOQ.OOj 2Q2.oj 31! 100.00! 197.0
6.4 4.7 6.51 64
I . . . : _________L. .  i _  P = L A °5 lL _ L  _  L . . .  1  X .  P  =10.683] ;
I 3-4 = 3-4-cell embryo; 5-8 = 5-8-cell embryo; M = morulae; e = early blastocyst E = 
r expanded blastocyst h = hatching blastocyst H = completely hatched blastocyst f/d = 
[fragmenting or degenerating embryos, m = mrLIF; h = hrLIF; ab = anti h-LIF monoclonal 
! antibody; DS = Develpmental Score: p values derived from Cochran-Mantel-Haenszel (CMH)
!_ statistics.
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APPENDIX iii CONTINUED
Category A, Experiments - 2-6 
Developmental Indices, Percents, and Totals 
Protocol 3
144
,DSf Day3[ mi %[ Scr cj %I Scr hi %I Scrr ci %i Scr abi %■ Scr1 c' %. Scr
‘ 0| 2 ! ; ! , : :
; 1 | 3-4 ; 1
' 2 5-8 1 ; !
: 3 m i ’ i (
4 e! ! : |
5 Ei ' ,
6 hi
7 HI ,
-1 di ; ! 1 ,
Toti ' :
I ; : P ‘ i
: : ; '
Day4| m| % Scr! ci % Scr hi %; Scr: c! % i Scr ab; %. Scr ci % Scr
0 2| 4 1 4.21 i 0.0! 2 1.451 0.0 2i 3.51 0.0! 1 : 1.001 0.0
1 3-4i 3| 3.161 3.01 2 1.451 2.0 1 0.001
2; 5-8! 2! 2.11! 4.0l 2! 1.45! 4.0 : ’ 1 ' ‘ 1 0.99 2.0
3i mi 5i 5.26i 15.0! 2| 1.451 6.0 11 1.751 3.0 i 2! 2.001 6.0 4i 6.78! 12.01 1: 0.99 3.0
41 e! 231 24.21; 92.0! 58! 42.031 232.0 15! 26.321 60.0! 54 : 54.001216.0 5| 8.47! 20.0| 49: 48.51 196.0
5! Ei 291 30.531145.01 32! 23.19! 160.0 20! 35.091100.01 14 i 14.001 70.0 27! 45.76; 135.0! 22, 21.781110.0
6: hi211 22.1112G.0i 31 > 22.461188 0 15! 26.32 ! 90.0 i 24 i 24.00 i 144.0 151 25.42| 90.01 24; 23.761144.0
7 H! 3! 3.161 21.01 4: 7.02! 28.01 3 1 3.001 21.0 i '
-1' d 5 ; 5.26 i -5.0 i 9j 6.52i -9.0 2! 2.001 -2.0 81 13.56! -8.0! 4 3.96: -4.0
1 Toti 95 i 100.001401.Ol 138i 100.001 581.0 57 i 100.00 i 281.011001100.00 i 455.0 591100.001249.01101 i 100.001451.0
Devel. Indices 
' P =
4.2! 4.2 4.91 4.6 4.2: 4.5
0.965| p= 0.037! p= 0.807!
, ■ '
' ! i 1
Devel I b6i Day 31 Protoi : :





4i ei 7' 10.451 28.01 1: 1.61; 4.0 2: 6.67' 8.0! 3i 10.341 12.0 1 3.13: 4.0
5! E! 21 i 31.341105.0! 15! 24.1si 75.0 15! 50.00! 75.0! 3i 10.34! 15.0 11= 35.48! 55.0! 9i 28.13: 45.0
. 6! hi 13| 19.40j 78.0( 18 29.03 108.0 8! 26.67! 48.01 12! 41.38 72.0 6l 19.35! 36.01 101 31.25! 60.0
■ 7! h | 14| 20.90i 98.0! 16 25.81 112.0 5 1 16.67! 35.0! 6! 20.69 42.0 12| 38.711 84.01 11 34.38 ! 77.0
: -1| d 121 17.91 -12.0) 12| 19.35| -12.0 > 51 17.241 -5.0 2! 6.45! -2.01 1 3.131 -1.0
: i Tot 167! 100.00 297.01 62! 100.00 i 287.0 301100.001166.0 29! 100.00! 136.0 31 100.00 i 173.0! 32 ‘ 100.00! 185.0
Devel. Indices ^
; - r -  T : p =
4.41 j i 4.6 5.5 4.7 5.6' 5.8
0.298! ' p = I 0.607! p= 0.805!
' I  ' I 1 1
I I 1 : : i ! i ! ■
i Devel b6l Day31 Protoi
! Day 6 ml %i Seri ci %: Scr hi %! Seri ci %i Scr abi % Scr: c ; %• Scr
: ot 2 I ,
. i; 3-4 : 1 I :
: 2i 5-8!
! 3; : : ;
4: ei 3| 4.69i 12.0j 1! 1.61! 4.0 ; 4| 13.79 16.0 I
! 5, E| 151 23.44 75.0: 5i 8.06! 25.0 9 1 30.001 45.01 | 51 16.131 25.01 7 '  21.881 35.0
: 6 h| 3 |_ 4.69 18.0| 6 1 9.68 36.0 j j | 5l 17.24! 30.0 3! 9.681 18.0 j 2 6.25! 12.0
i 7 H 28 43.75 196.01 37 j 59.68 259.0 20! 66.67 140.0 151 51.72 105.0 21! 67.74il47.0i 22 68.75i 154.0
! -1 d 15 23.44 -15.01 131 20.97 -13.0 1 3.33 -1.0 5 1 17.24 -5.0 2 6.45 i -2.0 i 1 3.13! -1.0
i Tot 64 [100.00 286.0 621100.00 311.0 30 100.00 184.0 291100.00 146.0 311100.00! 188.01 32! 100.001200.0
iDevel. Indices
L ' l T - T l l
► 4.s| I 5.0 i i 6-1i ; 5.0 1 ! 6.11 : i 6.3
L. P = .0-124; . ______L  . .I PT [01371 i  1 . . i_ p = i 0.937! '
13-4 = 3-4-cell embryo; 5-8 = 5-8-cell embryo; M = morulae; e = early blastocyst; E = expanded blastocyst; h = hatching 
{blastocyst; H = completely hatched blastocyst; f/d -  fragmenting or degenerating embryos, m = mrUF; h = hrLIF; ab = anti h- 
|LIF monoclonal antibody; DS_= Develpmental Score; p values derived from Cochran-Mantel-Haenszel (CMH) statistics.
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APPENDIX iii CONTINUED
Category A, Experiments - 2-6 
Developmental Indices, Percents, and Totals 
Protocol 3








Day4|m+abl %| Scr: c! %; Scr h+abi %i Scr: c; %. Scr
01 2] 5 16.67! 0.0I 1! 3.23! 0.0!
1' 3-4! 4j 13.33! 4.0 i ' ; 1
2; 5-8 i 1 ! 3.23! 2.0
3! mi 1! 3.331 3.0i 1! 3.23: 3.0 1, 3.231 3.0
( 4 ;  ei 1 ; 3.33! 4.0j 3| 9.68! 12.0 li 3.231 4.0! 1, 3.23! 4.0
5; El 14i 46.67 ! 70.0! 71 22.58| 35.0 19! 61.291 95.01 9 1 29.03i 45.0
61 hi 2! 6.67| 12.0114! 45.16i 84.0 10! 32.26! 60.0(19! 61.29-114.0
7! H| 1, 3.33! , 1! 3.23: 7.0
-1i d| 2; 6.67! -2.0i 5! 16.13! -5.0
! Tot! 30i 100.00! 91.01 31 i 100.001131.0 31 -100.00! 159.0131 -100.001173.0
;Devrel. Indices ^  3.0! 4.2 5.11 5.6




; Day5im+abi %i Scr: c: %i Scr h+abi %; Scr! c  %! Scr
. 0 1  2! ■
1 3-4
2| 5-8 i
• 3 i m t
: 4| ei 2i 6.67' 8.0I 2 ! 6.25! 8.0 1: 3.23! 4.0
: 5! Ei 7! 23.331 35.0I 3| 9.381 15.0 5: 16.131 25.0! 5: 16.131 25.0
6i hi 8 25.00! 48.0 9: 29.03! 54.0! 12 38.71: 72.0
7: H! 101 33.33i 70.0i 12' 37.50i 84.0 15i 48.39! 105.0113! 41.94! 91.0
-1 d: 11 36.67 -11.0! 7 21.88! -7.0 2: 6.45I -2.0!
Toti 30 '100.00! 102.0|32! lOO.OOl 148.0 31! 100.00 i 182.0 i 31. 100.00:192.0
Devel. Indices ^  3.4 4.6 5.91 6.2
p = 10.135 i p= 0.795 i
I . i
Devel! | T ,
Day6lm+ab! %i Scr! c: %! Scr h+abi %| Scr- ci Scr
0! 2| ;
■ 11 3-4l | :
2: 5-81 ! i : :
; 3 ; m| i
4 ej 2| 6.67' ! 21 6.25! 8.0 , '
: 5 Ei 21 6.67! 10.0!
! 6 hi ; i ; 3 9.38! 18.0 11 35.48! 66.0! 4! 12.90| 24.0
Ht 14( 46.67| 98.0(19 59.38 133.0
-11 121 40.001 -12.01 8! 25.00









%l Scr; ci %l Scr
18 58.06(126.0 25! 80.65|175.0







3-4 = 3-4-cell embryo: 5-8 = 5-8-cell embryo; M = morulae; e = early blastocyst; E -  
expanded blastocyst: h = hatching blastocyst: H = completely hatched blastocyst: f/d = 
fragmenting or degenerating embryos, m = mrUF; h = hrLIF; ab = anti h-LIF monoclonal 
antibody; DS = Develpmental Score; p values derived from Cochran-Mantel-Haenszel 
(CMH) statistics._____________  ________________________  ________
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APPENDIX iv 146
Category A, Experiments 2 - 6  
Day2 
Raw Data
Treatment = ! 'm | j c ! h | i c : abi c m+ab c h+ab c
Protocol = i Series 1 2  3 . 1 2 3 1 2  3 1 2 3 1 2  3 1 2  3 1 2  3 1 2 : 3 1 : 2  3 1 2  3
2-Cell 2&3 t , i i 4 1 ■ ■ : 4 1
4 i
, 5&6 8 :  i 1 : 1 1 1 2  2 .3
9 4 9 2 1 : . ■ , 1 2 ' 7 1
10 1
12B • ; i 1 i ■ • !
Tot 2 8 0 0 6 0 10 3 ! 0 ' 0 l 2 ! 6 j 3 0 0 I 0 ' 0 i 4 5 0 ; 0 0 2 0 7 1 0 0 0 0 1
3-4-Cell 2&3 1 ! 1 5 111 ! 3 { 26 | 8 3 ! 3 26 8 4 4 6
' 4 12! 9 5 ; 9 ! 7 : 1 9 :
5&6 7 . 8 ! 1 ' 5 8 .  1 2 '1 0 :1 3 141 ' ' 3 14! 9
9 101 5 7 14! 131 2 7 14! 4 10 1 7 3 5 1
10 1 1 1 i 6 4 1 2 4
12A 3 1
12B 9 4 4 9
Tot 3-4 3 2 i 0 i 0 134! 11:26 39: 0 : 0 37: 38 34 42; 0 0 19141 :27 3 0 0 4 4 6 11 0 0 3 5 1
5-8-Cell 28.3 9 ; 8 121 6 4 , 6 21 11! 6 21
4 29! 35! 29! 35: 33: 35!
5&6 6 14110 6 : 2 i 4 1 I 3 ; 2
9 9 : 9 2 . 1 7  8 1 ! . 121 11 ; 5 13! 8 . 1 1 i 2 7 i 9 7 12
10 5 12115113 12! 10j 16 ! 10 9 14 13 15 9 141 10' 8 7 11 '16 12
12A 10 ! 12! 14116
12B 7 : 10l 10 6 i 1
Tot 5-8 69| 0 ' 0 !83| 74! 53 511 0 ' 0 !54| 27139 55I 0 ! 0 !70| 24!43 22! 0 0 122121 i 10 141 0 0 '20123 24
M ; 2&3 5 ! : 6 i 3 : 4 1 : ;
4 5 : , ; 2 ' 10! 2 5 i : 2 i
9 6 ! , ; 1 . , ' i 6 ! ' 4 1 1 6  7 1 ; 4 3  3
10 9 : 3 ; 2 2 ; • 5 ! 2 , 1 3 : 4 2 4  4 2
12A 3 3 ; 2
12B 1 . 2 1 '
Tot M 28I 0 0 !15i 8 : 7 12! 0 ! 0 7 6 0 8 0 0 3 7 0 5 0 0 3 6 7 5 0 0 8 3 5
f/d 5&6 1
9 1 ;
10 2 , 1 1
Tot f/d
F0000CM 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 1  0 0 0 0 0 0 0 0
: i i i ■ i ' i ! I i i '■
m -  mrLIF: h = hrLIF; ab = anti-hrUF monoclonal antibody: c = controls; all concentrations = 1000 U/ml; No embryos developed
beyond the morulae (m) stage on day 2 of development. M = morulae; e = early blastocyst: E = expanded blastocyst: h = hatching
blastocysts; H completely hatched blastocysts: f/d = fragmenting or degenerating embryos. Developmental stages without data points
for experiments were omited.
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Category A, Experiments 2 - 6  
Day 3 
Raw Data
Treatment = ' m c r  h '  c O
I---L8 m+ab '  c : h+ab c
Protocol = ISerie 1 2 13 1 2  3 1 2 1 3 1 2 3 1 ' 2 ; 3 ; 1 2 i 3 1 . 2 3 1 2 3 1 : 2 3 1 2  3
2-Cell 4 : : ; 1 1 . 1 - • ■ j 1 ■ : !
i 5&6 ■ : 1 i 1 1 1 ; : : ; . 3 1 ! ' , ; 3
9 i j 3 | l 5 2 ;  ! : 1 i . ■ i ; ; ; ; . ' 2 , ; 5 1 :
10 . i ! ! ; I i i ; . 1
Tot 2 0 i 0 | 0 I 5 I 0 i 6 3 I 0 ! 0 ! 2 ; 0 I 3 0 I 0 ! 0 i 1 : 0 i 3 0 0 0 2 0 5 0 0 0 : 0  1
3-4-Cell : 2&3 i : > i i 2 i 1 1 • ; i 1 1 :
5&6 1 i 1 ! ; ; ■ 1 2 1 : 2 :
: 9 , ! : 4 I ! 8 2 ; 3 6
10 : i 2 : 1 1
Tot 3-4 1 i 1 0 . 4 ; 0 i 8 5 0 0 : 0 0 , 3 4 0 0 2 0 3 0 0 0 3 0 6 0 0  0 0 0  0
5-8-Cell 2&3 2 2; 1 , 2
5&6 i 2 , 1 5 : 1
9 i : 3 2 6 4 | I 1 1
! 10 1 2 : ■ , 2 ; j . ! 1 ;
12B . 1 1 i : , ; , i I
Tot 5-8 , o i i o ; 5 0 : 2 8 I 2 : 0 ! 6 I 0 i 1 8 0 , 0  3 0 . 1 1 | 0 ! 0 ! 0 i 0 I 1 O O O O O O
M 2&3 3 ! 4 I | 3 | i 8 9 115) : 7 1 '27 10; 11! ' 7 i 27 ; '
; 4 391 i ! 39j 28| ! '39| 38! i 39 !
5&6 14! 13j i 14 j i 14 13113! 15i 9 101141 H 5I 9 '■ I
; 9 5 i n ;  ; 4 !  1 8 5 7 14 T3 j 7 ; '12] !14 7 ; 1 4 : 8 1 2 11! 101 8 : 7
10 5 I 6 | 8 i 4 7 5 2 9 8 , 8  2 5 9 9  1 2 8 2 1 ; 3
12A 5 9 10 12
; 12B 13| 6 j 12 '13
Tot M 84I49I 0 90 0 52 65.38 0 70! 0 ; 59 79I40I 0 i 75 0 55 16 23 0 9 0 4 19 12 0 9 0 10
e 2&3 12111! 121 . 7 2 2 3 4 2
4 6 6 16; 6 8 6
5&6
9 10| 4 lOi 3 : 1 8 4 8 1 2 13 4 5 8 9
10 1 0 il0 i 8 : 11 6 11! 13! 6 4 ; 9 , ,10 10 5 7 '  15i 7 14 14! 11
12A 11! 7 6 4 i
12B 3 ! 9 j 4 3 j
Tot e ! 52l41| 0 ! 3 6 1 0 j 25 2 4 I2 L  0 22 ] 0 I 9 15(21 j 0 ! 20 0 ; 12 13 i 8 0 17 0 13 111 19 ! 0 ,22: 0 ] 20
f/d < 9 ; ’ i i  i  2 ! i ; : ; 1 ! 1 i 1 1 ‘ -1
: "0 1 ! ! ! , : 1 ! 3 j
12A ; : ’ 1 : ,
> ! 12B I , ! . ! ; ; ; :
Tot f/d 1 : 0 i 0 ! 0 : 0 ! 2
OOOOi0.
O
0 ■ 1 ! 0 i 3 0 i 1 0 0 0 1 1 0  1 0 0 0 0 0 0
: m = mrLIF; h = hrLIF; ab = anti-hrLIF monoclonal antibody; c = controls; all concentrations = 1000 U/ml; No embryos developed 
beyond the earty blastocyst stage on day 3 of development. M = morulae; e = early blastocyst: E = expanded blastocyst: h = 
hatching blastocysts; H completely hatched blastocysts: f/d = fragmenting or degenerating embryos. Developmental stages without 
data points for experiments were omited.
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I Treatment = ! m i " i ' Fcf ]  h ! ; 'T c j ja b i ' ic i ’ m+ab: : c I h+ab i c!
Protocol = ' Series 1 2 ! 3 I 1 i 2i 3 1 : 2 : 3 1 1 1 2 1 3 1 ! 2 I 3 I 1 ; 2i 3 1 2 3 1 2 3 1 , 2 3 1 2 :3
j 2-Cell i 2&3 i 1 ; i , ■ ; i ! ,
i 4 : i • j ! ! ; 1 ; ■ !
9 i : 4 ■ 2 i : 2 , ; 1 : ’ 5 1
10 i . . 1
Tot 2 0 0 4 2 O'O 2 I 0 ! 2 : 1 io io 0 0 0 , 0 0 0 0 0 5 , 0 0 . 0 0 1 0 0 0
3-4-Cell 9 3 2 i ' : 1 1 : , 4
10 1 1 ' ;
Tot 3-4 0 0 ! 3 ! 2 ,0 :0 0 .  O O ! 0  0 .0 2 I 0 0 0 Oi 0 0 0 4 0 0 :0 0 0 0 0 0 0
5-8-Cell 2&3 1 : : i •
9 : 2 1 2 : 2 1 ; 1
10 ; ; 1 : , ! : i 3 , 1 ,
12B . 1 :
Tot 5-8 0 1 2 2 0 i 0 4 ; 0  j 0 i 0 solo 3 0 0 1 0 0 0 0 0 1 0 : 0 0 . 0 0 0 0 0
M , 2&3 1 j ■ ; 1 i 1 : 2 1
5&6 ! ; 1 ■ 1 ; , 2 i 5 i 1 , 4 |
9 '  1 ; 1 i ■ i  ; | ; i 1 1 1 1 3 1
i 10 i 1 ; ' i 2 ; 1 ! , '
12A 1 : 1 ; 1
128 1 i 2 ; 1 '
Tot M 1 : 4 ! 5 2 I0 I0 5 0 1 2 0 10 5 3 4 1 0 0 1 0  1 1  ; 0 i 0 3 ! 0 0 1 0  0
e 2&3 6 7 3 9 .  !
4 31! ! : 34 ■ ! 20 34 40 34!
5&6 1 5 !1 3 i1 5 |131 i 13 i 1 2 ;1 0 !1 4 ! i 1 0 :1 3 1 5 ,1 5 !
9 : 2 7 3 6 ; 6 2 3 2 3 1 2 1 1
; 10 1 , 1 ; 1 ; . 2  ; 1 : 1 : 5
12A 4 . 1  1 1  : ! ; .
12B 6 ' 3 ; 1 ! : : : ' :
Tot e 63 i 23;23 5 8 !0 1 0 41 j 12 j 151 54 i 0 1 0 5 6 !1 6 , 5 ! 4 9 !0 1 0 3 2 1 3  010 6 : 2 1 1 0  0
i E 2&3 ! : i 8 1 1 5  6 i 12! 9 i 8 6 , ;
9 9 i 12! 2 : 1 ; 5 10! 5 7 7 6 1 1 1 1 6 9 3 3 7 ! 10 9 5
; 10 11 12 5 7 a ' i o i i o ;  1 9 9 8 5 10 11 11 4 10 i 13 10 4
12A 10 11 13 12
12B 9 ; 12! 9 12!
! Tot E 39 i 47 i 29 i 3 2 1 0 i 0 2 1 1 31: 2 0 ,1 4  j 0 i 0 2 8 1 2 4 127 22 0 :0 16 : 20 14 7 0 0 17 23 19' 9 0 0
h 2&3 8 ! 8 ; 12! 6 2 4 9 2 ; 3 6
4 13! .10! , 8 ; 10 4 101 ,
9 6 1 : 5 4 ;  ' ! 7 2 5 , 5 4 2 2 3 6 9
10 4 ! 3 i 6 9 . 3 6 2 14. 2 , 7 , 7 , 9 4 4 2 12; 2 4 10
12A 1 3  1 : 3 1  :
12B 1 ■ 2 ! 2 I 2 ! : : :
Tot  h 33 i 16 i 2 1 131! 0 0 13 i 1 5 '1 5 i 2 4 1oi 0 8 !1 7 !1 5 i 2 4 !0 1 0 9 8 2 14 0 0 2  5 10 19:010
H 2&3 1 : ' ; i l i 2 : ; , ,
5&6 : • .  i  i ' 3 ! 4 ,  1 ! !
: 10 ! i 3 i i  j : , : ; ! 1 1 . 1 : 1 ;
Tot H i 1 f 0 i 3 I 0 | Of 0 0 | 3 : 4 ! 3 IOIO 0 |  0 ! 0 ; 0 010 0 i 1 1 0  010 0 1 , 0 1 O'O
] f/d ! 2&3 : : ! ! ; 3 i ! ; ; 1 | 1
4 1 : l : 2 ! ! i ; , 2 . 2 , , 2 : ■
i : 5&6 1 1 i ; , 5 2
i 9 I ; 4 ; 6 i 1 2 : 2 5 2 ,
• 10 : ! 1 ' ! ; ‘ 1 : ! 1 I
Tot f/d 1 1 . 1 . 5 . 9 ,0 ;0 3 l  0 !_0 | 2 10LQ 4 1 1 i 8 .  4 : 0 .0 _ L :  0 . 2 .  5 . 0; 0 2 0 . 0 . 0  .0 .0 .
m = mrLIF; h = hrLIF; ab = anti-hrLIF monoclonal antibody; c = controls; all concentrations = 1000 U/ml; M = morulae; e = early 
blastocyst; E = expanded blastocyst; h = hatching blastocysts; H completely hatched blastocysts; f/d = fragmenting or degenerating 
embryos. Developmental stages without data points for experiments were omited.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX iv CONTINUED
Category A, Experiments 2 -6  
Day 5 
Raw Data
Treatments 1 ; m l j j c | h | | c i ! abj : ! c : | m+ab | ; c i h+ab 1 c ;
Protocol = iSerie 1 I 2 | 3 ! 1 I 2 3 1 I 2 3 ! 1 i 2 i 3 i 1 2 • 3 ! 1 i 2 I 3 11 2 ! 3 i 1 ! 2 : 3 : 1 2 ! 3 1 2 : 3
e 9 i 1 I 4 I 1 | | 5 |  : 2 I , ! 4 : 1 , 2 1 : 1
10 ! 2 I 1 ! . ' 1 1 : ! 1 - i ’ 1 2 2
; 12A : 3 ■ 3 ■ 'i ! i  | i : i '
i 12B 1 I ; ; i i i : :
Tot e ' 1 I 4 I 7 1 1 ! 0 ! 0 5 0 2 3 0 0 5 1 0  1 0  0 2 0 2 2 0 0 2 1 0 1 0  0
E 9 ! 6 ! 3 i 5 5 7 1 5 3 ! 9 i 6 * i ,1 2 4 3 7 8 1 . 3
10 2 : 8 ! 2 ; 1 ; 4 5 8 2 : ' 5 4 2 3 3 6 3 5 6 4 2
; 12A 9 . 3 ! 5 ! 8 | ; j
12B 7 5 • 11 • 6
TotE is ; 221 21 1151 0 : 0 9 ; 10!151 3 ! 0 I 0 110 7 111! 9 i 0 ! 0 ! 4 8 7 3 0 0 12 14 5 : 5 0 0
h 9 2 : 5 1  . 2 : 7 4 i 4 4 5 1 5 2 8 1:  1 3 4 7
10 4 ‘ 6 ! 5 ! 7 I i 6 6 : 4 8 ■ 4 4 5 5 4 6 7 1 2 5 5
12A 5 7 5 2
12B 5 ! 4 ! 3 1 7 !
Tot  h ; 16! 22113118i 0 i 0 6 i 131 8 i 12l 0 ; 0 i 8 9 : 6 ;10l 0 0 6 14 0 . 8  0 0 2 5 9 , 1 2 . 0 : 0
H • 9 131 2 i ; ; I 1 3  4 2 .  ; 7 4 5 10 5 3 4 3 10! 5
; 10 9 ! 1 ; 8 I 8 ! 3 5 1 4 !  3 8 8 6!  6 4 10 9 5 8 5 8
12A 2 3 4 6 i !
12B 3 I 6 I 2 i 2 I
Tot H 27!1211 4 i161 0 1 0 4 8 : 5  6 : 0  0 : 3 15! 121111 0 0 16 9 1 0 1 2 1 0  0 9 11 15.13 0 0
f/d 9 1 j 11 , 11! 5 5 i 2 2 1 1 1 7  4 1
10 1 1 1 2 2 1 1 1 2 1
12A , 1
12B 1 1 I
Tot f/d 1 3 , 1 2 1 1 2 ;  0 i 0 7 ! 0 l 0 ! 5 | 0 ! 0 i 4 1 2  1 0  0 2 0 1117  0 0 6 0 2 0 0 0
m = mrUF: h = hrLIF; ab = anti-hrLIF monoclonal antibody: c = controls; all concentrations = 1000 U/ml: M = morulae: e = early 
blastocyst: E = expanded blastocyst: h = hatching blastocysts: H completely hatched blastocysts; f/d = fragmenting or degenerating 
embryos. Developmental stages without data points for experiments were omited.
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Category A, Experiments 2 -6  
Day 6 
Raw Data
Tratment = ’ "m i ’ j c T " h ’ j • c "abi ' i c i" im+abi " c h+ab \ " i c ’
Protocol = Serie 1 2 i 3 i 1 I 2 i 3 1 I 2 ; 3 i 1 : 2 1 3 1 ! 2 ; 3 I 1 I 2 j 3 1 ! 2 3 1 1 2  3 1 2 3 1 2 3
e 9 2 2 : : , 6 1 . ! 4 1 4 , : ; : 2 i 1 1
i 10 : ! i H  : 1 ; . 2 : 2 1
12A : 2 ! 1 : i ; ' i l l ! i
12B 1 : ' ! .
Tote 1 , 4 3 ; 1 i o I o 6 i 1 0 i 4 i 0 0 4 0 0 0 0 0 0 , 0 , 2 , 2 0 . 0 3 1 1 0  0 0
E ' 9 : 3 , ■ : 3 1 4 ' 5 1 . 4 , 5 1 j 3 2 1 4
: • 10 1 ! 2 2 i . 3 2 : 5 .  1 4 2 , 1 2 2 : 4 1 3
12A 4 ; 3 5 2 1 :
12B 3 1 8 3
TotE  i 8 9 15i 5 0 0 6 3 9 0 0 0 9 3 : 5 7  0 0 3 : 7 2 0 0 0 2 4 3 0 0 0
h . 9 1 1 2 • 21 1 : 2 1 3 3
10 1 ; 2 1 1 1 ; 3 5 1 3 3 2 1 I 2 3 1 3  4 1
12A 1 ! 1 2 2
12B 1 3 •
Tot  h 3 I 5 3 6 I 0 , 0 0 5 0 5 , 0 0 1 i 5 I 3 ! 2 I 0 0 2 : 4 , 0 l 3 , 0 : 0 1 4 7 : 4 , 0 0
H 9 141 8 : 2 1 1 111(11] 5 i i 4 112| 10| 111 ■ 12! 10 ! 1 : 6 I i 101 10 111111
1 10 141101121 9 i 1 0 1 9 ; 101 8 113111111 11; 10 :13! 131 9 12 7 1141
[ 12A 11 i lOi 8 112| ‘ i ' i
12B 11112 8 i 9 1 ; t ■ ;
Tot H 50I40 28i37i 0 ! 0 loi21 !20l 151 0 ' 0 12:25(21:221 0 : 0 23! 20 14119! 0 0 191 22 18125! 0 0
f/d i 9 1 14112! 6 ; . s i 2 2 1 1 121 8 4 1 2
10 : 2 1 ! ' 3 1 1 2 1 1 2 1
12A
12B 1 2 1 ,
Tot f/d 1 ; 5 15i 131 0 , 0 9 1 1 5  0 0 4 0 2 1 0 , 0 2 0 12 8 0 0 6 ! 0 2 2 0 0
m = mrLIF; h = hrLIF: ab = anti-hrLIF monoclonal antibody; c = controls: all concentrations = 1000 U/ml: M = morulae: e = early 
blastocyst; E = expanded blastocyst: h = hatching blastocysts: H completely hatched blastocysts: f/d = fragmenting or degenerating 
embryos. Developmental stages without data points for experiments were omited.
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Category A, Experiments 2 -6  
Day 7 
Raw Data
I Treatment = ! f m [ [ c 1 h : C • ;abi c . m+abi c h+ab ■ c
, Protocol = Serie 1 ; 2 i 3 ; 1 I 2 I 3 1 ; 2 ; 3 ! 1 ! 2 i 3 1 2  3 1 2  3 1 ! 2 3 1 2 : 3 1 2  3 1 2  3
e 9 ' 4 i i i • > : i 1 12 1
10 2 . 3 2 ; ■ : i 1 : 1 2 : 2
12A , 2 : 1 ;
12B 1 i ' i : i I . !
Tote 1 6 i 1 ! 0 , 0 I 0 2 3 . 0 0  0 : 0 2 1 2 : 1 0  0 0 : 1 0 ; 1 0 0 2 1 2 0 0 0
E 9 ' i  i I 1 ; 1 i 1 , 1 2
10 2 ; 2 ; ■ 3 i 5 ; 1 . 2 . 1 1 1 1 1 : 3
12A 4 ■ 3 ; 5 I 2 !
12B 3 : 1 ' 8 : 3 !
TotE 9 ; 5 I15| 5 i 0 I 0 3 0 ' 5 0 0 i 0 2 3 2 0 0 0 1 2 0 0 0 0 1 2 3 0 0 0
h 9 1 : , : ; 1 : ; : 3 ’ : 1 1
10 1 : 1 ' 1 i . 1 • ' 6 • 1 2 2 2 1 1 1 : 1 : 2 1 ,1
12A 1 : 1 ; 2 | 2 !
12B : 1 . , 3 |
Tot h 2 3 , 3 ! 6 ! 0 i 0 0 i 2 ; 0 : 6 ; 0 0 1 5 2 2 0 0 1 2 1 2  0 , 0 0 : 2 0 1 0  0
H 9 141 9 ,  i : 1 ; 131 3 : 9 :10i 121 13 . 11 ,
10 13i 12! 13! 15| 8 1111 9 ; 10, 8 13| 111 121 12 131131 11! 15 9 14 i
12A 11 i 10i 8 ; 12
12B 11 j 12! 8 i 9 i ; I 1 ; ; .
Tot H 49i 43i 29f 36I 0 i 0 9 1241201101 0 i 0 11122!21!25I 0 ! 0 12! 25 131131 0 ; 0 11! 26 9 14 0 0
f/d 9 1 16 14. 15| 1 I 4 ! 141 ; 111 1 ■ 3 i 4 151 151161 161 16116!
10 1 1 3 ' 2 1 ■ 1 ! 3 I 1 : 1 . 1 1  1 1 , 1 ;
12A 1 :
12B 1 , 2 .  1 i
Tot  f/d 2 : 6 !  16] 151 0 : 0 17! 2 ! 5 :141 0 10 141 2 1 4 4 0 0 16: 1 161161 0 . 0 171 0 17; 16i 0 0
m = mrLIF; h = hrLIF; ab = anti-hrLIF monoclonal antibody; c = controls; all concentrations = 1000 U/ml: M = morulae: e = early 
blastocyst: E = expanded blastocyst: h = hatching blastocysts: H completely hatched blastocysts: f/d = fragmenting or degenerating 
embryos. Developmental stages without data points for expenments were omited.
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Category A, Experiments 7 
Developmental Indices, Percents, and Totals 
Protocol 1 Only
i Day 3 1000 I 2000 , 5000 , 10000!
Dl Trt = m rLIF! % Scr mrLIF !  % i mrLIF 1 % Scr mrLIF • %  ; Scr c % Scr
; ; '
0 2 1 : 1 . 1.67 ; o . o
1; 3-4 5 ; 8.33 5.0 3 i 5.00 : 3.0 5 8.33 5.0 ; | 10 15.38 ! 10.0
2| 5-8 3 ! 5.00 6.0 1 | 1.67 i 2.0 2 3.33 I 4.0 4 6.67 : 8.0 11 16.92 22.0
3| M 49 ' 81.67 147.0 49 i 81.67 ! 147.0 44 ! 73.33 1132.0 50 83.33 '  150.0 3 4 .0 1 52.31 102.0
4! e 3 I 5.00 12.0 6 i 10.00 ; 24.0 9 15.00 I  36.0 6 10.00 24.0 5.0 7.69 20.0
-1 d ' ; 5.0 7.69 -5.0
Tot 60 i 100.00 170.0 60 100.00 i  176.0 60 : 100.00 1177.0 60 100.001182.0 65 100.00 149.0
Devel. Indices 2.8 2.9 : 3.0 3.0 2.3
p = 0.005 I  P = 0.001 '  P = 0.001 ; p =  0.001
I i -
! Day 4
i ;  % Scr % Scr % Scr %  Scr % Scr
0! 2 i i j
1! 3-4 7 11.67 7.0
2! 5-8 1 : 1.67 2.0 ; : , 10 16.67 20.0
3! M 5 8.33 15.0 4 6.67 12.0 7 ; 11.67 21.0 4 6.67 12.0 12.0 20.00 36.0
4i e 13 : 21.67 52.0 22 36.67 88.0 20 ! 33.33 80.0 19 31.67 1 76.0 19.0 31.67 76.0
5 E 29 48.33 145.0 24 40.00 120.0 18 ! 30.00 90.0 25 41.67 i 125.0 12.0 20.00 60.0
6i h 8 13.33 48.0 5 8.33 30.0 12 ! 20.00 72.0 12 20.00 72.0 '
71 H 1 ; 1.67 7.0 3 5.00 21.0 I
-1! d 3 , 5.00 -3.0 2 3.33 -2.0 3 . 5.00 -3.0 i i
Tot 60 1100.001266.0 60 100.00 269.0 60 : 100.00 260.0 60 100.001285.0 60 100.00 199.0
Devel. Indices ► 4.4 4.5 4.3 4.8 3.3
P = 0.001 P = 0.001 p = 0.001 p =  0.001
‘ '
Day 5 i ;
% Scr % Scr % Scr % . Scr % Scr
4| e 8 1 13.33 j 32.0 13 21.67 52.0 5 8.33 20.0 10 16.67 ' 40.0 11 18.33 44.0
5l E 21 ; 35.00 105.0 14 23.33 70.0 11 18.33 55.0 17 28.33 : 85.0 19 31.67 95.0
61 h 12 i 20.00 72.0 16 26.67 96.0 17 28.33 i 102.0 18 30.00 i 108.0 11 18.33 66.0
7| H 16 1 26.67 112.0 11 18.33 77.0 18 30.00 i 126.0 14 23.33 ! 98.0 11 18.33 77.0
-1: d 3 ; 5.00 -3.0 6 10.00 -6.0 9 15.00 -9.0 1 i 1.67 i -1.0 8 13.33 -8.0
j Tot 60 ! 100.00 318.0 60 100.00! 289.0 60 100.00 294.0 60 <100.001330.0 60 100.00 i 274.0
Devel. Indices ► 5.3 ; 4.8 4.9 ; 5.5 4.6
i p = 0.077 P = 0.615 P = 0.105 p = : 0.034
! Day 6 : : : j
, , % Scr % Scr % Scr % Scr % Scr
4| e 4 ! 6.67 16.0 6 10.00 24.0 3 5.00 12.0 3 5.00 : 12.0 3 5.00 12.0
5 I E 9 I 15.00 i 45.0 4 6.67 20.0 5 8.33 25.0 10 ! 16.67 : 50.0 14 23.33 70.0
6! h 4 I 6.67 | 24.0 3 5.00 18.0 24 40.00 144.0 5 j 8.33 ! 30.0 10 ; 16.67 60.0
7| H 37 61.67 ! 259.0 38 63.33 266.0 17 28.33 1119.0 41 ; 68.33 i  287.0 24 I 40.00 168.0
- 1 !
d 6 '  10.00 ! -6.0 9 15.00 -9.0 11 18.33 -11.0 1 1.67 ; -1.0 9 i 15.00 -9.0
i Tot 60 ! 100.001 338.0 60 100.00| 319.0 60 100.001289.0 60 i 100.00! 378.0 60 ' 100.001301.0
Devel. Indices ► 5.6 j ! 5.3 j 4.8 i 6.3 5.0
i I i P =  10.110 ! p =  10.277 ; p = 0.798 i p = 10.002
3-4 = 3-4-cell embryo; 5-8 = 5-8-cell embryo: M = morulae; e = early blastocyst: E = expanded blastocyst: h = hatching 
blastocyst; H = completely hatched blastocyst: f/d = fragmenting or degenerating embryos, m = mrLIF; p values derived 
from Cochran-Mantel-Haenszel (CMH) statistics. Developmental stages without data points for experiments were omitted.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX vi
Category A, Experiment 7 
Raw Data
153
[bevel 7 ' 7 ' : T Devel [ r  ; . [ Devel I
Day 2 i T rt=  ; l i  2 ! 5| 101 c Day 3 1! 2! si 10! c Day4 1! 2: 5 r10
i Exp i ! 1 1 Exp| i i ; 1 Expj
[2-Cell : 1 21 21 11 j 1 2-Cell { 1| 1 1| ! ! 2-Cell 1 1|
I 2[ ! j 1 1 11 3 : 2l | , ; 2! :
: 3! ! 11 3! j 1 i 3) ! ' 3i
4 ; 1 ! 1 ; : 4i ; 11 . 4:
I I ' l l ' ; ;
3-4 Cell i 1110! 9| 12! 12| 12 3-4 Cell! 1: , i 2 3-4 Cell! 1!
211 2 [15!121121 8 ! 2! 2! 3 2: 4 2!
3| 14j 131 10! 15l 11 3 1 1 !  3: 3 3!
4! 13113113 i 15 (13 ' 4! 2; ! M 4i
, j ! ■ i i
;5 -s c e ii; i |  3 3i 2: 3! 3 5-8 Cell! 1 , 1 !  3! 3 5-8 Cell! 11 1'
2! 3 1! 2 2| 4 2i 1, ' 2 2!
31 1 1: 2! 113 i 3! : 1! ' 3 3
! : 4! 2 11 2! 2 , 4! 1! 1! 1! 1 ! 3 4 ‘ ! i
;
M 1 ’ 1 Ml 1 i 141 1 4 '15 !11 ! 9 M! 1 : 3! 1! 4!
2 2[ 12! 9 | 10!13! 9 2! 1! 2 3
3i 3! 12! 1 4 j 7[ 14! 8 3: 1 : 1
4; i 4 l 1 1 [1 2 |12!13; 8 4: 2! 2
•e 11 e| 1l : 1| ! 1! 1 e; 1! 1; 2 2: 1
2! , ; : i 2; ; 3 l 3! 2! 2! 6l 6! 6. 3
31 ! ! 3! 2| 1: 4! 2! 1 3i 5! 3! 2
4[ ! 4! 1! 1! 2! 1, 3 4! 3! 4! 3; 8
: j
'e : 11 E : 1 e! 1: 4 ; 3 r  3
2l 2! 2 ! 6! 7'  5; 5
3' 3! 3 12 7' 4! 9
4 ; 4: , 4! 7! 7! 8; 8
; , 1 ;
:h ; 1 ( 1 i hi 1! ! h; L  1! 11 2! 5
! 2 1 i ; 2! • 2 3! 2: 4
! i 3i : 3; 3i 3; 3 5: 3
4! 4 4: 1 1- 3!
'H 1 ; H| 1, H! 1, 1
2! 2 2! 1!
3i 3 , : : 3!
4 j ■ . ■ i 4 1 1 , ; 4i 1, 1
I : ; ; i .
d ; 1 ! : i dl 1! i ! d! 1: 2! 2
2! ; 2! i ' ' 2; : 1! ;
3! 3 1 . , : : 3! 2!
4|  : i i i ! 4 1 ! ’ 1 4 1 1 :  1
' ! j ! I . 1 ! i ! ! !
; i ■ ;
Tot 61 i 60160162! 61 Totl 16 0 161 j 60 62!60 Tot! ! 57! 56! 54! 55
M = morulae; e = early blastocyst: E = expanded blastocyst: h = hatching blastocyst:
H = completely hatched blastocyst: f/d = fragmenting or degenerating embryos: m = mrLIF;
!c = control. 1 = 1000; 2 = 2000: 5 = 5000; 10 = 10000; all values in U/ml mrLIF; c = control
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Raw Data
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:Oevel ’ I I ’ Devel ! 1 Devel
Day 5 - . 11 2! 51101 c Day 6 1 ' 1; 2! 5110: c Day 7! ; 1 1 21 5110! c
Exp i ; Exp i ■ Exp |
| 2-Cell i 1! i . j 2-Celli 1! , i : 2-Cell | 1!
i • 2i , ! ; i i 2 ! ' ; ! 21 ;
; 3i * i , 3 ! : , 31
' 4 1 4!
3-4 Cell' 1 3-4 Cell I 1 j i 3-4 Celli 1 :
2! 2! , ! • 2
31 3i !
- t . 3 - . ,
4' 4| 4!
: . ,
5-8 C ell 1, 5-8 Cell I 11 5-8 Cell! V
2; 2: 2!
3 : 3! 3i
4! 4i ' i 4i
t ! 1 - i ! ! i ; 1
M| 1 1 | i ' i Ml 1| j i | Ml 11 !
2\ ' : ; i I 21 ! ! I ; 2 ! i ; ;
3 ! ! I ; 3i : 3 :
4 ; 4| 1 : 41
i ■ I :
ei 1 4| 5i 2! 2| 3 e 1i 3 5 2 ei 1' 1i 2! 3
2 3| 3| 1: 3 (5 2 1 ; : 1 i 2 :1 ' 2 1 : 2!
3 2' T 1i 3: 3 1 1! 3
4 1; 3 1 4 : 3 4 1 4 i 11 2! 3'
Ei 1 6! 2! 2 4 2 ! 4 Ei 1: 1i 2! 2 41 4 E: 1 2: 1 1
2 6, 7! 2 5! 4 2; 4 1 1i 1! 3 6 2! 2! 1
3! 5 3; 3! 3i 7 3| 2! 11 . 2 3! 1 1
4l 4 ; 2! 4j 5! 5 4 2 2 4 2 4i 11 1
hi 1 1 2i 5i 4i 51 2 h| 1, I : 21 2 hi 1! 1; 1
' 21 1! 1i 51 4| 4 2| 1; : 2 2 1i 1; 2
' 3l 6! 5 41 71 3 ' 31 2! 11 • 2! 3 3l . : 1
' 4| 3! 51 4i 21 2 4| 1 ! ' 2! 1 1 3 4i 1! .1
Hi 1i 2! 2! 3 4| 1 Hi 1131 5112 l14 | 2 H| 11101 8! 9 i 131 3
2! 5i 3 5 2l 2 2! 9| 10l 11 9! 6 2 !1 1 i 13 i 12 j 12!10
3 4 : 3| 5 4i 5 3, 101111 1 1 i 12! 9 3114:13111:15 12
4' 5 3: 5 4i 2 4! 10! 12! 10! 11! 7 4 ;1 0 !1 3 i 12! 12: 7
i i
di 1( 1: 1| 4i i 5 d| 1, 3| 3| 61 5 di 1: 41 3! 61 7
! 2| 1. 2! 1 ; 2! ! 21 2| 1| 2! 11 11 2! 1j 2CMCMCO ! 3i 1| 21 2 i 1 ! 3l 1! 1, 3| 1
i 4| 2: 2! 1i I 3 i 4 2! 2! 1 3 4! 3 1 11 1! ' 6
1 ! ! : i 1 1 ' ! ! 1 I i i . 1 ;
Toti ! 6 0 16 0 160 j 98160 Toti i 65160166166160 Toti ! 601601 59! 60160
M = morulae; e = early blastocyst: E = expanded blastocyst: h = hatching blastocyst:
H = completely hatched blastocyst: f/d = fragmenting or degenerating embryos: m = mrLIF; 
c = controL 1 = 1000; 2 = 2000; 5 = 5000; 10 = 10000; all values in U/ml mrLIF; c = control
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CATEGORY B EXPERIMENTS 
IMPLANTATION, PREGNANCY, AND RESORPTION RATES 
RAW DATA
Controls ! i 1 i I i ; P P P 1 * R
Exp Reap ! Trt Cone | #  Fem #PG Fem j #Em Age I Hmi Body M | CR I TL i L i W  | M | #  R I Hm 1 Oi
6 M5 i 1 5000 o I I : I , ! ! i :
6 M6 { 0 ! ! i i ; ' : ;
7 M1 j 1 5000 0
I : ! i : ■ r ' ! ' ■
! I 1 !
8 M1 5000 0
8 M2 2 2 ! 1 171R 0 .341 151 41 111 9 0.21 1 |R 3
! ! 2 17 {R 0.35! 17! 51 131 81 0 .2 !
8 1 M3 01 I
9|M1 1 5000I 0| f
9IM2 1 1 i 1 17|L 0.7! 2 0 ; 81 10 j 101 0 .2 ! 3 i L 4
i 1 L 3
' L 6
9|M3 2 2\  1 17|L 0 .631 2 0 ! 81 11 ! 91 0.21 4IL 2
! 2 171L ! 0 .731 2 0 | 81 101 8 ! 0.21 L 3
, i L 3
t ! ; L 4
i ; ; i . i . . . .
: ; i i : • .
10 M1 1 5000 01 I
101 M2 2 2 | 1 171R 0.72! 2 l ! 81 111 101 0.3! 6 IL 3





M1 i 1 5000 0 i !
12|M1 1 5000 0 I | i
M2 0 ; t ! ;
{M3 I 0 \ I ;
13lM1 ! 1 | 5000 0
M2 0 ;
M3 4 4 1 11 171L 0.76! 2 0 ! 8 ! 91 9 0 .1 !
I 21 : 0.48| 181 71 91 9! 0 .1 !
; 3i 0 .69 1 2 1 ! 81 10 ) 101 0 .2 :
4! 0.49: 18' 7! 101 9! 0.1 i
14|M4 1t 5000 0
M5 , 0 3lR 2
1 , ; :R 6
! , 1 i ;R 4
|M6 1 1l 1i 17! L 0.87; 20! 91 91 91 0.1 i 3 k 7
: i ; 1 L 2
1 j ! ; L 4
15 j M1 i 1 ! 5000 Oi
i i
j
j { i ! i j j i i
16 1M1 ; 1! 5000 0| I : I i ; i
M2 31 3i 1! 17 R  i 0 .391 16 6! 91 91 0 .2 1 1jR 5
i i i 2! 17 R 0 .451 16! 61 91 91 0.11
i ; I 3| 17 R  ! 0 .531 181 7! 91 101 0 .2 1
; . ! j i : i : i i ■ : ■ ; ; :
17IM1 I 11 5000 0| i I I i
M2
i j 0 I ! i : i . ! j : : ; j
M3 i 0
1 ! 1 I ! I l l  ! '
! ! 1 1 1 ! 1 1 ' : 1 1
#  Fem = #  females included in experiment: #  P(3 Fem = #  females with fetuses; #  em = numerical assignment to embryos within
same female: age = fetal age in days of development: Hm = right (R) or left (L) uterine horn w/ fetuses; Body M = body mass of
fetuses; CR = Crown-rump length; TL = tail length; PL = placental length: PW  = placental width; PM = placental mass. TOT #  R
total #  resorptions; NPG R = #  resorptions in females with no viable pups: PGR = #  resorptions in females with viable pups; R Oi = .
diameter of resorptions, (all lengths in millimeters, all masses in grams)
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CATEGORY B EXPERIMENTS 
IMPLANTATION, PREGNANCY, AND RESORPTION RATES 
RAW DATA
!" r U £ i ~ r r T “  ‘ I I  “ T P I" P ; p : R
Exp | Reap ! Trt Cone # Fem #PG Fem I #Em Age Hm | Body M CR TL ; L I W I M # R Hml Di
6 I M3 i 2 5000 0 i I ! i ; ! 2 L 3
6 i M3 i 2 5000 0 I I ; L 3
; 7 , M2 1 2 5000 0 , , 1 R 8
: 8 1 M6 ! 2 5000 1 1 I 1 i 17 R I 0.47 18 6 13 . 10 0.27; 4 L 3
i i . ! ! R 3
9 | M4 ; 2 5000 0 R 3
. 9 . M5 2 5000 0 R 3
' 9 : M6 ' 2 5000 0 !
9 M7 2 5000 6 6 ' 1 ! 17 ; 0.37 17 5 13 : 10 0.36; 2 L 3
2 17 0.42 17 ; 6 L 3
3 17 L ; 0.37 15 6 9 8 0.141 L 4
i 4 17 0.41 15 ; 6 8 8 0.15;
'
i 5 17 j 0.46 18 7 : 10 ! 8 0.18|
: : I : 6 17 : 0.33 14 ; 5 10 : 9 : 0.171
i 10 i M3 : 2 5000 1 1 i 1 17 1 0.44 17 7 11 | 10 ; 0 .181
i 10 i M4 r r 5000 1 1 ■ 1 17 R I 0.38 16 : 6 10 i 8 i 0.151 2 L 2
: 1 j R 2
I 10 I M5 2 5000 1 1 : 1 17 R 0.53 19 7 . 9 9 0.181 3 R : 4
R 3
R 1
11 ; M2 2 5000 3 3 1 17 L 0.69 19 : 8 : 8 8 0.101 4 ; L 3
' j 2 17 L 0.54 18 ; 9 10 : 10 0.15 i L 3
: 3 17 L 0.63 20 ; 9 9 ! 8 0.11; L 3
L 5
11 i M3 2 5000 3 3 ; 1 17 L 0.66 21 9 ; 8 7 ; 0.131
, 2 17 L 0.60 18 : 8 I 10 , 10 10.20 I
3 17 L 0.76 22 , 9 11 ; 11 10.21 !
1 12 [ M5 2 5000 < 2 2 1 17 L 0.53 19 ! 7 i 9 ! 9 i 0 .231
2 17 0.60 19 i 8 11 : 11 ; 0 .241
! 13 ! M4 ; 2 5000 ; 2 2 1 17 R 0.72 21 I 9 : 11 i 11 ;o . i7 i
, ] , 2 17 R 0.72 21 9 9 9 0.14!
M5 2 5000 1 3 3 1 17 L 0.69 20 9 10 10 0.18! 1 L 2
! 2 17 L 0.58 19 i 7 ! 9 : 9 ,0.181
: 3 17 L 0.74 21 , 8 11 11 0.17:
14 : M2 2 5000 i 2 2 1 17 R 0.28 13 : 5 : 10 10 0.14 2 R 4
, 2 17 R 0.29 14 4 10 12 ;0.20i R 4
M3 2 5000 4 4 1 17 R 0.66 18 8 9 9 0.13: 1 R 2
2 17 R 0.65 20 7 9 , 9 0.16
3 17 R 0.51 18 6 10 11 ,0.21
■ 4 17 R 0.63 19 8 9 9 0.14
16 ; M3 2 , 5000! 5 5 1 17 R 0.47 16 ; 6 i 8 I 9 10.16 2 R 6
i 1 ! ! i 2 17 R 0.52 17 I 6 : 9 I 9 i 0.16| R 2
i I ! iI 3 17 R 0.50 16 I 7 i 9 . 9 ! 0.18!
i : i 1 i 4 17 ! R 0.55 17 I 6 i 8 9 ; 0.16
i ; I ! i ! 5 17 S R 0.53 17 i 8 j 9 8 i 0.20 !
; M4 i 2 ! 5000 j 4 4 1 17 I L 0.58 17 I 6 ; 9 11 i 0.18 2 L 2
I i | i !  i 2 17 , L 0.49 16 1 7 8 11 ! 0.17 L 2
I i ; ■ I 3 17 ! L 0.57 18 i 7 : 8 10 ! 0.18| :
i 1 ! i I 4 17 i L 0.57 17 ' 7 I 9 9 : 0.14 !
17 ! M4 ! 2 ! 5000 | 5 i 5 1 17 i L 0.48 17 ' 5 ! 8 8 0.10 1 ' L 2
i
' i 
1 ! i i 2 17 I L 0.42 14 ! 4 1 9 9 ! 0 .141
I
‘ ! 3 17 I L 0.53 17 i 7 | 8 8 ,0.14|
! 1 ! i 4 17 ! L 0.44 15 j 6 ! 8 8 ‘ 0.15
i
I ! i i
I
I 5 17 I L 0.38 15 6 1 9 9 10.13 i
#  Fem = # females included in experiment; #  PG Fem = #  females with fetuses; # em = numerical assignment to embryos
within same female: age = fetal age in days of development; Hm = right (R) or left (L) uterine hom w / fetuses; Body M = body
mass of fetuses; CR = Crown-rump length; TL = tail length: PL = placental length: PW = placental width: PM = placental mass.
TOT #  R = total #  resorptions; NPG R = # resorptions in females with no viable pups; PGR = #  resorptions in females with
Iviable.pupsLRDi = diameter.of resorptions, (all lengths in millimeters^all masses in grams __ __ _
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P ! P I P
Exp Reap
--------- 1--------------- 1---------------------
j Cone I #  Fem #PG Fem j #Em i Age \ Hm i Bod M j CR TL L W  | M ; #  R | Hm i DI
6 M1 I 5000 0 , i
6 M2 i 5000 0 i 1 L 5
7 M3 i 5000 0 ! ! I
8 M7 5000 0 i ; ! :
8 M8 5000 0 ;
i 9 M9 ! 5000 0 ! ;
9 M10 , 5000 0 | ;
; 9 M11 ; 5000 o !
10 M6 , 5000 o
10 M7 i 5000 0
10 M8 5000 0 j
11 M4 : 5000 0 ,
12 M6 5000 0 '
M7 ; 5000 0 !
M8 i 5000 0 !
I 13 M6 ! 5000 4 ' 1 1 17 ; R ! 0.40 i 16 6 8 8 10.13!
,* '
2 17 R i 0.50 ; 18 7 10 o o to
! 3 17 [ R ! 0.34 ! 16 7 9 00 o o>
i 4 17 R i 0.38 I 16 7 9 8 0 .11 ,









I 17 | M7 ' 50001 0 | I , I |
! i M8 ; . 3 ! : 1 : 17 L i 0.54 17 i 7 : 9 i 10 i 0.17 i 2 ; L 2
; 2 17 L i 0.49 17 ' 7 : 13 i 9 ; 0.32; L 2
! 3 17 L | 0.47 16 ! 7
M9 0 '
 ̂ __ I______ ______ _______ ___ _  ̂_ ..... . i i__ :
;# Fem = #  females included in experiment: #  PG Fem = # females with fetuses: #  em = numerical assignment to embryos 
within same female; age = fetal age in days of development: Hm = right (R) or left (L) uterine horn w/ fetuses; Body M = 
body mass of fetuses; CR = Crown-rump length: TL = tail length: PL = placental length: PW = placental width; PM = 
placental mass. TOT #  R = total #  resorptions; NPG R = #  resorptions in females with no viable pups: PGR = # resorptions 
in females with viable d u o s :  R Di = diameter of resorptions, (all lengths in millimeters, all masses in grams)________________
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CATEGORY C EXPERIMENTS 
SKELETAL DEVELOPMENT AND LIF 
RAW DATA
ET I Grp i II | Clear I I j at L13 ■ % OS I ! | i
Exp| M # |T rt Em#| H-Ln H-Os| HO/L Ribs | V Spc Excocc| S-Ln i S-Os ! SO/L I ! i
8 ! 2 ! C I a 1 2.25 0.50 | 0.22 13 ; 1.25 50 1.75 | 0.38 ! 0.21 i i 1
8 ! 2 1 c b I 2.44 0.69 { 0.28 1 1.00 i 20 1.75 ! 0.50 ! 0.29
8 ' 6 L a i 3.00 1.13 i 0.38 13 I 0.63 } 100 2.50: 1.00 0.40
9 ! 2 1 c a 3.75 1.50 j 0.40 13 i 0.50 100 2.88 ! 1.50 ! 0.52 H-Ln = total length of humerus
9 ! 3 ; c a ; 3.13 1.13 | 0.36 13 i 0.50 100 2.75 i 1.38 : 0.50 H-Os = length of diaphyseal
9 ! 3 1 c b ' 3.50 1.13 | 0.32 13 0.50 100 2.75 i 1.25 i 0.45 ossification center in
9 I 7 | L a I 2.75 0.75 | 0.27 13 0.75 100 2.25 | 0.75 i 0.33 humerus
9 7 I L b i 2.63 0.75 0.29 13 0.63 100 1.63 ; 0.75 . 0.46 HO/L = index of H-Os/H-Ln
9 7 1 L c ! 3.00 0.75 0.25 13 1.00 100 2.58 ! 0.63 j 0.24 Ribs = number of ribes
9 7 d ! 2.50 0.38 0.15 1 13 1.25 100 1.88 i 0.63 : 0.34 V Spc = dorsal space between
9 7 1 L e i 2.25 0.63 0.28 | 13 1.13 100 1.63 ! 0.75 ! 0.46 vertebral pedicles
9 7 i L f ! 2.75 0.81 0.29 13 0.88 100 2.25 ! 0.75 : 0.33 Exocc = estimated percent of
10 2 a : 3.13 1.00 0.32 ! 13 0.63 100 2.63 I 1.13 0.43 ossification in exocdpital
10 2 ' c b 3.25 1.25 0.38 ! 13 0.63 100 2.13 ! 1.38 | 0.65 bone
10 3 1 L a 2.75 0.75 0.27 13 1.00 100 2.13 i 0.75 : 0.35 S-Ln = total length of scapula
10 4 ! L a 3.00 0.88 0.29 13 0.75 100 2.25 i 0.88 ! 0.39 S-Os = length of ossification center
10 5 a 3.25 1.00 0.31 13 0.88 100 2.25 i 1.00 i 0.44 in scapula
11 2 a 2.63 1.25 ! 0.48 13 1.00 • 3.00 1.50 ! 0.50 SO/L = index of S-Os/S-ln
11 2 L b 2.50 1.00 0.40 ! 13 0.38 70 2.50 1.00 0.40
11 | 2 L c 3.50 1.13 0.32 13 0.88 . 1.75 I 1.00 0.57
11 3 L a 3.00 1.00 I 0.33 13 0.63 100 2.50 1.13 ! 0.45
11 3 L b 3.50 1.25 0.36 13 0.63 100 2.75 1.25 ! 0.45
11 3 L c 3.00 1.00 0.33 13 0.75 100 2.25 1.00 0.44 : J
12 5 L a 3.50 1.00 0.29 13 0.75 100 2.50 | 1.00 0.40
12 5 b 3.13 0.88 i  0.28 13 0.75 100 3.28 I 1.00 0.30 . ;
13 i 3 C a 3.00 1.00 i 0.33 13 1.25 100 2.25 1.13 0.50
13 3 C b 3.00 1.38 0.46 13 0.50 100 2.63 1.13 0.43 : ;
13 | 3 c c 3.25 0.75 i 0.23 13 0.75 100 2.50 i 1.00 0.40 ;
13 , 3 c d 3.38 1.50 0.44 13 0.50 100 2.75 1.00 0.36
13 4 L a 3.00 1.00 0.33 13 1.25 100 2.75 1.25 0.45
13 4 L b 3.25 1.00 0.31 13 0.75 100 2.75 1.25 0.45 ;
13 ! 5 L a 3.50 1.63 0.47 13 0.88 100 3.00 1.50 0.50 ,
13 5 L b 3.25 1.25 0.38 13 1.00 100 2.63! 1.25 0.48
13 6 A a 2.50 0.50 0.20 13 1.00 100 2.13 0.50 0.23 !
13 i 6 A b 2.25 0.38 i 0.17 13 1.50 20 1.75 0.38 0.21 ;
13 6 A c 3.00 0.75 0.25 13 0.88 80 2.25 0.88 0.39 !
13 6 A d 2.50 0.63 0.25 13 1.00 70 2.00 ! 0.56 0.28
14 3 L a 3.25 1.00 0.31 13 0.50 100 3.00 1.00 0.33
14 3 L c 3.38 1.00 0.30 13 0.50 100 2.63 1.13 0.43
14 3 L d 3.25 1.00 0.31 13 0.75 100 2.50 1.00 0.40
14 6 c a 4.00 1.88 0.47 13 1.25 100 3.13 1.75 0.56
16 2 C a 3.00 1.00 0.33 13 0.75 100 2.50 1.00 0.40
! '
16 2 C b 2.75 0.75 0.27 13 1.00 100 2.25 0.88 0.39
16 2 c c 2.75 0.63 0.23 13 0.75 30 2.13 0.63 0.29
16 3  1 L a 2.88 0.75 0.26 13 1.00 100 2.00 1.00 0.50
16 3 i L b 3.00 1.25 0.42 13 0.75 100 i 2.50 1.25 0.50
16 3 ! L d 3.00 0.88 0.29 13 0.63 100 2.50 1.00 0.40 i i
16 3 «- e 2.75 1.00 0.36 13 0.88 80 2.25 0.75 0.33
I ;
16 4 L a 3.00 0.75 0.25 13 1.00 70 2.50 1.00 0.40 I ;
16 4 L b 2.88 0.50 0.17 13 0.88 30 2.25 0.38 0.17
16 4 L c 3.25 1.00 0.31 13 0.75 90 2.50 1.00 0.40 | i I :
16 4 L d 3.13 0.88 0.28 13 1.00 30 2.50 0.88 0.35 I ; ! !
17 4 L a 3.00 0.75 0.25 13 1.00 20 2.25 0.63 0.28 ! i
17 4 c 2.88 0.75 0.26 13 0.88 30 2.25 0.63 0.28 I ' '
17 4 d 2.75 0.50 0.18 13 1.00 40 2.00 0.38 0.19 i !
17 4 L e 2.75 0.63 0.23 13 0.88 40 2.13 0.63 0.29 i l l :
17 8 A a 3.13 0.63 0.20 13 0.88 50 2.38 0.63 0.26 i ! ! i
17 8 A b 3.00 0.63 0.21 14 0.75 30 2.50 0.50 0.20 I I I !
17 8 A c 3.00 0.63 0.21 13 0.75 40 2.25 0.50 0.22 ! i  !
18 2 L a 3.13 0.75 0.24 13 0.75 10 2.25 0.50 0.22 i i i 'i i i i
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